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„Ich kann freilich nicht sagen, ob es besser werden wird, wenn es 
anders wird; aber soviel kann ich sagen: es muss anders werden, wenn 
es gut werden soll.“ 
 
Georg Christoph Lichtenberg 1742–1799 
 
 
[Certainly, I cannot tell if it will be better, when it changes; but what I can say so far: it will have to be different to be good.] 
  
   
INTRODUCTION
  
 
Optical-guided surgery & development of SMARgeting probes for cancer                                                                  Introduction 
- 1 - 
 
PREAMBLE 
 
 In most cancers, tumor resection is the first therapeutic indication before 
chemotherapy or radiotherapy assuming that the tumor is removable. Since the patient 
survival strongly depends on the exhaustiveness of the tumor resection, innovative methods 
improving the quality of cancer surgery are needed to lower the risks of postoperative local 
recurrence. 
 Actually, several approaches for image-guided surgery are in development for clinical 
application, thereunder the design of optical imaging devices. This technology, working in an 
optical window with improved information out-come, the near-infrared (NIR), showed an 
improvement in the quality of the surgery in preclinical studies. First studies in clinics have 
been done by different research groups, but the translation from preclinics into clinics needs 
the adaptation of the imaging device for the operation block to warrant correct surgery. 
Nevertheless, for a real clinical employment these systems are restricted to one imaging probe 
being the only one approved for use in human (FDA; ANSM) with the imaging properties 
needed. This is a critical point for the development and translation of NIR-optical imaging 
systems in clinical application, especially as the tracer used is non-specific and thus limited in 
its application.  
 Relating to this, a portable clinical imaging device (Fluobeam
TM
) for optical guided 
surgery has been developed, working with a tumor targeting probe (AngioStamp™) in the 
NIR window. The combination of imaging device and specific tracer allowed speeding up 
high quality surgery in preclinical studies. 
 One part of my work was the transfer of this technology into a clinical veterinary 
phase, that is to say the clinical surgery of spontaneous tumors in cats, in order to evaluate 
this system regarding clinical surgery in humans.  
 In parallel, cancer diagnosis and therapy lack of specificity towards the tumor cells, 
limiting a precocious detection and safe treatment. Conventional cytostatic and cytotoxic 
treatments lead to adverse effects, which limit the dose of administration.  
Consequently, clinical cancer research claim the development of new sensitive and 
performing diagnostic methods and of efficient therapeutics with reduced adverse effects.  
Introduction                                                          Optical-guided surgery & development of SMARgeting probes for cancer                                              
- 2 - 
 
 Therefore, cancer research is pushed towards the development of targeting strategies. 
This corresponds to the use of new molecules emerging from biological knowledge of cancer 
and reacting specifically with the cancer cell. 
 Among the specific physiopathological phenomenon of cancer, targeting of tumor 
angiogenesis represents a promising strategy to limit tumorigenesis. Tumor neo-vessels differ 
from quiescent vessels concerning their structure but also in their functioning by 
overexpressing membrane receptors and other specific recognition elements on the surface of 
endothelial cells. At the same time these receptors are over-expressed by certain tumor cells 
themselves, which allows a targeting of the tumor directly. In order to efficiently target these 
receptors synthetic ligands have been developed with very high specificity and selectivity. 
Other potential targets are enzymes over-expressed in the tumoral tissue. A group of these 
enzymes are amongst others in correlation with the receptors of angiogenesis and necessary 
for tumor cell invasion and spreading. Due to their cleavage activity they incorporate a target 
for activatable molecules in the sense of pro-drugs or quenched imaging agents.  
 In this context my laboratories have developed the vector “RAFT-(cRGD)4”, in the 
following simply called RAFT-RGD. This molecule is based on decapeptide scaffold with 
two independent domains, allowing the combination of two different functions. One domain 
presents a ligand in a multivalent fashion, whereas the other domain carries the vectorization 
agent: therapeutics or imaging agents.   
The RAFT-RGD showed its capacity of targeting tumor and endothelial cells expressing the 
receptor integrin αvβ3 in vitro and in vivo, which allowed the fluorescence imaging in vivo of 
integrin αvβ3 positive tumors and serves also as the already mentioned tracer AngioStamp™. 
 My second project was the design of an innovative fluorescent molecule for cancer 
diagnosis and therapy, thus a pharmacodiagnosticum (or theranostic). The molecule 
constructed is a derivative of the RAFT-RGD combined with a cassette, cleavable by 
enzymes overexpressed in tumors. A fluorophore, quenched by another molecule in the 
cassette, is set free, when the peptide sequence connecting these molecules, is cleaved.  
The result is an increase in the fluorescence signal. The molecule, afterwards called RAFT-
RGD-MMP, was synthesized and tested in first studies in vitro and in vivo using different 
tumor cell lines in order to study the capacity of dual-targeting compared to a mono-target 
approach. 
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I. Tumorigenesis 
I.1. Characteristics of tumorigenesis 
 Cancer can be considered as a general term covering a plethora of different 
malignancies. These pathogenic conditions are characterized by changes in certain physical 
properties normally preserving cell homeostasis.  
 Cell homeostasis consists in the maintenance of a balance between the loss and repair 
of cells. In the case of tumors, an imbalance occurs between reduced cell loss and excessive 
cell growth. 
 Hanahan and Weinberg
1,2
 described eight biological capabilities acquired by cancer 
cells called hallmarks of cancer. Mentioned are the sustaining of proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, activating invasion and metastasis, reprogramming of energy metabolism, and 
evading immune destruction. 
 These mechanisms are needed for and lead to the multistep development called 
tumorigenesis. The term tumorigenesis describes the process of initiating and promoting the 
development of a tumor. In general it consists of three consecutive steps: 1) initiation of cell 
changes to be able to form tumors, 2) promotion, which is the growth of existing tumors and 
3) progression, which is characterized by increased growth speed and invasiveness of the 
tumor cells (Figure I-1).  
  
                                                 
1  Hanahan, D., und R. A. Weinberg. „The hallmarks of cancer“. Cell 100 (2000): 57–70. 
2 Hanahan, Douglas, und Robert A. Weinberg. „Hallmarks of Cancer: The Next Generation“. Cell 144, Nr. 5 (March 4, 
2 Hanahan, Douglas, und Robert A. Weinberg. „Hallmarks of Cancer: The Next Generation“. Cell 144, Nr. 5 (March 4, 
2011): 646–674. 
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 Due to genomic instability and the inflammatory state of premalignant and malignant 
lesions, generation of the listed characteristics occurs. This is due to exposition to a 
carcinogen, either of chemical, physical or viral origin. Leading to activation of certain 
oncogenes and/or the inhibition of tumor suppressor genes, initiation and progression of 
cancer takes place.  
 After all, normal cells transform into “immortal” cells with higher activity in cell 
growth and cell-division. They possess means of modifying their environment and 
deregulating the physiological fine-tuned balance in order to support their development and 
spreading.  
This is reflected for example by defect negative-feedback loops, like the oncoprotein Ras or 
the kinase mTOR, whose inhibition leads to enhanced proliferation. Other differences, 
compared to normal cells, is the evasion of growth suppressors, like retinoblastoma-
associated and TP53 proteins, the enhancement of proliferation signaling and the resisting to 
physiological cell death, as well as inducing angiogenesis.  
 Hanahan et al. describe also that necrotic cells can recruit inflammatory cells of the 
immune system. In the context of neoplasia, this can actively promote tumor progression, 
Figure I-1: Stages of tumorigenesis. 
-After: H. Cortés-Funes  “Antiangiogenesis Agents”Drugs Today 2002, 38(Suppl. A): 11- 
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because such cells are capable of enhancing angiogenesis, cancer cell proliferation, and 
invasiveness
3
.  
Necrotic cells can release bioactiveregulatory factors, which can directly stimulate 
neighboring viable cells to proliferate, with the potential, to facilitate neoplastic progression. 
It is known that some tumors are densely infiltrated by cells of the immune system and 
thereby mirror inflammatory conditions arising in non-neoplastic tissues.  
Inflammation is in some cases evident at the earliest stages of neoplastic progression and is 
demonstrably capable of facilitating the development of neoplasias into cancers.  
Additionally, inflammatory cells can release chemicals, notably reactive oxygen species that 
are actively mutagenic for nearby cancer cells, accelerating their genetic evolution towards 
states of heightened malignancy. 
 Apart from dysregulation of physiological mechanisms, cancer cells have certain 
morphological properties which make them histologically identifiable. The dedifferentiated 
cells are presenting rounded cytoskeleton, with reduced cell-to-cell and cell-to-extracellular 
matrix adhesion. The nucleolus is characterized by hypertrophy, macro- and 
microsegregation
4
 and the neoplastic cell population is highly genotypically and 
phenotypically heterogeneous. 
 Besides, tumor cells are more or less organized in a supporting tissue. This so called 
tumor stroma consists of fibroblasts, smooth muscle cells, blood and lymphatic vessels and 
infiltrated immune cells, such as macrophages, mastocytes and lymphocytes, which are all 
embedded in an extracellular matrix (ECM)
5
 (Figure I-2). Furthermore the tumor 
microenvironment consists of soluble factors such as cytokines and growth factors. 
 
 The vascularization and sprouting of new blood vessels in the tumor stroma is 
important for tumor growth and invasion of the surrounding tissue and metastasis. It 
represents not only the supplying system for nutrients, oxygen and the elimination pathway of 
waste but also a transport system for metastatic cells to reach the organs of metastasis 
manifestation. Thus, it is also an access point for molecules, either diagnostic or therapeutic 
ones.  
                                                 
3 Hanahan, Douglas, und Robert A. Weinberg. „Hallmarks of Cancer: The Next Generation“. Cell 144, Nr. 5 (March 4, 
2011): 646–674. 
4 Baba, Alecsandru Ioan A I, und Cornel C Câtoi. Comparative Oncology. Bucharest: The Publishing House of the Romanian 
Academy, 2007.  
5 Li, Zhi-Wei, und William S Dalton. „Tumor microenvironment and drug resistance in hematologic malignancies“. Blood 
reviews 20, Nr. 6 (November 2006): 333–342. 
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I am going now to give a brief description of the process of angiogenesis in order to introduce 
the interest in targeting certain structures or enzymes for specific tumor imaging and therapy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
Figure I-2: The Cells of the Tumor Microenvironment. 
(Upper) An assemblage of distinct cell types constitutes most solid tumors. Both the parenchyma and stroma of tumors 
contain distinct cell types and subtypes that collectively enable tumor growth and progression. (Lower) The distinctive 
microenvironment of tumors.  
(hatched background represents the extracellular matrix) 
-Adapted after Hanahan & Weinberg, Hallmarks of Cancer: The Next Generation, Cell Volume 144, Issue 5 2011 646 – 674.- 
Optical-guided surgery & development of SMARgeting probes for cancer                                                                  Introduction 
- 7 - 
 
II. Angiogenesis 
 
 The formation of blood vessels is an important physiological process during 
embryogenesis and development.  
Angiogenesis itself is the process of forming new blood vessels from existing ones. Therefore 
vascular basement membrane degradation is needed and remodeling of the ECM for 
migration of endothelial cells invasion of surrounding tissue and lumen formation is 
necessary.  
 Establishment of an arterial network requires vascular remodeling by perivascular 
mural cells including pericytes and vascular smooth muscle cells (Figure II-1).  
 
 
 
 Bone marrow-derived stem cells have been reported to play a critical role in 
contribution to growing vessels by the mechanism of differentiation into vascular endothelial 
cells
6
.  
 Physiological angiogenesis in adults does only occur in certain cases like wound 
healing or during the menstrual cycle of a woman. Therefore it is a symptom of pathology 
like rheumatoid arthritis, retinopathy, psoriasis, arteriosclerosis or cancer
7
.  
 While the tumor does not exceed 1-2 mm
3
, the tumor cells do get enough oxygen and 
nutrition by simple diffusion
8
. Exceeding this size, the inhibitors of the angiogenesis are 
                                                 
6 Lyden, D, K Hattori, S Dias, C Costa, P Blaikie, L Butros, A Chadburn, u. a. „Impaired recruitment of bone-marrow-
derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth“. Nature medicine 7, 
Nr. 11 (November 2001): 1194–1201. 
7 Carmeliet, Peter. „Angiogenesis in health and disease“. Nature medicine 9, Nr. 6 (Juni 2003): 653–660. 
Figure II-1: Blood vessel formation. 
 - Cao, Yihai. “Therapeutic Angiogenesis for Ischemic Disorders: What Is Missing for Clinical Benefits?“ Discovery Medicine 9, Nr. 46 
(March 3, 2010): 179–184.- 
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oppressed and the pro-angiogenetic factors, like vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF) and tumor necrosis factor-α (TNF-α), are secreted by 
the tumor cells, the tumor stroma, inflammatory cells or the ECM
9
. This is a process, which 
takes normally place due to stress (metabolic like hypoxia, hypoglycemia, low pH; mechanic, 
inflammation and/or gene dysregulation), and is called “angiogenic switch”. This implies the 
shift of the balance to more pro- than anti-angiogenic signals and often occurs at an early, 
premalignant stage
10
. 
 The endothelial cells that form existing blood vessels, respond to angiogenic signals in 
their vicinity by proliferating and secreting proteases. These proteases break open the blood-
vessel wall to enable migration towards the site of the angiogenic stimuli. Then proliferating 
endothelial cells organize themselves into new capillary tubes by altering the arrangement of 
their adherence-membrane proteins. Finally, through the process of anastomosis, the 
capillaries, emanating from the arterioles and the venules, join to provide a continuous blood 
flow. This sustains tumor cell metabolism and sets up escaping avenues for metastatic tumor 
cells (Figure II-2). 
 Thus the tumor induces its proper vascularization, which allows its development and 
spreading
11,12
. 
  
                                                                                                                                                         
 
8 Folkman, J. „Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction“. Cancer 
metastasis reviews 9, Nr. 3 (November 1990): 171–174. 
9 Carmeliet, P, und R K Jain. „Angiogenesis in cancer and other diseases“. Nature 407, Nr. 6801 (September 14, 2000): 249–
257. 
10  Rundhaug, Joyce E. „Matrix Metalloproteinases and Angiogenesis“. Journal of Cellular and Molecular Medicine 9, Nr. 2 
(2005): 267–285. 
11 Gimbrone, M A, Jr, S B Leapman, R S Cotran, und J Folkman. „Tumor dormancy in vivo by prevention of 
neovascularization“. The Journal of experimental medicine 136, Nr. 2 (August 1, 1972): 261–276. 
12  Folkman, J, und D Hanahan. „Switch to the angiogenic phenotype during tumorigenesis“. Princess Takamatsu symposia 
22 (1991): 339–347. 
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Figure II-2: Tumor development and angiogenesis. 
- Siemann DW., Vascular targeting agents. Horizons in Cancer Therapeutics: From Bench to Bedside. 2002;3(2):4-15.- 
 
 Compared to normal blood vessels, tumor blood vessels have a chaotic vasculature 
and are tortuous, leaky, and dilated or uneven in diameter, with reduced attachment of 
pericytes
13
. 
 Various classes of adhesion molecules are involved in tumor angiogenesis, such as 
members of the integrin, cadherin, selectin and immunoglobulin families. 
Here I will focus on the integrins, as the αvβ3 integrin, represents our target. 
  
                                                 
13 Rundhaug, Joyce E. „Matrix Metalloproteinases and Angiogenesis“. Journal of Cellular and Molecular Medicine 9, Nr. 2 
(2005): 267–285. 
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II.1. Integrins 
  
 The integrins modulate physical processes like migration and invasion of the cell as 
well as intracellular pathways leading to cell survival and proliferation as well as cell death by 
anoïkis when cells loose contact with the ECM. The function of these receptors ranges from 
cell-substrate-attachment mediation to intracellular signal transduction. The signalization in 
all its complexity is accentuated by the capacity of the integrin to modulate the mediated 
signals of other membrane receptors and the other way round
14
. 
As integrins do not have an intrinsic enzymatic activity, they recruit different enzyme partners 
for signal transmission. 
 
II.1.1. Integrin composition 
 Integrins are heterodimeric cell surface receptors composed of noncovalently 
associated transmembrane glycoproteins, α and β, which connect adhesive proteins in the 
ECM to the cytoskeleton. There are at least 18 different α subunits and eight different β 
subunits identified, which represent - in an associated form - over 24 receptors for different 
spectra of extracellular ligands (Figure II-3)
15
.  
 The α and β subunits consist of a large extracellular domain (700-1100 amino acids) 
and a short cytoplasmic domain of 30 to 50 amino acids. The N-terminal extremities, next to 
the extracellular domain of the α subunit, contain regions, which are capable to bind divalent 
cations (Mg
2+
, Ca
2+
). The β subunit has cystein-rich regions in its extracellular domain and a 
folded N-terminal, forming a large loop (Figure II-4)
16
. 
  
                                                 
14
 Porter, J C, and N Hogg. “Integrins Take Partners: Cross-talk Between Integrins and Other Membrane Receptors.” Trends 
in Cell Biology 8, no. 10 (October 1998): 390–396. 
15  van den Steen et al., 2006, Journal of biol. Chem.. 281, 18626-18637. 
16  Humphries, M.J. (2000) “Integrin structure” Biochem Soc Trans 28(4): 311-39 
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Figure II-3: The members of the human integrin superfamily and how they combine to form 
heterodimeric integrins. 
At least 18 α subunits and eight β subunits have been identified in humans, which are able to generate 24 different 
integrins. Integrin subunits that bind to each other to form a heterodimer are connected by solid lines. Each integrin has 
distinct ligand-binding specificity and tissue and cell distribution. 
- Niu G, Chen X. Why Integrin as a Primary Target for Imaging and Therapy. Theranostics 2011; 1:30-47.- 
Figure II-4: The extracellular region of a human integrin. 
The crystal structure represents a net form of integrin αVβ3 with no bound RGD  
-Takada, et al. “The Integrins.” Genome Biology 8, no. 5 (2007): 215.- 
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II.1.2. Integrin conformation & substrate recognition 
 The association αβ determines the specificity of the integrin for its substrate. The 
interaction ligand-integrin is modulated by the avidity and the affinity and is strongly 
influenced by the ligand’s conformation and the possible multimeric formation. The 
transmission of the signal in the cell is guaranteed by the “key-lock-principle”. Nevertheless, 
as one ligand can be recognized by more than one integrin, cooperative and competitive 
effects between integrins lead to complex signaling. Thus precise analysis of its environment 
by the cell is more than a simple physical interaction of cell and ECM. 
 Being a dimer, different conformations of integrins can be observed, which modifies 
their affinity towards their ligand and their state of activation (Figure II-5). Integrin-ligand 
affinity is modulated by chemical allostery, mechanical allostery and integrin clustering. 
Several integrins are basically not active (Figure II-5, B), but expressed on the cell surface in 
an inactive form (Figure II-5, A). This results in a lack of ligand-receptor interaction and 
consequently no signal is emitted
17
. The cell glycocalyx is also of importance, as it occupies 
the cell-substrate space and thus influences the diffusion of reactants, limiting the attachment 
of both integrin and ligand to surfaces
18
. 
 
 
 
 
 
 
 
 
 
 
 
                                                 
17 Takagi, Junichi, and Timothy A Springer. “Integrin Activation and Structural Rearrangement.” Immunological Reviews 
186 (August 2002): 141–163. 
18 Boettiger, David. „Mechanical control of integrin-mediated adhesion and signaling“. Current opinion in cell biology 
(August 1, 2012). 
A  
 B 
Figure II-5: Intergin formation: A) inactive, bend form; B) active form 
-After: Bass, Mark D. „SHARPINing integrin inhibition“. Nature Cell Biology 13, Nr. 11 (November 2, 2011): 1292–1293.- 
 B
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 Concerning their specificity for their ligands, integrins can be classified in different 
groups: laminin integrins, collagen integrins, leucocytes integrins, and integrins recognizing 
the short peptide sequence Arg-Gly-Asp (RGD)
19
. 
 Upon engagement, integrins cluster at the attachment site and recruit multiple 
intracellular cytoskeletal proteins, such as α-actinin, talin, and filamin, as well as signaling 
proteins, including focal adhesion kinase and integrin-linked kinase
20,21
. The formation of 
focal adhesion contacts is a prerequisite for adhesion, spreading, and migration through 
structures of the ECM. 
II.1.3. Integrin turn-over 
 An important aspect is also the possible internalization of integrins by endocytic 
routes, such as the formation of circular dorsal ruffles during macropinocytosis and clathrin-
dependent or -independent endocytic pathways. This implicates the rapid trafficking of 
integrins to early endosomes. Nevertheless the majority of these internalized integrins are 
rapidly recycled back to the plasma membrane (t1/2 of integrin recycling often in less than 15 
min)
22
.  
II.1.4. Roles of integrin 
 As playing a principal role in the maintenance of tissue-cohesion and cell migration, 
integrin dimers are also implicated in the progression of several pathologies, making them a 
potential therapeutic target
16
. Integrins control also diverse other cellular processes, including 
proliferation, apoptosis and differentiation, thus are implicated in development, immune 
responses and progression of diseases. 
 Concerning cancer, the transformation of cancer cells is inter alia characterized by the 
disorganization of the cytoskeleton and the loss of adherence. Analyzing the modifications of 
expressed integrins in healthy tissues and tumor tissue, it has been observed that the integrins 
                                                 
19 Takeda, Ikuko, Shin-Ichiro Maruya, Takashi Shirasaki, Hiroki Mizukami, Takenori Takahata, Jeffrey N Myers, Seiji 
Kakehata, Soroku Yagihashi, and Hideichi Shinkawa. “Simvastatin Inactivates Beta1-integrin and Extracellular 
Signal-related Kinase Signaling and Inhibits Cell Proliferation in Head and Neck Squamous Cell Carcinoma Cells.” 
Cancer Science 98, no. 6 (June 2007): 890–899. 
20 R.E. Seftor, E.A. Seftor, M.J. Hendrix, Molecular role(s) for integrins in human melanoma invasion, Cancer Metastasis 
Rev. 18 (1999) 359–375.  
21 R.O. Hynes, Integrins: versatility, modulation, and signaling in cell adhesion, Cell 69 (1992) 11–25. 
22 Bridgewater, Rebecca E, Jim C Norman, und Patrick T Caswell. „Integrin trafficking at a glance“. Journal of cell science 
125, Nr. Pt 16 (August 15, 2012): 3695–3701. 
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do either positively either negatively participate in the phenotype of tumor transformation
23
 
(Table II-1). 
 
 
 
 
 
Table II-1: Role of integrins in the tumor progression. 
-After: Desgrosellier, Jay S, und David A Cheresh. „Integrins in cancer: biological implications and therapeutic 
opportunities“. Nature reviews. Cancer 10, Nr. 1 (January 2010): 9–22.- 
 
  
                                                 
23 Mizejewski, G J. „Role of integrins in cancer: survey of expression patterns“. Proceedings of the Society for Experimental 
Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 222, Nr. 2 (November 
1999): 124–138. 
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II.2. The integrin αvβ3 
 For example αv integrins are highly expressed in tumor vasculature, where they can be 
accessed with peptides containing the RGD integrin recognition motif
24,25,26
.  
This approach will be discussed later on in the section “imaging probes for NIR imaging” on 
page - 40 -. 
 The expression of β3 integrins is mostly associated with the ability of tumors to 
metastasize
27
, as integrin αvβ3 has been linked to enhance transendothelial migration and 
production of MMP-2. 
 Concerning internalization processes αvβ3 integrins recycle through a “short-loop” 
pathway which returns these heterodimers from the early endosomes back to the plasma 
membrane without transiting through the perinuclear recycling compartment. This is said to 
be the control key to directionally persistent migration and branching morphogenesis of 
endothelial vessels
28
. Bridgewater et al. report also that inhibition of this receptor via small 
molecules (e.g. Cilengitide) in endothelial cells enhances the recycling of VEGF receptor 2. 
Thus, it is protected from degradation and increases its presence on the cell surface. This in 
turn promotes cell migration, aortic sprouting and tumor angiogenesis in vivo. 
 The integrin αvβ3is probably the integrin the most strongly involved in the regulation 
of angiogenesis (Figure II-6) and up-regulated in endothelial tumors, wounds and 
inflammation. This was demonstrated as it is widely expressed on blood vessels of tumor 
biopsy samples but not on vessels in normal tissue
27
. Up-regulated not only in angiogenic 
endothelial cells but also in several tumor cells
29
, it represents an attractive target for cancer 
targeting. 
 
 
 
 
 
 
                                                 
24 Eliceiri, B P, und D A Cheresh. „Adhesion events in angiogenesis“. Current opinion in cell biology 13, Nr. 5 (Oktober 
2001): 563–568. 
25 Pierschbacher, M D, und E Ruoslahti. „Variants of the cell recognition site of fibronectin that retain attachment-promoting 
activity“. Proceedings of the National Academy of Sciences of the United States of America 81, Nr. 19 (Oktober 
1984): 5985–5988. 
26Ruoslahti, Erkki. „Antiangiogenics meet nanotechnology“. Cancer cell 2, Nr. 2 (August 2002): 97–98. 
27 Danhier, Fabienne, Aude Le Breton, und Veronique Preat. „RGD -based strategies to target alpha(v) beta(3) integrin in 
cancer therapy and diagnosis“. Molecular pharmaceutics (September 11, 2012).  
28 Bridgewater, Rebecca E, Jim C Norman, und Patrick T Caswell. „Integrin trafficking at a glance“. Journal of cell science 
125, Nr. Pt 16 (August 15, 2012): 3695–3701. 
29 Weis, Sara M, und David A Cheresh. „αv Integrins in Angiogenesis and Cancer“. Cold Spring Harbor perspectives in 
medicine 1, Nr. 1 (September 2011): a006478. 
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Figure II-6: Roles of the αvβ3 integrin in angiogenesis. 
The integrin binds and activates MMP2 to help breaking down of the extracellular matrix. It regulates cell 
attachment, spreading and migration. 
-After: Danhier, Fabienne, Aude Le Breton, und Veronique Preat. „RGD -based strategies to target alpha(v) beta(3) integrin 
in cancer therapy and diagnosis“. Molecular pharmaceutics (September 11, 2012).- 
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III. Proteases and cancer 
 
 The interest in proteases, or proteolytic enzymes, in research is enormous. The mass of 
scientific articles represents a jungle of information and a broad spectrum of scientific 
domains is represented. 
 This is not astonishing as proteases play an important role in various physiological 
processes in all kinds of creatures. While catalyzing the breakdown of proteins by hydrolysis 
of peptide bonds, they are involved in the control of a large number of key physiological 
processes such as cell-cycle progression, cell proliferation and cell death, DNA replication, 
tissue remodeling, haemostasis in the sense of coagulation, wound healing and the immune 
response. And besides they are also involved in several pathological mechanisms.  
 To allude to some examples, there is inflammation, wound healing, infectious and 
degenerative diseases and cancer. After all they influence cell behavior, survival and death in 
their function as processing enzymes, characterized by a highly selective cleavage of specific 
substrates
30,31
. Thus, dysregulation of protease activity in general can lead to pathologies such 
as cardiovascular and inflammatory diseases, cancer, osteoporosis and neurological 
disorders
30
.  
 For instance 679 known and putative human peptidases are listed by the MEROPS 
protease database
32
 and additional 423 non-catalytic homologues in humans alone (as on 
August 2010). Of these proteases, at least 273 have been found in extracellular compartments 
or in the lumen of secretory compartments, 277 in intracellular compartments, and 16 in the 
cell membrane at the surface
33
. 
Rawlings et al. distributed the peptidases in 5 main mechanistic classes: Metalloproteases, 
Serine proteases, Cysteine proteases, Threonine proteases and Aspartic proteases (Figure 
III-1), plus proteases groups of unknown or unclassified catalytic mechanism
34
. 
 MatrixMetalloproteases (MMPs) and Cathepsins have a special role as they are 
upregulated in cancer, but with a controversial role 
31
. In general, molecular biology studies 
                                                 
30 Turk, Boris. „Targeting proteases: successes, failures and future prospects“. Nature reviews. Drug discovery 5, Nr. 9 
(September 2006): 785–799. 
31 Drag, Marcin, und Guy S Salvesen. „Emerging principles in protease-based drug discovery“. Nature reviews. Drug 
discovery 9, Nr. 9 (September 2010): 690–701. 
32
 http://merops.sanger.ac.uk/ 
33 Cudic, Mare, und Gregg B Fields. „Extracellular proteases as targets for drug development“. Current protein & peptide 
science 10, Nr. 4 (August 2009): 297–307. 
34 Rawlings, Neil D, Alan J Barrett, und Alex Bateman. „MEROPS: the database of proteolytic enzymes, their substrates and 
inhibitors“. Nucleic acids research 40, Nr. Database issue (January 2012): D343–350. 
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demonstrated the contribution of proteases to all stages of tumor progression. In the case of 
MMPs this includes an association in tumor growth, progression, metastasis and dysregulated 
angiogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure III-1: Distribution of tumour-protective proteases in the human degradome. 
Human proteases are distributed in 5 classes and 69 different families. Each individual enzyme is indicated by a grey line, 
and those with tumour-protective properties are shown in red. Numbers at the edge represent the different protease families of 
each catalytic class, according to the MEROPS database numbering. 
-López-Otín, Carlos, und Lynn M. Matrisian. „Emerging Roles of Proteases in Tumour Suppression“. Nature Reviews 
Cancer 7, Nr. 10 (Oktober 1, 2007): 800–808.- 
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III.1. Matrixmetalloproteases (MMPs) 
 
 MMPs are a family of at least 23 zinc-dependent endopeptidases (they cleave protein 
substrates in the middle of the molecule) with hydrolytic activity for a diverse spectrum of 
extracellular proteins, especially components of the ECM. They can be divided in two 
structurally distinct groups: secreted MMPs and membrane-type MMPs (MT-MMPs). The 
secreted MMPs are then classified as collagenases, gelatinases, stromelysins and matrilysins 
due to their substrate specificity. 
 
 
MT-MMPs (# 6) Secreted MMPs 
Two: anchored mediated by 
glycosylphosphatidylinositol 
Four: transmembrane 
domain 
Collagenases Gelatinases Stromelysins Other MMPs 
MMP-14 = MT1-MMP 
MMP-1 = interstitial 
collagenases; 
MMP-8 = neutrophil 
collagenase; 
MMP-13 = rodent 
interstitial collagenase 
MMP-2 = 
Gelatinase 
A 
MMP-9 = 
Gelatinase 
B 
 
MMP-3 = 
stromelysin-
1 
MMP-10 = 
sroemysin-2 
MMP-11 = 
stromelysin-
3 
MMP-7 = 
matrilysin 
MMP-12 = 
metalloelastase 
 
Figure III-2: Table: Classes of the MMP family 
 -After:Pepper, M S. „Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis“. 
Arteriosclerosis, thrombosis, and vascular biology 21, Nr. 7 (Juli 2001): 1104–1117.- 
 
 
III.1.1. MMP structure 
 MMPs consist of a catalytic domain with an active site cleft containing a catalytic zinc 
ion for substrate cleavage (Figure III-3). It is linked via the so called Hinge region to the C-
terminal hemopexin-like domain (PEX). The hemopexin C domain is comprised of four 
hemopexin modules (I-IV), each representing a blade of beta-propeller structure. It allows 
MMPs to unwind/distort the triple helix of fibrillar collagens, so that the catalytic domain can 
cleave them
35
. The propeptide domain is at the N-terminal extremity. Gelatinases have 
additionally 3 type-II-fibronectin repeats for gelatin binding. MT-MMPs are membrane-
                                                 
35 Rundhaug, Joyce E. „Matrix Metalloproteinases and Angiogenesis“. Journal of Cellular and Molecular Medicine 9, Nr. 2 
(2005): 267–285. 
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bound enzymes. Therefore they have additionally a transmembrane α-helix, linking a 
cytoplasmic domain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Secreted MMPs are first inactive pro-enzymes (Zymogens) until they are activated in 
the extracellular compartment
36,37
. Their activation is initiated by a specific multistep 
mechanism termed “cysteine switch”, where the N-terminal propeptide domain is cleaved: A 
conserved unpaired cysteine residue in the pro-domain forms a coordinate bond with the zinc 
ion located in the active site. Cleavage of the pro-domain results in a disruption of the zinc-
                                                 
36 Pepper, M S. „Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis“. 
Arteriosclerosis, thrombosis, and vascular biology 21, Nr. 7 (Juli 2001): 1104–1117. 
37 Faust, Andreas, Bianca Waschkau, Jens Waldeck, Carsten Höltke, Hans-Jörg Breyholz, Stefan Wagner, Klaus Kopka, 
Walter Heindel, Michael Schäfers, und Christoph Bremer. „Synthesis and evaluation of a novel fluorescent 
photoprobe for imaging matrix metalloproteinases“. Bioconjugate chemistry 19, Nr. 5 (Mai 2008): 1001–1008. 
Figure III-3: Domain structure for the major classes of MMPs. 
Major domains include the signal peptide (SP), prodomain (Pro), catalytic domain with the active sitezinc (Zn) 
bound to cysteine residues within this domain and "cysteine switch-residue" in the prodomain, the hinge domain 
(HG), the hemopexin domain, and in some cases either a transmembrane domain or GPI-anchor domain (GPI). A 
furin cleavage site between the prodomain and the catalytic domain is found in some MMPs. In the gelatinases, 
fibronectin-like type II repeats (FN) are also present. 
-Brauer, Philip R. „MMPs--role in cardiovascular development and disease“. Frontiers in bioscience: a journal 
and virtual library 11 (2006): 447–478.- 
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cysteine bond, followed by the loss of the amino-terminal pro-domain
38
. This enables the 
catalytic domain to degrade the specific substrate when it binds also to the active side cleft, 
containing the catalytic zinc ion, of the MMP. 
 Hydrolyzation by MMP-9 and -2 takes place at the Gly-Val bond, or Gly-Leu bond 
(also by MMP-1;-8;-13; -14)
39
.  
 
III.1.2. MMP tuning 
 Normally, MMP expression is finely balanced at different levels and spatial restriction 
of extracellular proteolysis and matrix integrity is preserved by different mechanism.  
First of all MMPs are secreted and may be stored in extracellular depots as precursor 
zymogens. They are susceptible to autolysis and the autolytically generated PEX domain of 
gelatinases binds to tissue inhibitors of MMPs (TIMPs) and substrates (see section VI, page - 
54 -). 
MMPs are subsequently tightly controlled by several endogenous inhibitors, such as the 
plasma inhibitor R2-macroglobulin and the four TIMPs
40
. In malignant tissues, MMPs and 
TIMPs are produced by both stromal cells of the tumor and by neoplastic cells as well as 
infiltrating inflammatory cells or endothelial cells themselves
41
.  
For example in inflammation, MMP-9 is predominantly expressed in neutrophils, 
macrophages, and mast cells
42
.  
 Thus, a dyscontrol of this balance leads to a pathological over-expression. 
As the tumor stroma turnover affects the growth of the tumor, the serum levels of MMPs and 
their inhibitors reflect this
43
. 
 
  
                                                 
38
 H. Nagase, Activation mechanisms of matrix metalloproteinases, Biol. Chem. 378 (1997) 151–160. 
39
 Selective Modulation of Matrix Metalloproteinase 9 Functions via Exosite Inhibition, Janelle Lauer-Fields et 
al, Journal of Biological Chemistry, Jluy 18,2008, Vol. 283, No. 29, PP. 20087-20095. 
40 Faust, Andreas, Bianca Waschkau, Jens Waldeck, Carsten Höltke, Hans-Jörg Breyholz, Stefan Wagner, Klaus Kopka, 
Walter Heindel, Michael Schäfers, und Christoph Bremer. „Synthesis and evaluation of a novel fluorescent 
photoprobe for imaging matrix metalloproteinases“. Bioconjugate chemistry 19, Nr. 5 (Mai 2008): 1001–1008. 
41 Rundhaug, Joyce E. „Matrix Metalloproteinases and Angiogenesis“. Journal of Cellular and Molecular Medicine 9, Nr. 2 
(2005): 267–285. 
42 Hofmann, Uta B., Roland Houben, Eva-B. Bröcker, and Jürgen C. Becker. “Role of Matrix Metalloproteinases in 
Melanoma Cell Invasion.” Biochimie 87, no. 3–4 (March 2005): 307–314. 
43 Turpeenniemi-Hujanen, T. „Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid 
cancers“. Biochimie 87, Nr. 3–4 (April 2005): 287–297. 
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III.1.3. Role of MMPs in angiogenesis 
 MMPs play an important role in the proteolysis of the ECM. This is important for 
some physiological process like angiogenesis, but also in pathological ones, especially in 
tumor progression.  
 MMP-2 and MMP-9, showing collagenolytic activity, enable endothelial cells to 
invade the basement membrane of vascular structures, where type IV collagen is the major 
component.   
In studies, using knockout mice or MMP inhibitors, it has been demonstrated that MMP-2, 
MMP-9 and MT1-MMP are pro-angiogenic while MMP-3, MMP-7, MMP-9 and MMP-12 
may inhibit tumor-inducing angiogenesis. A reason is their angiostatin production by 
plasminogen hydrolyzation in certain environments
44
. On the contrary Rundhaug et al. report 
an anti-angiogenic effect of soluble PEX domain of proMMP-2: Degradation of MMP-2 can 
result in the appearance of soluble PEX which binds to the integrin αvβ3 and inhibits 
consequently binding of the MMP-2 to this receptor
45
. This reflects the double-faced role of 
these enzymes in this process and the different possible interactions between receptor and 
enzyme.  
 In tumor angiogenesis, MMP-2 and MMP-9 are considered to play an important role 
for the angiogenic switch. 
 
III.1.4. Gelatinases and solid cancers 
 As already mentioned MMPs play a role in tumor formation, such as tumor invasion 
and angiogenesis (Figure III-4). In particularly, Gelatinases (MMP-2 and MMP-9) are 
associated in these processes in different manners, like tumor aggressiveness, metastatic 
potential
46
 and poor clinical prognosis in malignant tissues, in which they are constantly 
detected
47,48,49
. MMP-9 was shown to contribute to the angiogenic switch during multistage 
                                                 
44 Jin, Young-June, Iha Park, In-Kee Hong, Hee-Jung Byun, Jeongsuk Choi, Young-Myeong Kim, und Hansoo Lee. 
„Fibronectin and vitronectin induce AP-1-mediated matrix metalloproteinase-9 expression through integrin 
α(5)β(1)/α(v)β(3)-dependent Akt, ERK and JNK signaling pathways in human umbilical vein endothelial cells“. 
Cellular signalling 23, Nr. 1 (Januar 2011): 125–134. 
45 Rundhaug, Joyce E. „Matrix Metalloproteinases and Angiogenesis“. Journal of Cellular and Molecular Medicine 9, Nr. 2 
(2005): 267–285. 
46 Yang, Jie, Zhihong Zhang, Juqiang Lin, Jinling Lu, Bi-feng Liu, Shaoqun Zeng, und Qingming Luo. „Detection of MMP 
activity in living cells by a genetically encoded surface-displayed FRET sensor“. Biochimica et biophysica acta 
1773, Nr. 3 (März 2007): 400–407. 
47 Faust, Andreas, Bianca Waschkau, Jens Waldeck, Carsten Höltke, Hans-Jörg Breyholz, Stefan Wagner, Klaus Kopka, u. a. 
„Synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging of matrix 
metalloproteinases“. Bioconjugate chemistry 20, Nr. 5 (Mai 20, 2009): 904–912. 
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carcinogenesis of skin and pancreas
50,51
. This might be because basement membrane 
degradation is required for intravasation and metastatic spread by cancerous cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 One important point for differentiation between benign and malignant cancer is the 
presence or the lack of the basal membrane. While in benign tumors the basal membrane is 
present, in malignant tissue the invasive growth leads to its fragmentation, reduplication or 
disappearance. The basal membrane in malignant cells changes its structure or/and ratios 
between various components, such as: type IV collagen, laminin, heparan sulfate 
proteoglycan and fibronectin.  
 Neoplastic cells secrete MMP-9 (also called gelatinase B, 92kDa gelatinase, 92kDa 
type IV collagenase) that destroys type IV collagen, which facilitates metastasizing through 
the lysis of basal membranes from blood and lymphatic vessels. Thus, malignant cells are 
                                                                                                                                                         
 
48 Duncan, M E, J P Richardson, G I Murray, W T Melvin, und J E Fothergill. „Human matrix metalloproteinase-9: activation 
by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form“. European 
journal of biochemistry / FEBS 258, Nr. 1 (November 15, 1998): 37–43. 
49 Deryugina, Elena I, und James P Quigley. „Matrix metalloproteinases and tumor metastasis“. Cancer metastasis reviews 
25, Nr. 1 (März 2006): 9–34. 
50 Bergers, G, R Brekken, G McMahon, T H Vu, T Itoh, K Tamaki, K Tanzawa, u. a. „Matrix metalloproteinase-9 triggers 
the angiogenic switch during carcinogenesis“. Nature cell biology 2, Nr. 10 (Oktober 2000): 737–744. 
51 Rundhaug, Joyce E. „Matrix Metalloproteinases and Angiogenesis“. Journal of Cellular and Molecular Medicine 9, Nr. 2 
(2005): 267–285. 
Figure III-4: MMPs in tumor progression. 
-Modified from Vasala K., “Matrix Metalloprotease MMP-2 and MMP-9 in bladder Carcinoma”, Academic 
Dissertation University of Oulu, 2008- 
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disseminated, but they can also leave the vessels and implant in other tissues and organs, with 
the formation of metastases. 
III.1.5. The controversial role of gelatinases in tumorigenesis 
 MMP-2 correlates to local relapse in early stage breast carcinoma, cervical carcinoma 
(uterus) and so with poor survival, while its negativity is associated with a favorable 
prognosis. Concerning the prognosis this is also the case in bladder cancer and lung cancer 
(especially Non Small Cell Lung Cancer), colorectal and gastric carcinomas, melanomas and 
malignant brain tumors, where the MMP-2 protein expression correlates with the stage of 
carcinoma
52
. In prostate cancer the ratio of MMP-2 is also increased in high-grade or high-
stage tumors, said to be playing a role in prostate cancer cell invasion and –induced 
angiogenesis. 
 At the same time MMP-2 and MMP-9 over-expression, concomitant with MMP-1 
downregulation, is correlated with dramatic tumor escaping from antiangiogenic 
chemotherapy
53
. 
 In tumor progression the MMP-9 activity is up-regulated during the switch from the 
pre-vascular to the vascular phase. Its activity causes a 2-fold increase in the extracellular 
VEGF mobilization from matrix stores for making it more available to VEGF receptors
54,55
.  
Hofmann et al.
56
 reported that MMP-9 seems to be involved in the early steps of metastasis 
formation but not the later steps such as extravasation as in a melanoma cell invasion trial the 
majority of tumor cells expressed MMP-9, whereas experimental metastases did not express 
MMP-9 at all. Another instance of MMP-9 playing a multifaced role is its stimulating effect 
on proliferation of invasive squamous cell carcinoma in transgenic mouse models during early 
stages of cancer, but it restrictive impact on further malignant progression at later stages. Not 
astonishing the ideas of the significance of MMP-9 in cancer are controversial. 
 This controversial role of MMPs, MMP-9 respectively, as tumor-promoter and tumor-
suppressor is also shown in clinical studies. Over-expression of MMP-9 is associated with 
                                                 
52 Turpeenniemi-Hujanen, T. „Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid 
cancers“. Biochimie 87, Nr. 3–4 (März 2005): 287–297. 
53 Moustoifa, El-Farouck, Mohamed-Anis Alouini, Arnaud Salaün, Thomas Berthelot, Aghleb Bartegi, Sandra Albenque-
Rubio, und Gérard Déléris. „Novel cyclopeptides for the design of MMP directed delivery devices: a novel smart 
delivery paradigm“. Pharmaceutical research 27, Nr. 8 (August 2010): 1713–1721. 
54Pepper, M S. „Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis“. 
Arteriosclerosis, thrombosis, and vascular biology 21, Nr. 7 (Juli 2001): 1104–1117. 
55 Bergers, G, R Brekken, G McMahon, T H Vu, T Itoh, K Tamaki, K Tanzawa, u. a. „Matrix metalloproteinase-9 triggers 
the angiogenic switch during carcinogenesis“. Nature cell biology 2, Nr. 10 (Oktober 2000): 737–744. 
56 Hofmann, Uta B., Roland Houben, Eva-B. Bröcker, und Jürgen C. Becker. „Role of matrix metalloproteinases in 
melanoma cell invasion“. Biochimie 87, Nr. 3–4 (März 2005): 307–314. 
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favorable prognosis in patients with node-negative breast cancer and inversely correlates with 
liver metastasis in patients with colorectal cancer. Therefore, on the one hand a low level of 
MMP-9 in the early stage is correlated with an aggressive clinical course of mamma 
carcinoma, while on the other hand a high plasma MMP-9 activity is associated with worse 
overall survival. At the same time a hypothesis gives a favorable prognosis in association with 
MMP-9
57
. 
 Finally, Turpeenniemi-Hujanen cites that gene expression profiles in breast carcinoma 
do have shown that MMP-9 is included in genes that are associated with aggressive disease, 
whilst these genes are involved in the control of cell cycle, signal transduction, angiogenesis, 
metastasis and cell invasion in general. MMP-9 in lung cancer, like lung adenocarcinoma and 
NSCLC (Non Small Cell Lung Cancer), is in correlation with the disease’s prognosis and 
holds the role as a marker for aggressive behavior in NSCLC. In HNSCC (Head and neck 
squamous cell carcinomas) MMP-9 is suggested to play a great role in the impaired 
metabolism in cancer cells and the over-expression of the immunoreactive protein for MMP-9 
has found to correlate with worse prognosis, and even with aggressive relapses. High MMP-9 
expression in colorectal carcinoma and gastric carcinoma predicts early relapse and poor 
survival. It is also linked with tumor invasion and lymph node metastases in gastric carcinoma 
as well as in melanomas. Concerning malignant brain tumors, MMP-9 is suggested to be 
associated with neo-angiogenesis
57
. Also in hepatocellular carcinomas (HCCs), MMP-9 plays 
an important role in the tumor-stroma cross-talk which leads to tumor progression and 
metastasis and thus to a poor prognosis in human HCCs
58
(Figure III-5). 
 
 
 
 
 
 
 
                                                 
57 Turpeenniemi-Hujanen, T. „Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in 
solid cancers“. Biochimie 87, Nr. 3–4 (März 2005): 287–297. 
58
 Coulouarn, Cédric, Anne Corlu, Denise Glaise, Isabelle Guénon, Snorri S Thorgeirsson, und Bruno Clément. 
„Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment 
that drives progression in hepatocellular carcinoma“. Cancer research 72, Nr. 10 (Mai 15, 2012): 2533–
2542. 
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Figure III-5: Proposed model for molecular cross-talk between hepatocytesand activated HSCs in HCCs. 
-Coulouarn, Cédric, Anne Corlu, Denise Glaise, Isabelle Guénon, Snorri S Thorgeirsson, und Bruno Clément. 
„Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that 
drives progression in hepatocellular carcinoma“. Cancer research 72, Nr. 10 (Mai 15, 2012): 2533–2542.- 
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IV. Integrin αvβ3 and Gelatinases 
 
 Matrix Metalloproteases are known to be in correlation with certain integrins. 
Integrins are said to be regulating the activity of MMPs at the cell surface in inflammation, 
angiogenesis and tumor progression by mechanisms like gene expression, activation and 
localization
59
. 
IV.1. Integrin-Gelatinases interactions 
Respectively MMP-2 and MMP-9 are reported to be in a strong association with the integrin 
αvβ3.  
IV.1.1. Integrin-Gelatinases interaction mediated through SIBLINGs  
 Fedarko et al.
60
 describe, that SIBLINGs (Small, Integrin-Binding, LIgand, N-linked 
Glycoprotein) can specially bind (Kd ~ nM) and activate MMPs. Binding of the SIBLING to 
their corresponding partner leads to structural changes resulting in activation of pro-MMPs. 
This happened without removal of the inhibitory propeptide and re-activation of TIMP bound 
MMPs. The known partners are bone sialoprotein (BSP) and proMMP-2, osteopontin (OPN) 
and proMMP-3 and dentin matrix protein-1(DMP-1) and proMMP-9. The SIBLINGs, 
overexpressed during tumor metastasis, contain the integrin binding tripeptide RGD. The 
RGD domain interacts with the integrin αvβ3 and due to this binding the SIBLINGs form 
complexes with their proMMP partners.  
 The expression of these SIBLINGs by tumor cells promotes the migration and 
adhesion of activated endothelial cells, which are crucial during angiogenesis (Figure IV-1). 
OPN acts as a chemotactic and adhesion molecule for macrophages and promotes their 
infiltration of the tumor. Chen et al.
61
 showed that OPN also induces MMP-9 up-regulation in 
chondrosarcoma cells. As the receptor of OPN, amongst others, is the integrin αvβ3, they 
conclude after investigation that this takes place by activation of a αvβ3 integrin, FAK (focal 
                                                 
59 Kim, Dong Seok, Ok-Hee Jeon, Hee Doo Lee, Kyung Ho Yoo, und Doo-Sik Kim. „Integrin alphavbeta3-mediated 
transcriptional regulation of TIMP-1 in a human ovarian cancer cell line“. Biochemical and biophysical research 
communications 377, Nr. 2 (Dezember 12, 2008): 479–483. 
60 Fedarko, Neal S, Alka Jain, Abdullah Karadag, und Larry W Fisher. „Three small integrin binding ligand N-linked 
glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases“. FASEB journal: official 
publication of the Federation of American Societies for Experimental Biology 18, Nr. 6 (April 2004): 734–736. 
61 Chen, Ying-Ju, Ying-Ying Wei, Hsien-Te Chen, Yi-Chin Fong, Chin-Jung Hsu, Chun-Hao Tsai, Horng-Chaung Hsu, 
Shing-Hwa Liu, und Chih-Hsin Tang. „Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 
integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells“. Journal of cellular 
physiology 221, Nr. 1 (Oktober 2009): 98–108. 
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adhesion kinase), ERK (extracellular signal-regulated kinase), and NF-κB (nuclear factor 
kappa-light-chain-enhancer of activated B cells)-dependent pathway. 
 
 
 
Figure IV-1: SIBLINGs 
osteopontin (OPN), bone sialoprotein (BSP), dentin matrix protein 1 (DMP1), urokinase plasminogen activator (uPA). 
-Adapted from Bellahcène, Akeila, Vincent Castronovo, Kalu U. E. Ogbureke, Larry W. Fisher, und Neal S. 
Fedarko. „Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in 
cancer“. Nature Reviews Cancer 8, Nr. 3 (March 2008): 212–226.- 
 
IV.1.2. Integrin-Gelatinases interaction mediated through PEX binding 
 Brooks et al. also demonstrated that the Hemopexin-like domain (PEX) of MMPs 
represents a fragment with integrin binding activity. In the case of MMP-2 its PEX-fragment 
is forming a complex with the C-terminal of TIMP-2 (tissue inhibitor), which is need for cell-
membrane-associated activation and thereby facilitating matrix degradation and cellular 
invasion
62,63
.  
IV.1.3. Other interaction mechanisms of integrin and Gelatinases 
 Controversially to the PEX and SIBLING approach, Jiao et al. describe a direct 
binding of MMP-2 to the integrin αvβ3 via the C-terminus of active MMP-2 for regulation of 
                                                 
62 P.C. Brooks, S. Strömblad, L.C. Sanders, T.L. von Schalscha, R.T. Aimes, W.G. Stetler Stevenson, et al., Localization of 
matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3, Cell 85 
(1996) 683–693. 
63 P.C. Brooks, S. Silletti, T.L. von Schalscha, M. Friedlander, D.A. Cheresh, Disruption of angiogenesis by PEX, a 
noncatalytic metalloproteinase fragment with integrin binding activity, Cell 92 (1998) 391–400. 
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MMP-2 activation during tumor cell migration and a possible implication of MMP-2 in the 
regulation of integrin αvβ3 recruitment
64
. 
 In the cell-mediated collagen degradation and ECM re-arrangement MMP-2 is said to 
be bound and activated by integrin αvβ3
65
.  
 Nevertheless Nisato et al. denied the binding of the PEX C domain of MMP-2 to 
integrin αvβ3, but show only binding of active MMP-2 to the integrin αvβ3 or the binding of 
pro-MMP-2, in the absence of carrier proteins, to integrin αvβ3 and αvβ5. They deemphasize 
the role of secreted MMPs in in vitro angiogenesis in favor to MT1-MMP
66
, which is 
important for MMP-2 activation though. 
 Concerning MMP-9, Jin et al.
67
 think of a FN- and VN-induced MMP-9 expression 
altering the structure of the ECM surrounding endothelial cells. This is due to the α2β1 and 
αvβ3 integrin-mediated cell adhesion to FN or VN, which activate integrin-dependent 
intracellular signaling cascades that include PI3K (phosphoinositide 3-kinase), ERK  and JNK 
(c-Jun N-terminal kinase), which subsequently leads to the stimulation of AP-1 (activator 
protein-1)-dependent MMP-9 expression in the cell line HUVEC. 
 Other scientists describe that MMP-2 substrate cleavage of fibronectin (FN) and 
vitronectin (VN) influences the integrin receptor αvβ3, which leads to a down regulation of 
MMPs. 
 In the study of Kim et al.
68
 it is shown that saxatilin, a disintegrin, interferes in the 
balance between MMP-9 and its tissue inhibitor TIMP-1 at the transcriptional level.  
                                                 
64 Jiao, Yang, Xue Feng, Yinpeng Zhan, Ruifei Wang, Sheng Zheng, Wenguang Liu, und Xianlu Zeng. „Matrix 
metalloproteinase-2 promotes αvβ3 integrin-mediated adhesion and migration of human melanoma cells by 
cleaving fibronectin“. PloS one 7, Nr. 7 (2012): e41591. 
65 Danhier, Fabienne, Aude Le Breton, und Veronique Preat. „RGD -based strategies to target alpha(v) beta(3) integrin in 
cancer therapy and diagnosis“. Molecular pharmaceutics (September 11, 2012). 
http://www.ncbi.nlm.nih.gov/pubmed/22967287. 
66 Nisato, Riccardo E, Ghamartaj Hosseini, Christian Sirrenberg, Georgina S Butler, Thomas Crabbe, Andrew J P Docherty, 
Matthias Wiesner, u. a. „Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in 
angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 
are critical“. Cancer research 65, Nr. 20 (Oktober 15, 2005): 9377–9387. 
67 Jin, Young-June, Iha Park, In-Kee Hong, Hee-Jung Byun, Jeongsuk Choi, Young-Myeong Kim, und Hansoo Lee. 
„Fibronectin and vitronectin induce AP-1-mediated matrix metalloproteinase-9 expression through integrin 
α(5)β(1)/α(v)β(3)-dependent Akt, ERK and JNK signaling pathways in human umbilical vein endothelial cells“. 
Cellular signalling 23, Nr. 1 (Januar 2011): 125–134. 
68Dong Seok, Ok-Hee Jeon, Hee Doo Lee, Kyung Ho Yoo, und Doo-Sik Kim. „Integrin alphavbeta3-mediated transcriptional 
regulation of TIMP-1 in a human ovarian cancer cell line“. Biochemical and biophysical research communications 
377, Nr. 2 (Dezember 12, 2008): 479–483. 
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 Disintegrins are a family of cysteine-rich proteins, gained from snake venom to serve 
as inhibitors of platelet aggregation during blood coagulation. They are competitive inhibitors 
of the integrin receptors. 
They demonstrated that saxatilin reduces the MMP-9 expression in the human ovarian cancer 
cell line MDAH 2774 at the same time than it induces TIMP-1 expression. Finally, a decrease 
in the activity of MMP-9 can be observed. 
Rolli et al. even describes the cooperation of activated integrin αvβ3 with MMP-9 in the 
regulation of migration of metastatic breast cancer cells. They showed that only breast cancer 
cell variants with active αvβ3 integrin produced mature MMP-9. And only mature MMP-9 
enhanced αvβ3 integrin-dependent breast cancer cell migration
69
.  
This shows the close relationship between the integrin receptor αvβ3 and the ECM degrading 
gelatinases (MMP-2 & MMP-9) in cancer development, but also in inflammation. Thus, they 
both represent an attractive target for cancer research and clinics.  
                                                 
69 Rolli, Melanie, Emilia Fransvea, Jan Pilch, Alan Saven, und Brunhilde Felding-Habermann. „Activated integrin 
alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells“. 
Proceedings of the National Academy of Sciences of the United States of America 100, Nr. 16 (August 5, 2003): 
9482–9487. 
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V. Molecules for targeting and optical 
imaging of cancer 
 
 A variety of targeted and activatable imaging probes are massively being developed 
aiming at improving early cancers detection or other pathological situation such as 
inflammation. Different types of contrast agents can be attached to the targeting part of the 
molecules which can be detected by different physical means like X-ray and computed 
tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US), positron 
emission tomography (PET) or single photon emission computed tomography (SPECT). 
When optical imaging is concerned, we must use biocompatible near-infrared fluorophores as 
contrast agent.  
V.1. Choice of the Near-infrared window for in vivo optical imaging 
 
 Fluorescence imaging is a technique using photons as information source. This 
technique is already well-known in in vitro applications, especially in the biomedical domain 
on the molecular (DNA, proteins) or cellular level (flow cytometry, histological labeling). In 
vivo, good preclinical results have been reported, but in the clinic it is little used because of 
lack of tracers. An important point to mention is the regulatory context of tracers used in 
human clinic concerning legal and safety aspects. 
 Optical fluorescence imaging represents a non invasive, fast, cheap and very sensitive 
method, with major limits concerning its weak spatial resolution and the limited detection in 
depth. It is complementary to other imaging techniques like MRI and PET or SPECT
70
. 
The principle of fluorescence optical imaging corresponds to the optical contrast gained by 
collection of altered irradiated light after exposure to certain light sources like laser, LED or 
Xenon. 
 In order to use this imaging technique for medical imaging in patients, certain 
constraints due to the tissue limiting its application in vivo had to be minimized.  
These limits comprise light scattering during biological tissue penetration, which causes a 
strong loss in intensity and information for the exact localization of the fluorophore in the 
organism. Another loss in the fluorophore’s intensity is the absorption of the light of 
                                                 
70 De Grand, A.M., und JV Frangioni. „An operational near-infrared fluorescence imaging system proyotype for large animal 
surgery“. Technol Cancer Res Treat. 2, 2003. 
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excitation and emission. Furthermore natural fluorescence (called auto-fluorescence) of 
substances in the tissue, like porphyrines, strongly decreases the contrast. The sensitivity is 
not only compromised by autofluorescence, but also from nonspecifically or unbound probes, 
referred to as reagent background or nonspecific signal.  
 
 Autofluorescence caused by cells, tissues and biological fluids signal distortion is 
minimized either by using selective filters or by using probes that can be excited at more than 
500 nm. 
Conventional fluorescent techniques, which use probes in the visible light spectrum (400-600 
nm), thus have a spectrum associated with a relatively high level of nonspecific background 
light, resulting in a low SBR (signal-to-background-ratio). Light absorption by hemoglobin in 
the visible light spectrum (< 600 nm) and other components (e.g., water and lipids) in the 
infrared range (> 900 nm), offers an optical imaging window from approximately 650-900 
nm. Hence at these wavelengths, in the near-infrared (NIR), the absorption coefficient of 
tissue is at a minimum (see Figure V-1).  
At the same time, light scattering by dense media is also reduced in longer wavelengths, 
resulting in a greater penetration of the excitation light in the NIR. At the same time auto-
fluorescence is minimal in the NIR window, improving the contrast (Figure V-2). 
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Figure V-1: Absorption in tissue. 
 
 
 
 
 
  
Figure V-2: Autofluoresence of mouse organs under different optical conditions. 
The autofluoresence of the tissues has been imaged by using three different filter combinations (excitation/emission): 
Blue/green (460-550 nm/505-560 nm), green/red (525-555 nm/590-650 nm) and near infra-red (725-775 nm/790-830 nm). 
All images have been normalized the same way. 
(GB: gall bladder, SI: intestines, Bl: Bladder) 
-After Frangioni, 2003- 
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V.2. Basic principles of Fluorescence 
 Fluorescence is the emission of light by a substance that absorbed light or other 
electromagnetic radiation
71,72
.  
 
The genesis of fluorescence is described by the Jablonski diagram (Figure V-3): 
 
 
 
 
 
 
 
 
 
 
 
 
 This diagram illustrates the electronic states of a molecule and the transitions between 
them. At first is the excitation (1) of an electron: A photon of energy hνEX is supplied by an 
external source such as an incandescent lamp or a laser. This energy is absorbed by the 
fluorophore, creating an excited electronic singlet state (S1'). In the second stage, the so called 
excited-state lifetime (2), the excited state exists for a finite time (typically 1–10 
nanoseconds). During this time, the fluorophore undergoes conformational changes and is 
also subject to a multitude of possible interactions with its molecular environment. These 
processes have two important consequences. First, the energy of S1' is partially dissipated, 
yielding a relaxed singlet excited state (S1) from which fluorescence emission originates. 
Second, not all the molecules initially excited by absorption (Stage 1) return to the ground 
state (S0) by fluorescence emission. Other processes such as collisional quenching, Förster 
resonance energy transfer (FRET) and intersystem crossing may also depopulate S1.  
 The fluorescence quantum yield, which is the ratio of the number of fluorescence 
photons emitted (Stage 3) to the number of photons absorbed (Stage 1), is a measure of the 
relative extent to which these processes occur. 
                                                 
71 Brand, L and Johnson, M.L., Eds., Fluorescence Spectroscopy (Methods in Enzymology, Volume 450), Academic Press 
(2008). 
72 Kobayashi, H., Ogawa, M., Alford, R., Choyke, P.L and Urano, Y., “New strategies for fluorescent probe design in 
medical diagnostic imaging,” Chem Rev (2010) 110:2620–2640. 
 
Figure V-3: The Jablonski diagram illustrates the processes of optical absorption and subsequent 
emission of fluorescence. 
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 The third stage described the Fluorescence Emission (3): A photon of energy hνEM is 
emitted, returning the fluorophore to its ground state S0. Due to energy dissipation during the 
excited-state lifetime (internal conversion and vibrational relaxation), the energy of this 
photon is lower, and therefore of longer wavelength than the excitation photon hνEX. The 
difference in energy or wavelength represented by (hνEX – hνEM) is called the Stokes shift.  
 This explains why the energy of fluorescent photons is always less than that of the 
exciting photons 
 Fluorescence molecules or fluorophores have the property that one and the same can 
be excited and detected a couple of times unless it has not been destroyed irreversibly in the 
excited state (photobleaching).  
 
V.2.1. Extinction coefficient (EC) and quantum yield (QY) 
 While fluorophores are characterized by their proper wavelength range, Stokes shift 
and spectral bandwidth, fluorescence intensity per dye molecule is proportional to the product 
of extinction coefficient (EC) and quantum yield (QY) (Table V-1). The fluorescence output 
of a given dye depends on the efficiency with which it absorbs and emits photons, and its 
ability to undergo repeated excitation/emission cycles. Absorption and emission efficiencies 
can be quantified in terms of the molar EC for absorption and the QY for fluorescence. Both 
are constants under specific environmental conditions. The value of EC is specified at a single 
wavelength (usually the absorption maximum), whereas QY is a measure of the total photon 
emission over the entire fluorescence spectral profile. The range of these parameters among 
organic dye and autofluorescent protein fluorophores is approximately 5000 to  
200,000 cm-1M-1 for EC and 0.05 to 1.0 for QY. 
 
V.2.2. Quenching and FRET 
 Fluorophore-Fluorophore interactions, also called fluorescence quenching, represents 
a biomolecular process reducing the fluorescence QY without changing the fluorescence 
emission spectrum. This occurs due to transient excited-state interactions (collisional 
quenching), or by so called self-quenching, which is the quenching of one fluorophore by 
another. This can happen in the case of high loading density of a polymer with numerous 
copies of a fluorescent molecule. This is very often used to generate the so called “smart-
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probes” that contain fluorophores separated by a labile, cleavable function. These probes will 
be unpacked after they encounter a particular enzyme or physico-chemical conditions that will 
cut them in pieces thus releasing un-quenched fluorophores (Figure V-4). They can thus yield 
particularly high tumor/background signal ratios because of their non detectability in the 
native state. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Förster (also called Fluorescence) resonance energy transfer (FRET) is based on the 
through-space dipolar transfer of excited-state energy to acceptor molecules up to 75 Å 
removed from the donor fluorophore
73,74
(Figure V-5). 
  
                                                 
73 Royer, C.A., "Approaches to teaching fluorescence spectroscopy," Biophys J (1995) 68:1191–1195. 
74 Lakowicz, J.R., Principles of Fluorescence Spectroscopy, Third Edition, Springer (2006). 
Figure V-4: Protease-activatable fluorescence imaging probe. 
A) Schematic diagram of probe activation. The initial proximity of fluorochrome molecules to each other results in 
signal quenching. 
B) NIRF image (top) and bright light image (bottom) with nonactivated (left) and activated (right) probe. 
C) Chemical structure of repeating garft copolymer segment indicating quenching of Cy and enzymatic degradation 
site (green arrow). 
-After:  Mahmood, Umar, Ching-Hsuan Tung, Alexei Bogdanov, und Ralph Weissleder. „Near-Infrared Optical Imaging 
of Protease Activity for Tumor Detection1“. Radiology 213, Nr. 3 (Januar 12, 1999): 866–870.- 
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Figure V-5: Jablonski diagram - Principle of the Förster Resonance Energy Transfer (FRET). 
Figure V-6: Structure of activatable fluorescent KLA-containing conjugate. 
-Foillard, Stéphanie, Lucie Sancey, Jean-Luc Coll, Didier Boturyn, und Pascal Dumy. „Targeted delivery of 
activatable fluorescent pro-apoptotic peptide into live cells“. Organic & biomolecular chemistry 7, Nr. 2 
(Januar 21, 2009): 221–224.- 
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 Thus, FRET-based probes are providing additional information when compared to 
“self-quenched” ones, since we can follow the initial molecule as well as its two degradation 
products using spectral unmixing methods.  
Amongst others, this was demonstrated by Foillard et al. using the FRET effect for validation 
of an integrin targeting molecule cleavable by enzymes and thus releasing a moiety of the 
compound, which could be follow up in vitro
75
 (Figure V-6).  
 Other environmental factors with an impact on the fluorescent properties are the 
solvent polarity (solvent in this context includes interior regions of cells, proteins, membranes 
and other biomolecular structures), the proximity and concentration of quenching species and 
the pH of the aqueous medium. 
These characteristics are important for the comprehension of fluorescence used (Table V-1). 
  
                                                 
75 Foillard, Stéphanie, Zhao-hui Jin, Elisabeth Garanger, Didier Boturyn, Marie-Christine Favrot, Jean-Luc Coll, und Pascal 
Dumy. „Synthesis and biological characterisation of targeted pro-apoptotic peptide“. Chembiochem: a European 
journal of chemical biology 9, Nr. 14 (September 22, 2008): 2326–2332. 
 
Optical-guided surgery & development of SMARgeting probes for cancer                                                                  Introduction 
- 39 - 
 
Property Definition Significance 
Fluorescence 
excitation spectrum 
An X,Y plot of excitation 
wavelength versus number of 
fluorescence photons generated 
by a fluorophore. 
Optimum instrument setup should deliver 
excitation light as close to the peak of the 
excitation spectrum of the fluorophore as possible. 
 
Absorption spectrum 
An X,Y plot of wavelength 
versus absorbance of a 
fluorophore. 
To a first approximation, the absorption spectrum 
of a fluorophore is equivalent to the fluorescence 
excitation spectrum.* To the extent that this 
approximation holds, the absorption spectrum can 
be used as a surrogate for the fluorescence 
excitation spectrum. 
 
Fluorescence emission 
spectrum 
An X,Y plot of emission 
wavelength versus number of 
fluorescence photons generated 
by a fluorophore. 
Fluorescence emission spectral discrimination is 
the most straightforward basis for multiplex 
detection ‡ and for resolving probe fluorescence 
from background autofluorescence. 
 
Extinction coefficient (EC) 
Capacity for light absorption at a 
specific wavelength.§ 
Fluorescence output per fluorophore 
(“brightness”) is proportional to the product of the 
extinction coefficient (at the relevant excitation 
wavelength) and the fluorescence quantum yield. 
 
Fluorescence quantum yield 
(QY = Ф) 
Number of fluorescence photons 
emitted per excitation photon 
absorbed. 
See “Extinction coefficient.” 
 
 
 
Quenching 
Loss of fluorescence signal due 
to short-range interactions 
between the fluorophore and the 
local molecular environment, 
including other fluorophores 
(self-quenching). 
Loss of fluorescence is reversible to the extent that 
the causative molecular interactions can be 
controlled.** 
 
 
 
Photobleaching 
Destruction of the excited 
fluorophore due to 
photosensitized generation of 
reactive oxygen species (ROS), 
particularly singlet oxygen 
(
1
O2). 
Loss of fluorescence signal is irreversible if the 
bleached fluorophore population is not replenished 
(e.g., via diffusion). Extent of photobleaching is 
dependent on the duration and intensity of 
exposure to excitation light. 
The most effective remedy for photobleaching is 
to maximize detection sensitivity, which allows 
the excitation intensity to be reduced. Detection 
sensitivity is enhanced by low-light detection 
devices such as CCD cameras, as well as by high–
numerical aperture objectives and the widest 
bandpass emission filters compatible with 
satisfactory signal isolation. 
 
* Generally true for single fluorophore species in homogeneous solutions but not in more complex heterogeneous samples. 
‡ Multiplex detection refers to the process of simultaneously labeling a specimen with two or more fluorescent probes to allow 
correlation of multiple structural or functional features.  As well as specific association with their targets, the probes must have 
distinctive spectroscopic properties that can be discriminated by the detection instrument. 
§ EC (units: cm-1 M-1) is defined by the Beer-Lambert law A=EC•c•l, where A = absorbance, c = molar concentration, l = optical 
pathlength. 
** In the case of self-quenching, this can be accomplished by disruption of fluorophore compartmentalization, denaturation or 
fragmentation of biopolymer conjugates, or functionalization of the fluorophore to produce increased electrostatic repulsion and water 
solubility. 
Table V-1: Spectroscopic properties of fluorescent dyes. 
-adapted after invitogen.com- 
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V.3. Imaging probes for NIR imaging of cancer 
 Using fluorescence for imaging can be achieved either by the intrinsic properties of 
the tissue (label-free methods, not discussed here) or using exogenous optically active 
reporter molecules, targeting or not a defined biomarker
76
.  
So, analogous to radio-labeled agents, optical imaging probes can be non-specific or targeted.  
V.3.1. Non-specific agents 
 There are currently some non-specific agents available for research and clinical use, 
like fluorescein, indocyanine green (ICG), cresyl violet acetate, toluidine blue or Lugols’s 
iodine. 
Today only the two fluorescent markers, fluorescein and ICG, are available for injection in 
human.  
 Fluorescein can be functionalized but is easily bleached and emits light in the same 
wavelength as biological tissue’s autofluorescence. Only ICG, with an emission peak at 830 
nm, has optical properties that are suitable for NIR imaging, but cannot be functionalized 
because all the reactive chemical functions eventually accessible had been removed to 
generate this injectable form of ICG.   
It has been used for imaging angiogenesis and identification of hepatic segments for 
facilitation of hepatic resection
77,78
 and approaches have also been made in sentinel lymph 
node mapping (described in chapter IX, page - 78 -). 
In view of the non-specificity towards tumors these agents cannot help to determine the tumor 
margins, although certain applications are described in particular for liver cancer due to the 
disordered biliary excretion of ICG in cancer tissues and noncancerous liver tissues 
compressed by the tumor
79
. 
V.3.2. Specific agents 
 Several characteristics of cancer have been taken in consideration as probe targets, for 
example increased growth and growth factor signaling receptors, limitless replicative 
                                                 
76 Rosenthal, E., and K.R. Zinn. In Optical Imaging of Cancer: Clinical Applications, Springer 2009. 
77 Pierce, M.C., D.J. Jvier, and R. Richards-Kortum. “Optical Contrast Agents and Imaging Systems for Detection and 
Diagnosis of Cancer.” Int J Cancer. 123, 2008.1979-1990. 
78 Aoki, T., D. Yasuda, Y. Shimizu, et al. “Image-guided Liver Mapping Using Fluorescence Navigation System with 
Indocyanine Green for Anatomical Hepatic Resection.” World J Surg. 32, n.d., sec. 2008.1763-1767. 
79 Ishizawa, T., N. Fukushima, J. Shibahara, et al. “Real-time Identification of Liver Cancers by Using Indocyanine Green 
Fluorescent Imaging.” Cancer. 115, 2009.2491-2504. 
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potential, sustained angiogenesis, and increased proteolytic activity resulting in tissue 
invasion and metastasis (Figure V-7)
80
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Activatable or smart probes 
 
 Because of their differential expression in disease, proteases could be used to 
selectively deliver therapeutic or imaging agents. Proteases-activated prodrugs, 
nanotechnology – based drug delivery systems, hydrogels, gene delivery systems and imaging 
systems have been described for disease applications
81
. 
 Concerning cancer another approach based on this knowledge is to exploit the 
characteristics of the tumor in using activatable “smart” probes, which are cleaved by 
overexpressed proteolytic enzymes. Combining target and function, these molecules could be 
                                                 
80 Keereweer, S., J.D.F. Kerrebijn, P.B.A.A. van Driel, B. Xie, E.L. Kaijzel, T.J.A. Snoeks, I. Que, et al. “Optical Image-
guided Surgery - Where Do We Stand?” Mol Imaging Biol. 13, 2011. 199-207. 
81 Cudic, Mare, und Gregg B Fields. „Extracellular proteases as targets for drug development“. Current protein & peptide 
science 10, Nr. 4 (August 2009): 297–307. 
Figure V-7: Hallmarks of cancer and their targets for optical imaging. 
EGF epidermal growth factor, cRGD cyclic arginine-glycineaspartate, VEGF vascular endothelial growth 
factor, NIRF near-infrared fluorescence. 
-Hanahan, D., and RA Weinberg. “The Hallmarks of Cancer.” Cell. 100, 2000. 57-70- 
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used for the in vivo analysis of drug efficacy, pharmacodynamic properties and cancer 
detection.  
 The principle of activatable probes is a molecule showing little fluorescence at the 
time of administration (quenched or inactivated) and in presence of the targeted protease they 
are cleaved and thus gain in fluorescence intensity (Figure V-8)
82
. This allows the detection of 
proteases which can be associated with certain specific characteristics of the malignant tissue, 
e.g. invasive, aggressive or metastatic tendency of the tumor.  
 These probes lead to a higher SBR compared to nonspecific probes. For this reason 
such cleavable probes, activated by cathepsins and matrix metalloproteases (MMP) have been 
developed by Weissleder et al
83,84,85
.This type of smart contrast agent was used in conjunction 
with endoscopic imaging, demonstrating identification of colonic adenocarcinoma in a murine 
model, using a probe cleavable by cathepsin-B
86
.  
Even though in general showing reduced background signal (higher SBR), some non specific 
cleavage or degradation can occur, showing residual background noise. 
 The developed smart-agents are currently commercially available (Visen Medical, 
Boston, MA, USA). Another quenching approach for MMP detection is described by Tsien et 
al
87
, using activatable polyarginine-based cell-penetrating peptides made of negatively 
charged residues as inhibitory domain. 
 
 
 
 
 
 
 
                                                 
82 Ntziachristos, Vasilis. „Fluorescence molecular imaging“. Annual review of biomedical engineering 8 (2006): 1–33. 
83 Mahmood, U., and R. Weissleder. “Near-infrared Optical Imaging of Proteases in Cancer.” Mol Cancer Ther. 2, 2003.489-
496. 
84 Wunderbaldinger, P., K. Turetschek, and C. Bremer. “Near-infrared Fluorescence Imaging of Lymph Nodes Using a New 
Enzyme Sensing Activatable Macromolecular Optical Probe.” Eur Radiol. 13, 2003.2206-2211. 
85 Dufort, S, L Sancey, C Wenk, V Josserand, und J L Coll. „Optical small animal imaging in the drug discovery process“. 
Biochimica et biophysica acta 1798, Nr. 12 (Dezember 2010): 2266–2273. 
86 Alencar H, Funovics MA, Figueiredo J, Sawaya H, Weissleder R, Mahmood U. Colonic adenocarcinomas: Near-infrared 
microcatheter imaging of smart probes for early detection – Study in mice. Radiology. 2007; 244:232–238. 
87 Jiang, T., E.S. Olson, Q.T. Nguyen, M. Roy, P.A. Jennings, and R.Y. Tsien. “Tumor Imaging by Means of Proteolytic 
Activation of Cell-penetrating Peptides.” Proc Natl Acad Sci USA. 101, 2004.17867-17872. 
Figure V-8: Principle of enzyme detection via the disruption of intramolecular self-quenching.  
Enzyme-catalyzed hydrolysis of the heavily labeled and almost totally quenched substrates relieves the 
intramolecular self-quenching, yielding brightly fluorescent reaction products. 
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 Anyhow, these targeting molecules lack cancer specificity as in the case of cathepsins 
and MMPs, the enzymes aimed at are also products of macrophages and neutrophils, which 
represent hallmarks of inflammation
88
 and cerebral ischemia
89
.  
The difficulties of MMP targeting and definition of MMP smart probes are described later on 
in detail. 
 Another approach is a quenched-probe system which has been used to detect specific 
nucleic acid sequences. It uses an oligonucleotide in a stem-loop hairpin configuration, with a 
fluorescent reporter and quencher conjugated to opposite ends (Figure V-9). When hybridized 
to the complementary target sequence, the hairpin opens, producing a fluorescent state
90
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                 
88 Wunder, A., R.H. Straub, S. Gay, J. Funk, and U. Muller-Ladner. “Molecular Imaging: Novel Tools in Visualizing 
Rheumatoid Arthritis.” Rheumatology. (Oxford) 44, 2009.1341-1349. 
89 Klohs, J., N. Baeva, J. Steinbrink, et al. “In Vivo Near-infrared Fluorescence Imaging of Matrix Metalloproteinase Activity 
After Cerebral Ischemia.” J Cereb Blood Flow Metab, 2009.1284-1292. 
90Optical contrast agents and imaging systems for detection anddiagnosis of cancer; Mark C. Pierce, David J. Javier, and 
Rebecca Richards-Kortum Int J Cancer. 2008 November 1; 123(9): 1979–1990. 
Figure V-9: Five classes of molecular-specific optical contrast agent. 
From left to right in order of increasing size: Small molecules including glucose and peptides can be 
functionalized with fluorescent dyes. Aptamers can be designed to form activatable “smart probes”, with 
fluorescence quenched until target binding. Antibody probes are generally functionalized with fluorescent 
dyes in the Fc domain. Targeting molecules can be coupled to nanoparticlebased optical reporters, 
including gold nanoparticles and quantum dots. 
-Pierce et al. Int J Cancer. 2008 November 1; 123(9): 1979–1990.- 
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 Targeting probes 
 
 Apart from targeting proteases overexpressed by tumor cells, the increased 
metabolism and the expression of growth signaling receptors as well as angiogenesis are 
features of tumor cells that are exploited for the design of targeting NIR probes (Figure V-10). 
Here a fluorophore is engrafted onto a specific ligand or monoclonal antibody. The advantage 
of such agents is their excellent SBR in whole animals and the longer period of image 
collection compared to the short-lived radiotracers labeled with fluorine-18 or carbon-11.  
 To mention some examples, several groups have described the use of various 
monoclonal antibodies coupled to fluorophores for the imaging of the epidermal growth factor 
(EGF) receptor, Her2/neu receptor or the VEGF receptor (all of them enforced expressed 
growth factor receptors) in all kinds of different tumors
91,92,93
. The same principle but with a 
quenched fluorophore has been described by Kobayashi et al.
94
, which used avidin (targeting 
the d-galactose receptor) and trastuzumab (HER2 mAb) labeled with the TAMRA 
(fluorophore)-QSY7 (quencher) pair. Here, the probe is dequenched by cleavage after 
internalization into the cell, resulting in target-specific fluorescence imaging with high SBR. 
Another approach is mimicking ligands to target specific receptors. This is the case of the 
already described cyclic arginine-glycine-aspartate (cRGD) motif conjugated to 
fluorophores
95
, which are used to detect their receptor (αvβ3) integrin.  
 One approach in this sense is the direct visual detection of the increases αvβ3 
expression by binding of a small peptidomimetic antagonist coupled to a NIR fluorescent dye 
(VivoTag-S680), known as Integri-Sense (Visen Medical, Boston, MA, USA). It was shown 
to co-localize at the surface of both αvβ3 integrin positive endothelial and tumor cells. The 
signal is additionally enhanced by the internalization into αvβ3 integrin positive tumor cells, 
leading to a slower clearance of the probe from tumors compared to surrounding tissues
96
. 
This probe has been used to visualize liver metastasis from colon cancer in a rat model. 
                                                 
91 Gleysteen, J.P., R.D. Duncan, J.S. Magnuson, J.B. Skipper, K.R. Zinn, and E. Rosenthal. “Fluorescently Labeled 
Cetuximab to Evaluate Head and Neck Cancer Response to Treatment.” Cancer Biol Ther. 6, 2007.1181-1185. 
92 Lee, S.B., M. Hassan, R. Fisher, et al. “Affibody Molecules for in Vivo Characterization Oh HER2-positive Tumors by 
Near-infrared Imaging.” Clin Cancer Res. 14, 2008.3840-3849. 
93 Withrow, K.P., J.R. Newman, J.B. Skipper, et al. “Assessment of Bevacizumab Conjugated to Cy5.5 for Detection of Head 
and Neck Cancer Xenografts.” Technol Cancer Res Treat. 7, 2008.61-66. 
94 Ogawa, M., N. Kosaka, M.R. Longmire, Y. Urano, P.L. Choyke, and H. Kobayashi. “Fluorophore-quencher Based 
Activatable Targeted Optical Probes for Detecting in Vivo.” Mol Pharm. 6(2), 2009.386-395. 
95 Chen, K., J. Xie, and X. Chen. “RGD-human Serum Albumin Conjugates as Efficient Tumor Targeting Probes.” Mol 
Imaging. 8, 2009.65-73. 
96 Kossodo, S., M. Pickarski, S.A. Lin, et al. “Dual in Vivo Quantification of Integrin-targeted and Protease-activated Agents 
in Cancer Using Fluorescence Molecular Tomography (FMT).” Mol Imaging Biol., 2009. 
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Mieog & Hutteman et al.
97
 showed here that liver metastases could be delineated in spite of 
the normally high background signal in liver, kidneys, and bladder, which are the organs of 
clearance of the agent.  
 The use of the quenching technique has been described by our team in this respect as 
well, by means of the quenched cRGD molecule (RAFTc(-RGDfK-)(4)-Cy5-SS-Q), which 
becomes activated upon internalization into the cell
98
. 
Other ideas are based on the modification of tracers of other imaging technologies. Here, 
targeting probes of imaging technologies such as PET imaging are varied by conjugating 
them with a fluororophore for optical imaging. This is the case in a study of intracranial 
glioma, using glucose analog 2-deoxyglucose with IRDye800CW which targets the enforced 
expressed membrane glucose transporter protein GLUT
99
. 
 
 
                                                 
97 Mieog, J. Sven D., Susan L. Troyan, Merlijn Hutteman, Kevin J. Donohoe, Joost R. van der Vorst, Alan Stockdale, Gerrit-
Jan Liefers, u. a. „Toward Optimization of Imaging System and Lymphatic Tracer for Near-Infrared Fluorescent 
Sentinel Lymph Node Mapping in Breast Cancer“. Ann Surg Oncol. 18, 2011. 
98 Jin, Z.H., J. Razkin, V. Josserand, et al. “In Vivo Noninvasive Optical Imaging of Receptor-mediated RGD Internalization 
Using Self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4).” Mol Imaging. 6, 2007.43-55. 
99 Zhou, H., K. Luby-Phelps, B.E. Mickey, A.A. Habib, R.P. Mason, and D. Zhao. “Dynamic Near-infred Optical Imaging of 
2-deoxyglucose Uptake by Intracranial Glioma of Athymic Mice.” PLoS ONE. 4, 2009.e8051 
Figure V-10: Hallmarks of cancer and their targets for optical imaging. 
-After Keereweer, S, H J C M Sterenborg, J D F Kerrebijn, P B A A Van Driel, R J Baatenburg de Jong, und C W G M 
Löwik. „Image-guided surgery in head and neck cancer: current practice and future directions of optical imaging“. Head & 
neck 34, Nr. 1 (Januar 2012): 120–126.- 
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 Apart from ordinary molecules like peptides or glucoses, there exist nanoparticles.  
This subject will be presented at a short glance, as it is far too large for detailed explanation 
within my thesis. 
 
 Nanoparticles 
 
 Quantum dot nanoparticles are small crystals (2–10 nm diameter), made of inorganic 
semiconductor materials. The high quantum yields result in high signal intensity, enabling 
detection at lower concentrations compared to organic fluorophores. In addition, the 
fluorescence emission spectra can be tuned, depending on their size, allowing for multiplexed 
imaging. Furthermore, quantum dot nanoparticles have proven to be photostable and have the 
possibility to target multiple biomarkers, due to their ability to contain multiple probe 
molecules. Finally, multimodal targeted quantum dot-based nanoparticles coated with 
paramagnetic micellar shells have been described, allowing for both optical and magnetic 
resonance detection of tumor angiogenesis
100
. However, the toxicity of quantum dot 
nanoparticles is a serious concern. The problem is that most quantum dots are based on heavy 
metal cores (e.g., Cd-Se, Cd-Te), which have been reported to be cytotoxic in their soluble 
form due to the release of toxic Cd2+ ions and their surface chemistry and stability towards 
aggregation
101
. These issues raise significant hazards concerning the feasibility of the clinical 
application of quantum dot nanoparticles. 
 Silica nanoparticles have been developed as an alternative to quantum dots that 
combine the versatility and functionality of organic dyes with the stability and 
biocompatibility of the silica surface
102
. The biodistribution, including long-term quantitative 
tissue distribution, subcellular distribution, and the toxicity of silica nanoparticles were 
assessed in a mouse model. The results show an accumulation of the agent in lungs, liver, and 
spleen, because the small size of the silica nanoparticles which results in high permeability, 
potentially causing liver injury when intravenously injected
103
. Size, surface area, surface 
                                                 
100 Mulder, W.J., K. Castermans, J.R. van Beijnum, et al. “Molecular Imaging of Tumor Angiogenesis Using Alphavbeta3-
integrin Targeted Multimodal Quantum Dots.” Angiogenesis. 12, 2009.17-24. 
101 Kirchner, C., T. Liedl, S. Kudera, et al. “Cytotxicity of Colloidal CdSe and CdSe/ZnS Nanoparticles.” Nano Lett. 5, 
2005.331-338;  Lewinski, N., V. Colvin, and R. Drezek. “Cytotoxicity of Nanoparticles.” Small. 4, 2008.26-49. 
102 Choi, J., A.A. Burns, R.M. Williams, et al. “Core-shell Silica Nanoparticles as Fluorescent Labels for Nanomedicine.” J 
Biomed Opt. 12, 2007.064007. 
103 Xie, G., J. Sun, G. Zhong, L. Shi, and D. Zhang. “Biodistribution and Toxicity of Intravenously Administered Silica 
Nanoparticles in Mice.” Arch Toxicol. 84(3), 2009.183-190. 
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chemistry, solubility, and shape are probably all key features that play a role in determining 
the harmful potential for engineered nano-materials
104
.  
 
V.3.3. Double targeting 
 Up to now NIR fluorogenic probes do have potential for in vivo imaging, but in 
regards to their pharmacokinetic profile, the molecule stability or the non-specific 
degradation, leading to a high background noise improvements for their application have to be 
made. Concerning activatable probes, there are only limited platforms available, which can 
clearly image proteases’ activity in vivo after systemic administration, but most systems do 
show their proof-of-concept in vitro and ex vivo. The design of activatable probes needs also 
an increase in stability of the molecule as well as of the specificity of the molecule towards its 
target
105
.  
 Chemical attempts of improving either the molecule stability or the targeting 
specificity were made by using polymeric nanoparticles
106
or using PEGylated poly(L-
lysine)
107
. These are promising concepts, based mainly on the passive accumulation in the 
tumor tissue, the so called EPR (enhanced permeability retention) effect. Nevertheless, it is 
presumed that substrate sensitivity is decreased due to the high molecular weight polymer 
backbone, and the probably false fluorescence signals in vivo caused by the nonspecific EPR 
effect.  
 So another idea emerged: the combination of a relatively stable ligand with a second 
target or activatable sequence. This should lead to an increase in the specificity towards the 
cancer environment. The combination of two targets would also allow a design of molecules 
suitable for imaging and drug delivery. In the case of activatable sequences these molecules 
would offer the possibility to evaluate them by imaging methods and then serving as pro-drug 
vehicles.  
                                                 
104 Oberdorster, G., E. Oberdorster, and J. Oberdorster. “Nanotoxicology: An Emerging Discipline Evolving from Studies of 
Ultrafine Particles.” Environ Health Perspect. 113, 2005.823-839. 
105 Zhu, Lei, Jin Xie, Magdalena Swierczewska, Fan Zhang, Xin Lin, Xuexun Fang, Gang Niu, Seulki Lee, und Xiaoyuan 
Chen. „Dual-functional, receptor-targeted fluorogenic probe for in vivo imaging of extracellular protease 
expressions“. Bioconjugate chemistry 22, Nr. 6 (Juni 15, 2011): 1001–1005. 
106 Lee, S., Cha, E. J., Park, K., Lee, S. Y., Hong, J. K., Sun, I. C., Kim, S. Y., Choi, K., Kwon, I. C., Kim, K., and Ahn, C. H. 
(2008) A nearinfrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and 
protease activity determination. Angew. Chem., Int. Ed. Engl. 47, 2804–2807. 
107 Bremer, C., Tung, C. H., and Weissleder, R. (2001) In vivo molecular target assessment of matrix metalloproteinase 
inhibition. Nat. Med. 7, 743–748. 
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 For example Choi et al. conjugated multiple c(RGDfK) peptides to HSA-TIMP2 (HAS 
= human serum albumin) to enhance the binding capacity of the protein (RGD-HSA-TIMP2) 
to tumors and their vasculatures. In form of 
68
Ga-NOTA-RGD-HSA-TIMP2 they have been 
studied as potential PET probes for imaging αvβ3 integrin receptors in nude mice bearing 
human glioblastoma U87MG tumors
108
. 
 Kratz et al. describes studies of pro-drugs based on Doxorubicin conjugated to a 
divalent integrin targeting peptide E-[c(RGDfK)2], where a MMP-2/-9-cleavable octapeptide 
was introduced. The results show that the tumor inhibition capacity of the compound with 
MMP sequence was 6- to 10-fold higher compared to the control molecule in vitro
109
. 
The combination between the integrin αvβ3 and the Gelatinases seems to be a good approach 
for double targeting with an improvement in specific targeting of tumor. 
V.3.4. The integrin ligand RGD 
V.3.5. Integrin αvβ3 and the RGD 
 As described earlier the integrin αvβ3 is known to play an important role in 
angiogenesis
110
.  
The repertoire of ligands of the receptor integrin αvβ3 comprises a numerous proteins bearing 
an exposed or cryptic RGD tripeptide. Amongst these there are vitronectin, fibronectin, 
fibrinogen, thrombospondin, ostepontin, von Willebrand factor, and others. The development 
of the angiogenesis inhibitor Cilengitide was based on these findings (Figure V-11). 
RGD-based targeting has been successfully used to deliver drugs, biological
111
, imaging 
agents
112
, viruses
113
, and nanoparticles
114
 to tumor vasculature
115
.  
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 Ligands of the integrin αvβ3 
 
 The motif –RGD- (Arginine – Glycine – Aspartic acid) is a tripeptide represented in 
most proteins of the extracellular matrix. Being recognized by and interacting with at least 
half of the integrins, the affinity of the receptor for the substrate differs. Here the substrate 
specificity depends on the RGD conformation in the protein, as well as on the residual 
sequences. The endogene ligand of the αvβ3 integrin is the vitronectin. Nevertheless a binding 
to other proteins via the RGD is possible, as in the case of fibronectine, fibrinogene, 
collagene, von Willebrand factor and thrombospondin.  
 Consequently, different approaches of RGD containing peptides with integrin αvβ3 
specificity have been made (Figure V-11), ranging from linear RGD peptide sequences, cyclic 
RGD molecules, monomeric to multimeric RGD-based systems, RGD-based Semipeptides to 
nanoparticles, which are discussed in detail by Casiraghi et al
116
. 
Indeed cyclization is employed to improve the binding properties of RGD peptides conferring 
rigidity to the structure, providing a better presentation of the ligand (Figure V-12), and 
higher stability. Since the natural interactions between the αvβ3 integrin and RGD substrates 
may involve multivalent binding sites, the affinity is increased by multivalent cRGD 
presentation. 
 
  
                                                 
116 Auzzas, L, F Zanardi, L Battistini, P Burreddu, P Carta, G Rassu, C Curti, and G Casiraghi. “Targeting Alphavbeta3 
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Medicinal Chemistry 17, no. 13 (2010): 1255–1299. 
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Figure V-11: Chemical structures based on the RGD motif. 
A. The original RGD sequence; B. Cyclic RGD-peptide antagonist (c(RGDf[N-Me]V) or Cilengitide; 
C.Cyclic peptide c(RGDfK); D. ACDCRGDCFCG (RGD4C); E. Example of  
RGD peptidomimetic-containing the RGD sequence (S-247); F. Example of RGD-peptidomimetic; 
-After: Danhier, Fabienne, Aude Le Breton, und Veronique Preat. „RGD -based strategies to target alpha(v) beta(3) integrin 
in cancer therapy and diagnosis“.Molecular pharmaceutics (September 11, 2012).- 
 
 
 
 
 
Figure V-12: Representation of the extracellular domain structure of the integrin αvβ3, associated to the 
ligand  c[-RGDf(N-Me)V-] in presence of Mn
2+
.
 
Different kinds of illustrting the crystal structure in A) and  B) 
 
-Modified after: Xiong, Jian-Ping, Thilo Stehle, Rongguang Zhang, Andrzej Joachimiak, Matthias Frech, Simon L Goodman, 
und M Amin Arnaout. „Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-
Asp ligand“. Science (New York, N.Y.) 296, Nr. 5565 (April 5, 2002): 151–155.- 
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 cyclic RGD penta-peptides 
 
 As linear RGD containing sequences did not show the expected accumulation in the 
tumor but in the liver in clinical studies
117
 and are more sensitive to proteolytic degradation 
and changes in conformation, decreasing their integrin affinity, few cyclic peptides have been 
developed. 
 The first affinity and competition tests with the RGD moiety incorporated in cyclic 
penta- or hexapeptides have been started by the group of H. Kessler in the 1990s
118
.  
As a result the cyclopentapeptide c-[RGDfV] was recognized as selective ligand of the αvβ3 
integrin. Its affinity for the purified free or immobilized αvβ3 integrin (IC50 = 50 nM (= 
peptide concentration needed to inhibit 50 % of the integrin – ligand binding) is comparable 
to the affinity of its endogen ligand, the vitronectin (IC50 = 25 nM)
119
, but not as efficient in 
competition with fibrinogen or fibronectine and the immobilized αIIbβ3 (IC50 = 29 µM) and 
α5β1 (IC50 = 6.4 µM). After all the methyl derivate (c-[-RGDf(N-Me)V]), also known as the 
anti-angiognetic agent cilengitide, shows a strong inhibition of the vitronectine fixation of the 
αvβ3 integrin (IC50 = 0.58 nM) as well as a weak competition in regards to the vitronectine - 
α5β1 integrin – interaction
120
.  
 Cilengitide effectively inhibits angiogenesis and is currently being tested in phase II 
trials in patients with lung and prostate cancer as well as glioblastoma. Paradoxically, it has 
been found that infusion of very low concentration of RGD-mimetic inhibitors stimulates 
tumor growth and angiogenesis by the already mentioned promoting VEGF-induced 
endothelial cell migration. Thus integrin inhibition maybe not sufficient to completely block 
tumor angiogenesis
121
. 
 For optical imaging in vivo, the Chen’s group introduced monomeric, dimeric, and 
tetrameric cyanine-ligand c(RGDfk) displays based on a glutamate backbone. It was shown 
                                                 
117 Sutcliffe-Goulden, Julie L, Michael J O’Doherty, Paul K Marsden, Ian R Hart, John F Marshall, und Sukvinder S Bansal. 
„Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides“. European journal of nuclear 
medicine and molecular imaging 29, Nr. 6 (Juni 2002): 754–759. 
118 Gurrath, M, G Müller, H Kessler, M Aumailley, und R Timpl. „Conformation/activity studies of rationally designed 
potent anti-adhesive RGD peptides“. European journal of biochemistry / FEBS 210, Nr. 3 (Dezember 15, 1992): 
911–921. 
119 Burgess, K, D Lim, und S A Mousa. „Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with 
selectivity for the alpha V beta 3 receptor“. Journal of medicinal chemistry 39, Nr. 22 (Oktober 25, 1996): 4520–
4526. 
120 Xiong, Jian-Ping, Thilo Stehle, Rongguang Zhang, Andrzej Joachimiak, Matthias Frech, Simon L Goodman, und M Amin 
Arnaout. „Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp 
ligand“. Science (New York, N.Y.) 296, Nr. 5565 (April 5, 2002): 151–155. 
121 Danhier, Fabienne, Aude Le Breton, und Veronique Preat. „RGD -based strategies to target alpha(v) beta(3) integrin in 
cancer therapy and diagnosis“. Molecular pharmaceutics (September 11, 2012). 
http://www.ncbi.nlm.nih.gov/pubmed/22967287. 
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that the binding affinity of RGD multipresentation in subcutaneous αvβ3 integrin positive 
U87MG glioblastoma xenograft models, moved from 42.9 nM for the monomer to 27.5 nM 
for the dimer, and 12.1 nM for the tetramer, in agreement with the multivalency phenomenon. 
The tetramer displayed the highest tumor uptake and tumor-to-normal tissue ratio
122
.  
 Finally, the cyclopentapeptide –RGD- was strongly used for the vectorization of 
therapeutic agents and tumor detection
123
. The fact that using multiple ligands improves the 
targeting effect (Figure V-13), several approaches of designing multivalent composites 
containing cyclopentapeptides for tumor targeting have been made
124
.  
 
 
 
 
 
 
 
 
 
 
  
  
                                                 
122 Auzzas, L, F Zanardi, L Battistini, P Burreddu, P Carta, G Rassu, C Curti, and G Casiraghi. “Targeting Alphavbeta3 
Integrin: Design and Applications of Mono- and Multifunctional RGD-based Peptides and Semipeptides.” Current 
Medicinal Chemistry 17, no. 13 (2010): 1255–1299. 
123 Garanger, Elisabeth, Didier Boturyn, und Pascal Dumy. „Tumor targeting with RGD peptide ligands-design of new 
molecular conjugates for imaging and therapy of cancers“. Anti-cancer agents in medicinal chemistry 7, Nr. 5 
(September 2007): 552–558. 
124 Jin, Zhao-Hui, Veronique Josserand, Jesus Razkin, Elisabeth Garanger, Didier Boturyn, Marie-Christine Favrot, Pascal 
Dumy, und Jean-Luc Coll. „Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-
RGDfK-)4“. Molecular imaging 5, Nr. 3 (Juli 2006): 188–197. 
Figure V-13: Improved αvβ3 Integrin targeting. 
The specificity is improved using four cRGD compared to mono cRGD. As controls served the non-specific 
sequence cRAD instead of RGD and PBS. 
-After : Jin et al. „Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4“. Molecular 
imaging 5, Nr. 3 (Juli 2006): 188–197.   & 
Jin et al.„In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors“. 
Molecular cancer 6 (2007): 41.- 
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  The RAFT- c(RGDfK)4 
 
 In our laboratory we use the RAFT (Regioselectively Addressable Functionalized 
Template)
125
, which is based on the in the 1980s developed template TASP (Template-
Assembled Synthetic Protein) by Professor Manfred Mutter
126
. The RAFT allows the 
adequate steric organization on the template, representing an independent targeting and 
effecting moiety at the same time, due to the four to six lysine (K) residues and their 
orthogonal protection groups
127
. The cyclic decapeptide sequence of the RAFT is c[-Pro-Gly-
Lys-Lys-Lys-]2
128
. 
The sequence can be modified by introducing alanine residues instead of the lysine. Four 
c(RGDfK) moieties were anchored to four non contiguous lysine residues via oxime ligation 
chemistry (Figure V-14). 
 After leading to clustering of its receptor, the integrin αvβ3, by binding and creation of 
integrin dimers, the molecule is internalized via clathrin coated vesicles
129
.  
 
 
 
 
 
 
      
 
 
  
                                                 
125 Dumy, P.; Favrot, M.-C.; Boturyn, D.; Coll, J.-L. Synthesis and characterization of novel systems for 
guidance and vectorization of compounds having a therapeutic activity. Brevet PCT/FR2003/002773 WO 
2004/02894, 19 Septembre 2003. 
126 Carey, R I, K H Altmann, und M Mutter. „Protein design: template-assembled synthetic proteins“. Ciba Foundation 
symposium 158 (1991): 187–199; discussion 199–203, 204–212. 
127 Dumy, P.; Eggleston, I. M.; Cervigni, S.; Sila, U.; Sun, X.; Mutter, M. A convenient synthesis of cyclic peptides as 
regioselectively addressable functionalized templates (RAFT). Tetrahedron Lett 1995, 36, 1255- 1258. 
128 Dumy, P.; Eggleston, I. M.; Cervigni, S.; Sila, U.; Sun, X.; Mutter, M. A convenient synthesis of cyclic peptides as 
regioselectively addressable functionalized templates (RAFT). Tetrahedron Lett 1995, 36, 1255-1258. 
129Sancey, L., E. Garanger, S. Foillard, G. Schoehn, A. Hurbin, C. Albiges-Rizo, D. Boturyn, u. a. „Clustering and 
internalization of integrin alphavbeta3 with a tetrameric RGD-synthetic peptide“. Molecular Therapy. 17(5), Mai 
2009. 
Figure V-14: The RAFT-c(RGD)4 scaffold. 
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VI. Peptidic molecular probes for cancer 
targeting – the MMP smart approach 
 
Targeting MMPs 
VI.1. MMP Inhibitors (MMPIs) 
 As inappropriate proteolysis has been found to have a major role in cancer as well as 
cardiovascular, inflammatory, neurodegenerative, bacterial, viral and parasitic diseases, the 
idea to target these proteases and blocking them is widely explored by pharmaceutical 
companies
130
.  
 Inhibitors of MMPs include small molecules (like hydroxamates), blocking antibodies, 
natural inhibitors, including TIMP-1 to -4, prodomains, exosite domains and aptamers
131
. 
VI.1.1. Natural inhibitors – TIMPs  
 TIMPs (tissue inhibitors of metalloproteases) control the activity of MMPs in vivo by 
forming complexes with the latent or activated enzymes. Experimental models show their 
ability to decrease angiogenesis, growth, migration and metastasis, but also their participation 
in the activation of MMPs. In some tumors the role of TIMPs is associated with aggressive 
behavior of the disease in others rather with tumor progression. At the same time increased 
expression of TIMPs can show an antimetastatic effect, but they are also indicative of poor 
prognosis as in human melanoma cells a growth-stimulating effect of TIMPs could be 
observed
132
. 
 TIMPs have been described to form a 1:1 stoichiometric complex with all activated 
MMPs, with which they become covalently linked
133
. For example MT1-MMP functions as a 
cellular receptor and activator of Pro-MMP-2. They form a trimolecular complex on the cell 
surface with TIMP-2. While MMP-2, MT1-MMP, TIMP-2 and integrin αvβ3 are colocalized 
in caveolae in the basolateral compartment of human endothelial cells, MMP-9 and TIMP-1 
                                                 
130 Turk, Boris. „Targeting proteases: successes, failures and future prospects“. Nature reviews. Drug discovery 5, Nr. 9 
(September 2006): 785–799. 
131 Overall, Christopher M, und Carl P Blobel. „In search of partners: linking extracellular proteases to substrates“. Nature 
reviews. Molecular cell biology 8, Nr. 3 (März 2007): 245–257. 
132 Hofmann, Uta B., Roland Houben, Eva-B. Bröcker, and Jürgen C. Becker. “Role of Matrix Metalloproteinases in 
Melanoma Cell Invasion.” Biochimie 87, no. 3–4 (March 2005): 307–314. 
133 Pepper, M S. „Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis“. 
Arteriosclerosis, thrombosis, and vascular biology 21, Nr. 7 (Juli 2001): 1104–1117. 
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are distributed on the cell surface and concentrated in the Golgi region
134
. The natural 
inhibitor for MMP-2 and MMP-9 are TIMP-1 and TIMP-2, respectively. 
 
 TIMP-1 is a 32 kDa protein that inhibits MMP-9 catalytic activity by forming an 
enzyme-inhibitor complex with high affinity
135
. Dufour et al.
136
 demonstrated that the MMP-9 
PEX domain binds specifically to TIMP-1, and in a 1:1 binding ratio to the catalytic core 
domain, it inhibits the proteolytic activity of secreted MMPs.  
Concerning pro-MMP-2, its PEX-domain binds by interaction with blade IV to TIMP-2 
(crystallography analysis) (Figure VI-1). 
But also soluble PEX, a result of MMP-2 activation, can bind to TIMP-2 and thus inhibits 
MT1-MMP dependent MMP-2 activation
137
.  
 
 
  
                                                 
134 Pepper, M S. „Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis“. 
Arteriosclerosis, thrombosis, and vascular biology 21, Nr. 7 (Juli 2001): 1104–1117. 
135 Kim, Dong Seok, Ok-Hee Jeon, Hee Doo Lee, Kyung Ho Yoo, und Doo-Sik Kim. „Integrin alphavbeta3-mediated 
transcriptional regulation of TIMP-1 in a human ovarian cancer cell line“. Biochemical and biophysical research 
communications 377, Nr. 2 (Dezember 12, 2008): 479–483. 
136 Dufour, Antoine, Stanley Zucker, Nicole S Sampson, Cem Kuscu, und Jian Cao. „Role of matrix metalloproteinase-9 
dimers in cell migration: design of inhibitory peptides“. The Journal of biological chemistry 285, Nr. 46 
(November 12, 2010): 35944–35956. 
137 Nisato, Riccardo E, Ghamartaj Hosseini, Christian Sirrenberg, Georgina S Butler, Thomas Crabbe, Andrew J P Docherty, 
Matthias Wiesner, u. a. „Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in 
angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 
are critical“. Cancer research 65, Nr. 20 (Oktober 15, 2005): 9377–9387. 
Figure VI-1: The complex of proMMP-2 and TIMP-2. 
The pro-domain of proMMP-2 is shown in red, the catalytic domain in blue, the fibronectin type II repeats in green, the linker 
in grey and the hemopexin domain in purple. The TIMP-2 is shown in orange with the residues interacting with proMMP-2 as 
stick model in atom type. The important residues for this interaction on proMMP-2 are also represented as stick models. 
-After: Maskos, Klaus. „Crystal structures of MMPs in complex with physiological and pharmacological inhibitors“. Biochimie 
87, Nr. 3–4 (März 2005): 249–263.- 
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VI.1.2. Synthetic inhibitors 
 In the 1950s, the idea to design drugs which suppress protease activity began. This 
was one approach thought to battle cancer, where MMPs were the first proteases targets 
seriously considered for combating cancer because of their role in extracellular matrix 
degradation
138
. 
Inhibitors are classified according to their mechanism (Table VI-1). 
 
Canonical (lock-and-key) 
Binding to target in a substrate-
like manner (Michaelis-type 
complex); Ex.: serine protease 
inhibitors (serpins) 
Mostly competitive 
Exosite-binding inhibitors 
Blocking the active site by 
contiguous binding and partial 
covering (substrate-like); Ex.: 
cystatins, cystein cathepsins 
Mostly competitive 
Quasi-substrate-like 
Combination of canonical and 
exosite-binding mechanisms; 
Ex.: TIMPs 
Mostly competitive 
Allosteric 
Prevention of dimerization by 
binding in the interdomain 
region away from the active 
site; Ex.: X-linked inhibitor of 
apoptosis protein, which 
inhibits caspase 9 
Not competitive 
 
Table VI-1: Classification of protease inhibitors according to their mechanism  
-based on Turk, 2006- 
 
 
Two major groups of MMPIs have been developed: 
 Hydroxamates: Batimastat (BB94; British Biotech), Marimastat (BB2516; British 
Biotech); Prinomastat (AG-3340; Aguron); 
 Non hydroxamates: Neovastat (AE-941; Aeterna ; extract of shark cartilage) ; 
Rebimastat (BMS-275291 ; Bristol-Myers Squibb) ; Tanomastat (Bay-12-9566 ; 
Bayer),Pyrimidine-2,4,6-triones (or barbiturates) ( exhibition of specific activities for 
a subgroup of secreted MMPs comprising MMP-2,-8,-9,-14 and -16) 
                                                 
138 Turk, Boris. „Targeting proteases: successes, failures and future prospects“. Nature reviews. Drug discovery 5, Nr. 9 
(September 2006): 785–799. 
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 But all these MMP inhibitors have failed clinical trials because of severe side effects 
and/or no therapeutic benefit
138,139
. For instance only the tetracycline analog periostat (Colla-
Genex) for the treatment of adult periodontitis is on the market. It inhibits the activity and the 
synthesis of MMPs. 
 These failures can be traced back to the fact that the compounds are mostly broad-
spectrum MMP inhibitors arisen at a time of lack of knowledge of the various MMPs, their 
substrates and biology. So they lack of enzyme specificity and tent to cross-reactivity. 
Consequently MMP off-or anti-target activities reduce overall drug efficacy. 
 The unspecific MMP-inhibitor Batimastat for example induced liver metastases in 
mice and caused liver-specific over-expression of MMP-2 and -9 in tumor-free animals
140
. 
This paradoxical effect was not detectable after treatment with recently developed specific 
inhibitors of MMP-2 and -9. 
 It has also to be taken in consideration that while inhibiting the activity of a target the 
activation of downstream proteases or protease cofactor complexes might be blocked as 
well
139
.  
 For example off-target effects on non-MMP metalloproteases result in musculoskeletal 
toxicity and other affections of physiological events.  
 
 Finally, many potent protease inhibitors have poor safety profiles. Also research with 
protease-knockout mice has shown that even the most simple protein-processing events often 
have complex consequences, and that protease signaling in its broadest sense is often only a 
small part of disease biology in the whole organism and not always the best aspect to 
target
141
. Nevertheless Turk proposed that the ideal inhibitor, in the view of the 
pharmaceutical industry, would be a non-covalent reversible inhibitor, as such an inhibitor 
would provide better selectivity with fewer side effects than covalent inhibitors. He also 
pointed out that competitive inhibitors can saturation of substrate competition, which results 
in substantially higher doses of the compounds and in narrowing the safety window. 
 Another approach has been done by identifying specific gelatinase-inhibitory peptides 
from phage display libraries. A potent and selective MMP-2 and MMP-9 inhibitory sequence 
                                                 
139 Cudic, Mare, und Gregg B Fields. „Extracellular proteases as targets for drug development“. Current protein & peptide 
science 10, Nr. 4 (August 2009): 297–307. 
140 A. Krüger, R. Soeltl, I. Sopov, C. Kopitz, M. Arlt,V. Magdolen, et al., Hydroxamate-type matrix metalloproteinase 
inhibitor batimastat promotes liver metastasis, Cancer Res. 61 (2001) 1272–1275. 
141 Turk, Boris. „Targeting proteases: successes, failures and future prospects“. Nature reviews. Drug discovery 5, Nr. 9 
(September 2006): 785–799. 
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was a cyclic peptide, containing the sequence His-Trp-Gly-Phe. It has been shown that they 
inhibit tumor and endothelial cell migration in vitro and tumor growth and invasion in vivo
142
.  
Also triple-helical phosphinate transition state analogs have been described to be highly 
selective for gelatinases. Another progress has been done in the development of MMP 
selective inhibitors based on novel zinc binding groups
143
.  
 The discontinuation of a number of phase III trials and the limited success of the 
clinical application of clinical application of MMP inhibitors might also to be traced back to 
the fact that MMP inhibition may result in the stimulation rather than inhibition of 
angiogenesis, though they were presumed as molecules of antiangiogenic activity
142
. It is to 
take into notice that the inhibitor profile of an enzyme in cell-based assays and biochemical 
assays can differ, so both must be determined separately
144
.  
 
 Another approach of inhibitory peptide design is the mimicking of the noncatalytic 
PEX-domain of MMP-9
145
. Here Dufour et al. demonstrated that their designed peptides 
block MMP-9 dimer formation and thus inhibit cell migration. This concept was a creation as 
response to the failure of broad-spectrum MMP inhibitors, evaluated in the 1990s. The idea is 
as catalytic sites of most MMPs are highly homologous, leading to difficulties of producing 
non-cross-reactive inhibitors, to target the PEX domain as they are less homologue.  
 
 Apart from targeting MMPs by blocking them, their properties of specific substrate 
cleavage gained interest for the development of either pro-drugs or smart imaging agents (see 
section activatable probes). 
 
 In regard to the appearance of MMPs in diseases they form an attractive therapeutic 
object. One approach is the inhibition of their activity another is taking the advantage of 
differential expression in different stages of disease to selectively deliver therapeutic or 
imaging agents. 
  
                                                 
142 Pepper, M S. „Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis“. 
Arteriosclerosis, thrombosis, and vascular biology 21, Nr. 7 (Juli 2001): 1104–1117. 
143 Cudic, Mare, und Gregg B Fields. „Extracellular proteases as targets for drug development“. Current protein & peptide 
science 10, Nr. 4 (August 2009): 297–307. 
144 Overall, Christopher M, und Carl P Blobel. „In search of partners: linking extracellular proteases to substrates“. Nature 
reviews. Molecular cell biology 8, Nr. 3 (März 2007): 245–257. 
145 Dufour, Antoine, Stanley Zucker, Nicole S Sampson, Cem Kuscu, und Jian Cao. „Role of matrix metalloproteinase-9 
dimers in cell migration: design of inhibitory peptides“. The Journal of biological chemistry 285, Nr. 46 
(November 12, 2010): 35944–35956. 
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VI.2. MMP and “Smart” contrast agents and therapeutics 
 MMPs have been addressed with synthetic fluorogenic derivates as biochemical and 
pharmacological tool, as well as for targeted delivery systems. Most of these are FRET-based 
substrates designed from natural collagen-identified sequences, cleaved by MMPs. 
As already mentioned, “Smart” probes or also known activatable molecules have been 
designed to ameliorate the contrast and SBR of imaging probes, using over-expressed 
enzymes.  
 Gelatinases cleavable sequences are used in imaging and as drug delivering 
compounds. Most of these are FRET-based substrates designed from natural collagen-
identified sequences. 
In particular, the substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, was extensively used 
for monitoring MMP activities and for screening inhibitors. Knight et al.146 already showed 
with a MMP cleavable sequence and the quenching between dinitrophenyl (DNP) and 7-
methoxycumarin (Mca) the use of quenched precursors. 
 Trying to approach the native substrates of the gelatinases and improving the 
drawbacks of the first collagen-based molecules well-defined triple helical molecules, mainly 
described by Gregg B. Fields group, have been developed
147,148,149
. The idea was to synthesize 
structures, which would be stable enough to remain in triplehelical conformation in the 
conditions of assays. Therefore different approaches have been described. Fields et al. 
developed first a solid-phase synthesis, featuring a C-terminal covalent branch and 
incorporating specific sequences between this branch and a N-terminal (Gly-Pro-Hyp)n 
domain
150
(Figure VI-2).  
 Then “peptide-amphiphile” triple helices were designed, based on the non-covalent 
self-assembly of lipophilic molecules, N-terminally-linked to a peptide sequence. Finally, 
                                                 
146 Knight, C G, F Willenbrock, und G Murphy. „A novel coumarin-labelled peptide for sensitive continuous assays of the 
matrix metalloproteinases“. FEBS letters 296, Nr. 3 (Januar 27, 1992): 263–266. 
147 Akers, Walter J, Baogang Xu, Hyeran Lee, Gail P Sudlow, Gregg B Fields, Samuel Achilefu, and W Barry Edwards. 
“Detection of MMP-2 and MMP-9 Activity in Vivo with a Triple-helical Peptide Optical Probe.” Bioconjugate 
Chemistry 23, no. 3 (March 21, 2012): 656–663. 
148 Akers, Walter J., Baogang Xu, Hyeran Lee, Gail P. Sudlow, Gregg B. Fields, Samuel Achilefu, and W. Barry Edwards. 
“Detection of MMP-2 and MMP-9 Activity in Vivo with a Triple-Helical Peptide Optical Probe.” Bioconjugate 
Chemistry 23, no. 3 (2012): 656–663. 
149 Lauer-Fields, Janelle L, Thilaka Sritharan, M Sharon Stack, Hideaki Nagase, und Gregg B Fields. „Selective hydrolysis of 
triple-helical substrates by matrix metalloproteinase-2 and -9“. The Journal of biological chemistry 278, Nr. 20 
(Mai 16, 2003): 18140–18145. 
150 Lombard, Carine, Joëlle Saulnier, and Jean Wallach. “Assays of Matrix Metalloproteinases (MMPs) Activities: a 
Review.” Biochimie 87, no. 3–4 (March 2005): 265–272. 
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triple-helical peptides containing fluorophores for continuous assay methods have been 
synthesized. 
 
 
 
 
 
 
 
 
 The triple-helical peptide substrates were hydrolyzed in a similar manner to native 
collagens, cleavage occurring between Gly and Ile or Leu according to the chain type. The 
problem concerning these substrates is the difficulty in synthesis (not commercially 
available). 
Besides a couple of linear sequences as quenched molecules are commercially available, like  
Cy5.5-Gly-Pro-Leu-Gly-Val-Arg-Gly-Cys-Ferritin-black hole quencher-3 nanocages
151
.  
Substrate sequences for Gelatinases and other proteases can be looked up the already 
mentioned MEROPS peptide database. 
 Moreover, several delivery devices have also been designed, using polymeric 
vehicles
152, 153
, hydrogel matrix or liposomal devices functionalized with peptidic moieties 
embodying MMP cleavage sequences
154
.  
In order to obtain reasonable sized molecules, selectively cleaved by MMPs, with high 
plasma stability at the same time, Moustoifa et al. present a cyclopeptide approach for MMP 
directed delivery design. They argue that cyclization of linear peptides improves peptide 
stability in biological medium, preventing unspecific degradation. In order to allow a FRET 
                                                 
151Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): National Center for Biotechnology 
Information (US), 2004. http://www.ncbi.nlm.nih.gov/pubmed/22649804. 
152 Vartak, Deepali G, und Richard A Gemeinhart. „Matrix metalloproteases: underutilized targets for drug delivery“. Journal 
of drug targeting 15, Nr. 1 (Januar 2007): 1–20. 
153 Chau, Ying, Frederick E Tan, und Robert Langer. „Synthesis and characterization of dextran-peptide-methotrexate 
conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX“. 
Bioconjugate chemistry 15, Nr. 4 (August 2004): 931–941. 
154 Moustoifa, El-Farouck, Mohamed-Anis Alouini, Arnaud Salaün, Thomas Berthelot, Aghleb Bartegi, Sandra Albenque-
Rubio, und Gérard Déléris. „Novel cyclopeptides for the design of MMP directed delivery devices: a novel smart 
delivery paradigm“. Pharmaceutical research 27, Nr. 8 (August 2010): 1713–1721. 
Figure VI-2: Schematic structure of branched triple-helical peptides.  
-Fields et al. 2003- 
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system to work they therefore introduced two hydrolysis sites in the cyclic peptide, resulting 
in cleavage by MMPs, especially MMP-9 and good plasma stability. 
 
VI.2.1. Drug delivery 
 
 In regard to the facts described earlier, the use of proteases, like MMPs in order to 
ameliorate drug delivery methods has been more and more considered during the last decade, 
especially in the case of cancer treatment.  
Here is to say, that despite improvements and inventions in this field, no method has been 
developed which implies efficiency without causing severe side effects.  
 Up to now, surgical resection still remains the “tool” of choice in the battle against 
cancer. This therapy for primary tumors is though limited by tumor accessibility, tumor 
pathology and the eventual tumor spread or metastasis. Exploiting now the characteristics of 
enzymes which are over-expressed in cancer, the era of pro-drugs has begun. 
 Tumor-activated prodrugs rely on the facts that their activation occurs selectively in 
the tumor microenvironment. Therefore suitable characteristics of enzymes, serving in this 
manner, are: 
 
 their significant over-expression in cancerous tissue 
 a high affinity towards cleaving the pro-drug 
 significantly elevated activity in the tumor environment 
 no presence of the targeted enzyme in a pro-drug activating form in the patient serum 
 the ability of the enzyme for selective and rapid activation of the pro-drug 
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 Tumor-activated prodrugs 
 
 As summed up by Atkinson et al.155several MMP-targeted “prodrugs” directed to the 
matrix metalloproteases have been developed. 
 The success of the “enzyme prodrug strategy” relies on the identification of suitable 
enzymes differentially active in the immediate environment of tumor cells156. MMP-2 and -9 
substrate sequences have been used in prodrug strategies attempting to release doxorubicin, 
mephalan, camptothecin, vinblastine and a recombinant anthrax toxin
156,157
. 
 Gelatinases represents thus enzymes with a sufficient activity and a high 
representation in the tumor tissue for possible pro-drug use. 
 The combination of imaging and therapeutic agent on one molecule, like a linear 
peptide sequence which is cleaved by these enzymes, is of high interest. Linear peptides are 
easier to synthesize compared to triple helical peptides and functionalization is simplified 
because of less synthesizing steps compared to cyclic ones. At the same time the close 
relation between the integrin αvβ3 and the Gelatinases open up new vistas for a possible gain 
in tumor specific targeting.  
 Thus, a linear substrate peptide sequence for Gelatinases would be of concern for 
testing the double targeting approach with the well studied RAFT-c(RGD)4, for imaging and 
possible therapy. 
  
                                                 
155 Atkinson, J M, C S Siller, und J H Gill. „Tumour endoproteases: the cutting edge of cancer drug delivery?“ British journal 
of pharmacology 153, Nr. 7 (April 2008): 1344–1352. 
156 Kline, Toni, Michael Y Torgov, Brian A Mendelsohn, Charles G Cerveny, und Peter D Senter. „Novel antitumor prodrugs 
designed for activation by matrix metalloproteinases-2 and -9“. Molecular pharmaceutics 1, Nr. 1 (Januar 12, 
2004): 9–22. 
157 Ryppa, Claudia, Hagit Mann-Steinberg, Iduna Fichtner, Holger Weber, Ronit Satchi-Fainaro, Martin L Biniossek, und 
Felix Kratz. „In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] 
that targets integrin alphavbeta3“. Bioconjugate chemistry 19, Nr. 7 (Juli 2008): 1414–1422. 
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VII. Imaging and cancer 
VII.1. General presentation of the methods used in Medical Imaging 
 
 Medical and biomedical imaging techniques are non-invasive imaging technologies, 
which do not harm the organism barriers apart from injection of certain tracers. The 
techniques are either based on electromagnetic rays, like gamma rays, x-rays or on radio-
waves, ultrasounds and infrared rays (Figure VII-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
They imply diverse functional categories for different application: 
- Structural imaging, giving information about the organs anatomy, like position, 
volume or lesions 
- Functional imaging, giving information about the organism’s function, like physiology 
and metabolism; 
Figure VII-1: Representation of different medical imaging methods. 
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Due to their working principles, they fulfill certain characteristics concerning the spatial 
resolution and the sensibility. 
VII.1.1. X-ray computed tomography (CT) 
 
 CT is very commonly used on human patients. Based on the oldest form of medical 
imaging, X-ray fluorimetry, the technology called X-ray scanner or X-ray computed 
tomography (CT) has been developed. After reconstruction, the scanner allows the view of 
slices or three dimensional views.  
Biological tissues absorb at different degrees the X-rays, which is used for this technique. It 
measures the difference of absorption of the X-rays passing through the tissues. 
X-ray imaging is an efficient and rapid method for anatomical imaging, with a good spatial 
resolution between 10 to 100 µm, not limited in depth. 
The most used contrast agent is the x-ray absorbing iodine. It is mostly used for vascular 
imaging. Other contrast agents are for example metallic nanoparticles.  
Representing weak contrast properties, strong quantities need to be injected, limiting the 
development of new targeting contrast agents. 
As X-rays are radiation rays certain protective procedures have to be considered. Nevertheless 
the greatest risk for patients is contrast agent intolerance. 
In cancer diagnostic this technique is used in several different cancer types, such as brain 
cancer, head-and-neck cancer, lung cancer and metastases, detection of enlarged lymph nodes 
and detection of abnormalities in abdominal organs (liver, spleen, kidney, pancreas, adrenal 
gland). 
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VII.1.2. Magnetic resonance imaging (MRI) 
 
 MRI is another standard method of clinical imaging for soft tissues, developed in the 
1980s.  
MRI is based on the fact that when a sample, lying within a magnetic field, is subjected to a 
radio-frequency pulse its protons absorb energy and generate a detectable signal during the 
relaxation phase. The signal strength is a function of the proton number. The relaxation 
process can be described by two fundamental rate constants: T1 (longitudinal relaxation) and 
T2 (transverse relaxation)
158
. The sensitivity of this method is low (mM concentrations) but 
its spatial resolution extremely good (μm). MRI is very useful for detecting tumors and 
measuring morphologic parameters. It is often used for diagnostics or staging of brain tumors, 
primary bone tumors, soft tissue sarcomas and tumors affecting the spinal cord. In some early 
cancers, such as cervix or bladder cancer, MRI is preferable to CT by better differentiating 
healthy tissue from the neoplastic one, indicating the growth depth.  
 Because there is no damaging radiation, multiple imaging sessions can be performed 
safely, allowing longitudinal follow-up of tumor growth. Finally, contrast agents, influencing 
either the T1 or T2 relaxation time constants, are developed to allow functional 
imaging
159,160,161,162
. 
 
  
                                                 
158 Cassidy, Paul J, and George K Radda. “Molecular Imaging Perspectives.” Journal of the Royal Society, Interface / the 
Royal Society 2, no. 3 (June 22, 2005): 133–144. 
159 Louie, Angelique. “Design and Characterization of Magnetic Resonance Imaging Gene Reporters.” Methods in Molecular 
Medicine 124 (2006): 401–417. 
160 Barrett, Tristan, Hisataka Kobayashi, Martin Brechbiel, and Peter L Choyke. “Macromolecular MRI Contrast Agents for 
Imaging Tumor Angiogenesis.” European Journal of Radiology 60, no. 3 (December 2006): 353–366.  
161 Beaumont, Marine, Benjamin Lemasson, Régine Farion, Christoph Segebarth, Chantal Rémy, and Emmanuel L Barbier. 
“Characterization of Tumor Angiogenesis in Rat Brain Using Iron-based Vessel Size Index MRI in Combination 
with Gadolinium-based Dynamic Contrast-enhanced MRI.” Journal of Cerebral Blood Flow and Metabolism: 
Official Journal of the International Society of Cerebral Blood Flow and Metabolism 29, no. 10 (October 2009): 
1714–1726. 
162 Cuenod, C A, L Fournier, D Balvay, and J-M Guinebretière. “Tumor Angiogenesis: Pathophysiology and Implications for 
Contrast-enhanced MRI and CT Assessment.” Abdominal Imaging 31, no. 2 (April 2006): 188–193. 
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VII.1.3. Ultrasonography (US) 
 
 In general, ultrasonography is one of the most popular imaging techniques for clinical 
use, because of its cheap, fast and easy use. It is a non irradiative method, based on the 
detection of ultra-sound reflections of the different tissues of the organism, on so of the 
detection of the smooth tissues. In principal it represents a structural imaging, but allows also 
functional imaging, like blood flow due to the Doppler echography. Apart from intra-surgical 
use, it is applied in the fast detection of pathologies, like cancer of the bladder
163
. Its 
resolution is quiet precise, ranging from 10 to 500 µm (depending on the transducer used), 
nevertheless decreasing rapidly with depth. Other obstacles are the bones, as the ultra-sound 
does not pass, the necessary direct contact of the transducer to the patient and experience of 
the operator.  
 Concerning image-guided surgery, this accurate, cost-effective and safe in application 
method, ultrasound is one the most employed methods. It is already used in breast biopsy or 
for revealing operative liver anatomy. In liver lesions, it guides the surgeon towards the 
lesion, enabling him to avoid vital structures as blood vessels and bile ducts.   
 
VII.1.4. Nuclear imaging: PET and SPECT 
 
 Nuclear imaging is based on the detection of the disintegration of radioactive atoms, 
which are bound in the molecule structure of so called radio-pharmaceutics, given to the 
patient before imaging. 
 The images obtained give rather physiological than anatomical information, which is 
used due to administration of molecules with known biological behavior. The obtained 
images are mostly static but dynamic imaging is also possible (e.g. blood perfusion & 
circulation, glucose metabolism, level of ligand-receptor interaction). 
 Two technologies, based on the use of radio-elements are currently used: PET and 
SPECT. 
                                                 
163 Rooks, V, W D Beecken, I Iordanescu, and G A Taylor. “Sonographic Evaluation of Orthotopic Bladder Tumors in Mice 
Treated with TNP-470, an Angiogenic Inhibitor.” Academic Radiology 8, no. 2 (February 2001): 121–127. 
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 PET requires the use of radioactive isotopes that emit positrons, such as 
18
F, 
15
O, 
13
N, 
and 
11
C with a short half-time life (< 2 hours)
164
, while SPECT uses tracers that emit gamma 
ray or high-energy X-ray photons, such as 
123
I, 
125
I, 
111c
In and 
99m
Tc.  
Positrons move a short distance through tissues, losing energy as they collide with other 
molecules, and eventually combine with electrons (“annihilation”), producing two high-
energy gamma rays or photons traveling outward and in opposite directions.  
 In SPECT, a single photon per event is directly emitted, and this photon interacts with 
electrons and nuclei of nearby atoms within the tissue. Unlike positrons, these energetic 
photons do not “slow down” but are attenuated. Because there is only one photon per event, 
electronic collimation is not possible, and a physical collimator must be added.  
Sensitivities are on the order of 10
−14–10−15 M for PET and 10−14 M for SPECT, and spatial 
resolution can reach 1.3 mm for PET and is sub-millimetric for SPECT
165
. 
PET is used to measure increased metabolism via the up-take by metabolically active cells 
and overexpression of glucose transporters (GLUTs) using Glucose-mimetic FDG (
18
F-2-
fluoro-2-deoxy-D-glucose)
166
.  
 The problems are the limited administration time frame, because of short agents’ half-
life, and the restriction of these techniques into specialized centers (logistic, practice, 
finances). 
 For intra-operative evaluation of tumor localization and margin status in breast cancer 
surgery, a hand-held PET probe to detect the high-energy gamma rays during surgery has 
been developed
167,168
. SPECT is used for attempts in intra-operative lymph node-mapping
169
. 
 
  
                                                 
164 Levin, Craig S. “Primer on Molecular Imaging Technology.” European Journal of Nuclear Medicine and Molecular 
Imaging 32 Suppl 2 (December 2005): S325–345. 
165 Chatziioannou, A F, S R Cherry, Y Shao, R W Silverman, K Meadors, T H Farquhar, M Pedarsani, and M E Phelps. 
“Performance Evaluation of microPET: a High-resolution Lutetium Oxyorthosilicate PET Scanner for Animal 
Imaging.” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 40, no. 7 (July 1999): 
1164–1175). 
166 Keereweer, S., J.D.F. Kerrebijn, P.B.A.A. van Driel, B. Xie, E.L. Kaijzel, T.J.A. Snoeks, I. Que, et al. “Optical Image-
guided Surgery - Where Do We Stand?” Mol Imaging Biol. 13, 2011. 199-207. 
167 Keereweer, S., J.D.F. Kerrebijn, P.B.A.A. van Driel, B. Xie, E.L. Kaijzel, T.J.A. Snoeks, I. Que, et al. “Optical Image-
guided Surgery - Where Do We Stand?” Mol Imaging Biol. 13, 2011. 199-207. 
168 Strong, V.E., J. Humm, P. Russo, et al. “A Novel Method to Localize Antibody-targeted Cancer Deposits Intraoperatively 
Using Handheld PET Beta and Gamma Probes.” Surg Endosc. 22, 2008. 386-391. 
169 Klar, M, M Bossart, E Stickeler, I Brink, M Orlowska-Volk, und D Denschlag. „Sentinel lymph node detection in patients 
with vulvar carcinoma; Feasibility of intra-operative mapping with technetium-99m-labeled nanocolloid“. 
European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British 
Association of Surgical Oncology 37, Nr. 9 (September 2011): 818–823. 
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VII.2. Optical Imaging 
 
 Fluorescence Reflectance Imaging (FRI) is a very simple system using signal 
reflection, which allows two dimensional picture taking (Figure VII-2).  
 
 
 The imaging system consists of a NIR lamp (LED or laser) and a CCD camera, 
equipped with several filters in order to separate the scattered light and to eliminate the 
photons directly reflected by the object. The acquisition time is in the range of milliseconds to 
seconds. Several imaging systems based on 2D-FRI are now commercially available, such as 
the Photodynamic Eye (PDE; Hamamatsu Photonics, Hamamatsu City, Japan) and the 
Fluorescence-assisted Resection and Exploration (FLARE™) system170 from the Fragioni 
laboratory (Brookline, MA, USA). Two smaller systems are the Mini-FLARE™, also from 
the Frangioni laboratory
171, and the Fluobeam™ from Fluoptics (Grenoble, France) (Figure 
VII-3).The group of Ntziachristos is also engaged in the development of NIR guided 
                                                 
170 De Grand, A.M., and JV Frangioni. “An Operational Near-infrared Fluorescence Imaging System Proyotype for Large 
Animal Surgery.” Technol Cancer Res Treat. 2, 2003.553-562. 
171 Stockdale, A., R. Oketokoun, S. Gioux, and JV Frangioni. “Mini-FLARE: a Compact and Ergonomic Dual-channel Near-
infrared Fluorescence Image-guided Surgery System.” Abstract, 2010 
Figure VII-2: Principle of 2D-FRI and the Fluobeam™. 
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surgery
172,173,174. Others are the ArteMIS™ handheld system, developed by O2view (Marken, 
The Netherlands), as well as the “da Vinci® Si” System (Intuitive Surgical, Sunnyvale, CA) 
and the SPY Intraoperative Imaging System (Novadaq Technologies, Mississauga, Ontario, 
Canada). 
 
 
 
 In the NIR optical window, tissue penetration is around 1 to 2 cm (compared to 1 to 2 
mm in the visible light), showing a good sensitivity around 10
-12
 M and a spatial resolution of 
2 mm. The information obtained is semi-quantitative.  
 Other optical-based imaging systems adapted to in vivo imaging are actively being 
developed. For example, NIR Spectroscopy can be used to detect and localize cancer
175
 based 
on the intrinsic and differential absorption of photons of different NIR wavelengths by 
hemoglobin, deoxy-hemoglobin, water and lipids. Other techniques, like diffuse optical 
tomography
176
or time-domain optical mammography (Softscan
®
, Advanced Research 
Technologies
177
), are used to measure photon migration through the tissues in order to 
observe variations in the functional and structural NIR properties (e.g., scattering, oxy-, and 
                                                 
172 Themelis, George, Jung Sun Yoo, Kwang-Sup Soh, Ralf Schulz, und Vasilis Ntziachristos. „Real-time intraoperative 
fluorescence imaging system using light-absorption correction“. Journal of Biomedical Optics 14, Nr. 6 (November 
1, 2009): 064012–064012. 
173 Themelis, George, Niels J Harlaar, Wendy Kelder, Joost Bart, Athanasios Sarantopoulos, Gooitzen M van Dam, und 
Vasilis Ntziachristos. „Enhancing surgical vision by using real-time imaging of αvβ3-integrin targeted near-infrared 
fluorescent agent“. Annals of surgical oncology 18, Nr. 12 (November 2011): 3506–3513. 
174 Crane, Lucia M.A., George Themelis, K. Tim Buddingh, Niels J. Harlaar, Rick G. Pleijhuis, Athanasios Sarantopoulos, 
Ate G.J. van der Zee, Vasilis Ntziachristos, und Gooitzen M. van Dam. „Multispectral Real-time Fluorescence 
Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology“. Journal of 
Visualized Experiments : JoVE, Nr. 44 (Oktober 20, 2010). 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185642/. 
175 Nioka, S, and B Chance. “NIR Spectroscopic Detection of Breast Cancer.” Technol Cancer Res Treat. 4, 2005.497-512 
176 Choe, R., S.D. Konecky, A. Corlu et al. “Differentiation of Benign and Malignant Breast Tumors by in Vivo Three-
dimensional Parallel-plate Diffuse Optical Tomography.” J Biomed Opt. 14, 024020 
177 Keereweer, S., et al. “NIR Spectroscopic Detection of Breast Cancer”. Montreal, Canada, 2011 
Figure VII-3: Near-infrared intra-operative camera systems. 
a) FLARE™ camera system. b) Artist impression of Fluobeam™. c) ArteMIS™ camera system. d) The 
Photodynamic Eye. 
-Keereweer et al. 2011- 
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deoxy-hemoglobin concentrations), enabling differentiation between benign and malignant 
tumors
178
. Nevertheless, these techniques are not yet suitable for intra-operative use. 
 
 We used the Fluobeam™ (Fluoptics, Grenoble) in the current study, which I will 
mainly present here. 
It is a portable 2D-FRI device for real-time NIR-imaging (Figure VII-4), able to work under 
NIR-filtered ambient light conditions
179
. It is composed of a control unit, with a laser source 
emitting at 785 nm and a power supply for light-emitting diodes (LEDs), next to an optical 
head, with a highly sensitive charge-coupled device camera and white LEDs for the 
illumination of the field of view
180,181
. It works with all NIR-probes and is on the market with 
a cancer targeting probe called AngioStamp™, the commercial name of RAFT-RGD, 
targeting integrin αvβ3.  
  
                                                 
178 Intes X (2005) Time-domain optical mammography SoftScan: initial results. Acad Radiol 12: 934-947. 
179 Keramidas, M. et al. Intraoperative near-infrared image-guided surgery for peritoneal carcinomatosis in a preclinical 
experimental model. Br J Surg97, 737–743 (2010). 
180E. Mery, E. Jouve, S. Guillermet, M. Bourgognon, M. Castells, M. Golzio, P. Rizo, J.P. Delord, D. Querleu, B. Couderc, 
Intraoperative fluorescence imaging of peritoneal dissemination of ovarian carcinomas. A preclinical study. 
Gynecologic oncology 122 (2011) 155-162. 
181D.A. Heuveling, G.W. Visser, M. de Groot, J.F. de Boer, M. Baclayon, W.H. Roos, G.J. Wuite, C.R. Leemans, R. de Bree, 
G.A. van Dongen, Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention 
in the sentinel lymph node. European journal of nuclear medicine and molecular imaging 39 (2012) 1161-1168. 
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Figure VII-4: 2D-Fluoresence-reflectance imaging systems. 
The injected fluorescent tracer is excited by a given wavelength. The emitted signal is collected by a CCD camera, equipped 
with filters for separation of the scattered excitation rays emitted by the fluorescent tracer. 
A) 2D imaging system; B) Intra-operative imaging device (Fluobeam™, Fluoptics) 
-Modified after Dufort, S.  « Vectorisation de biomolécules pour l’imagerie et la thérapie des cancers », Thesis, 2010- 
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VIII. Imaging and surgery 
 
 Cancer therapy depends on the nature, location and stage of the tumor. 
Tumors are generally classified as either benign or malignant. To differentiate them, several 
characteristics have been evoked as listed in Table VIII-1.  
In clinics, primary tumors are defined into T0 to T4, which is also used in staging of cancer: 
T0 – means a clinically undetectable tumor 
T1 – refers to a small, strictly circumscribed tumor, which does not reach the organ limits; 
T2 – in this case the tumor reaches the organ limits; 
T3 – the tumor is fixed to the neighboring organs; 
T4 – refers to a tumor that has invaded the neighboring organs. 
  
CHARACTERISTICS/TUMORS BENIGN MALIGNANT 
Growth type Expansive Infiltrating 
Growth speed Slow (in general) Rapid (in general) 
Stabilization Frequent Exceptional 
Structure Typical Atypical (dedifferentiation − 
anaplasia) 
Mitoses Rare + Typical Numerous + Atypical 
Evolution Local Local + General 
Metastasizing No Yes 
Local consequences Variable (compressions, ...) Severe (infiltration, destruction, 
necrosis, ...) 
General consequences None (exceptions: secretory tumors 
or at particular sites) 
Constant + severe (in the 
generalization phase) 
Spontaneous evolution Usually favorable Always fatal 
Evolution after removal No recurrences Common recurrences 
Table VIII-1: Characteristics of benign and malignant tumors.  
-Baba et al., 2007- 
 
 Surgical resection, if feasible, produces a survival benefit for patients with disease 
limited to organ-specific sites, as these patients are able to undergo surgical resection at the 
time of diagnosis or following conversion therapy with the appropriate integration of 
chemotherapy.  
Unfortunately the long-term survival is directly linked to the exhaustive tumor removal with 
microscopic examination of margins showing no tumor cells (definition of « R0 » resection). 
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 Pre-operative contrast CT and MRI as well as intra-operative ultrasonography are 
currently used for diagnosis and guidance of resection. The translation of these images to the 
operation field remains a major difficulty for the oncological surgeon. Visual appearance and 
palpation is the only way to discriminate between tumor and normal tissue and consequently 
determine an adequate tumor-free margin during surgery. Intra-operative ultrasounds can 
reveal not previously detected lesions, and thereby help with resection boundaries
182
. 
VIII.1. Surgical approaches in cancer 
 
 Surgery is the oldest form of cancer treatment but is also used in diagnosis (staging) or 
cancer prevention (e.g. colon cancer). Most cancer patients will have some type of surgery as 
it often offers the greatest chance for cure, especially when metastasis did not yet occur. Up to 
now operation techniques have evolved in order to save as much healthy and functional tissue 
as possible. The most common types of surgery reach from preventive, diagnostic and staging 
to curative or palliative surgery employing different kinds of techniques. Some of the 
techniques used, apart from the standard “scalpel” one, are Laser surgery, cryosurgery, 
electrosurgery, Mohs micrographic surgery, minimal invasive surgery and others (Table 
VIII-2), like cryoabaltion and radiofrequency ablation (RFA). 
 
 
Surgery technique Method / Instrument 
Laser surgery 
Photoablation; photocoagulation; less invasive 
surgery; vaporization of cancer tissue; alternative 
scalpel  
Cryosurgery Liquid nitrogen spray or LN-cooled object  
Electrosurgery High-frequency electrical current 
Mohs micrographic surgery (microscopically 
controlled surgery) 
 
Minimal invasive / endoscopic surgery Laparoscopy/Thorascopy 
Others 
High intensity focused ultrasound; microwaves/radio 
waves (radiofrequency ablation/ RFA); magnets; 
Gamma Knife & CyberKnife 
Table VIII-2: Surgery Techniques. 
-After information of the American Cancer Society, 2008 & 13 mastery of surgery 2007- 
 
                                                 
 182 Jarnagin, W R, A M Bach, C B Winston, L E Hann, N Heffernan, T Loumeau, R P DeMatteo, Y Fong, und L H Blumgart. 
  „What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease?“ Journal of 
  the American College of Surgeons 192, Nr. 5 (Mai 2001): 577–583. 
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 Surgical resection represents the standard therapy in solid tumors like bone cancer 
(osteosarcoma, chondrosarcoma and ESFTs (Vertebral Ewing's Sarcoma Family of 
Tumors))
183
, glioblastoma or other brain tumors
184
, papillary thyroid carcinoma
185,186
, 
squamous cell carcinomas or different sarcomas and represents common cancer treatment for 
hepatic cancer
187
, breast cancer, prostate
188
 cancer, colon cancer
189,190,191
 and is still the most 
effective treatment of most tumors, e.g. for localized gastric lymphoma, for early, superficial 
disease within the oral cavity, for stage I and II oral cavity cancer, and as routine in the 
control of lymphatic disease in neck cancer
192
. Concerning microinvasive surgery, carcinomas 
should be excised with a security margin of at least 1- to 2-cm on the peripheral and deep 
aspects, whereas difficulties can be observed to discern margins. In some cases, a margin up 
to 4 to 6 cm is needed (e.g. gastric carcinoma)
193
.  
 Sometimes a complete organ resection (-ectomy) is the only treatment, like for 
example thyroidectomy for all patients with a thyroid carcinoma, except in cases of anaplastic 
cancer
194
, or complete operative resection in gastric adenocarcinoma, which remains the only 
potential curative modality
195
. 
 Any local therapy for malignant hepatic tumors with curative intend, be it surgical 
resection, RFA (radiofrequency ablation), or some other tumor-ablative technique, has a 
significant proportion of patients subsequently developing clinically detectable hepatic or 
extrahepatic recurrence from coexistent micrometastatic disease. A big problem is the fact 
that a high percentage of lesions are undetected (about 28% in the case of hepacellular cancer) 
                                                 
183 American Cancer Society, 2012 
184 Lu-Emerson, Christine, und April F Eichler. „Brain metastases“. Continuum (Minneapolis, Minn.) 18, Nr. 2 (April 2012): 
295–311. 
185 Abboud, Bassam, und Jenny Tannoury. „Surgical treatment of papillary thyroid carcinoma“. Le Journal médical libanais. 
The Lebanese medical journal 59, Nr. 4 (Dezember 2011): 206–212. 
186 Bilimoria, Karl Y., David J. Bentrem, Clifford Y. Ko, Andrew K. Stewart, David P. Winchester, Mark S. Talamonti, und 
Cord Sturgeon. „Extent of Surgery Affects Survival for Papillary Thyroid Cancer“. Annals of Surgery 246, Nr. 3 
(September 2007): 375–384. 
187 Cirocchi, Roberto, Stefano Trastulli, Carlo Boselli, Alessandro Montedori, Davide Cavaliere, Amilcare Parisi, Giuseppe 
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Cochrane database of systematic reviews (Online) 6 (2012): CD006317. 
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190 American Cancer Society, Intramural Research 2012 
191 „Treatment of non-localised, non-metastatic rectal cancer“. Prescrire international 21, Nr. 128 (June 2012): 158–162. 
192 Fleming, et al. “Surgery in the Management of Gastric Lymphoma.” Cancer Vol 49, March 1982.; Caroll, W.R. “25 - 
Surgery for Cancer of the Oral Cavity.” In Mastery of Surgery, 1:305–318. 5th ed. Boston, Massachusetts: Fischer, 
Josef E., 2007. 
193 Brennan, M.F. “80 - Total Gastrectomy for Carcinoma.” In Mastery of Surgery, 1:916–928. 5th ed. Boston, 
Massachusetts: Fischer, Josef E., 2007. 
194 Wells Jr., S.A. “35 - Total Thyroidectomy, Lymph Node Dissection for Cancer.” In Mastery of Surgery, 1:411–433. 5th 
ed. Boston, Massachusetts: Fischer, Josef E., 2007. 
195 Brennan, M.F. “80 - Total Gastrectomy for Carcinoma.” In Mastery of Surgery, 1:916–928. 5th ed. Boston, 
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and in multicentric cancer, like hepatocellular carcinoma, a singular isolated attempt to 
eradicate it in closed fashion is ineffective
196
. 
 Surgical tumor accessibility restrictions are dependent on the proximity to vital 
structures, the stage - in regards to metastases- and the individual health status of the patient - 
in regards to the general risks of surgery and anesthesia. 
 Eventually, the principle of tumor surgery is a complete fast and margin-negative 
resection, without unnecessary harm to vital and/or healthy tissues or structures and reduced 
risks of anesthesia or ischemia. Constrains are the tumor accessibility and visibility. Tumor 
margin delineation is crucial to avoid recurrence. Recurrences and patient’s recovery are also 
influenced by missed metastases and drained lymph nodes, unnecessary damage to healthy 
tissue out of precaution or the iatrogenic spread of malignant cells.  
In regards to all the restraints and in spite of all technical improvements, surgery still faces 
these challenges. This explains the interest in the development of (intra-operative) image 
guided surgery techniques.  
 As already mentioned current imaging modalities are CT and MRI (e.g. in 
neurosurgery
197
). CT, SPECT and US (and endoscopy) are used during surgery, for re-
evaluation of the situation or as control during surgery in minimal invasive interventions or 
the placement of electrodes or other material (see Ablation techniques).  
 All these modalities have certain advantages and disadvantages, as seen in Table 
VIII-3. 
Generally, there are limits concerning sensitivity, resolution, exposure to radioactivity and 
room needs. The facilities require substantial capital investment, safety precautions and the 
interpretation of the images can be challenging, requiring experience and understanding of 
artifacts that are common in the intra-operative setting
197
. 
Another problem is that in case of IRM, CT or SPECT, the surgery needs a break for image 
acquisition, whereas US needs direct tissue contact and is not feasible in open surgery.  
 Therefore optical imaging in the NIR window represents an easy-to-use real-time 
technique, which does not interfere into the visual appearance of the surgical field, and 
                                                 
196 Curley, S.A., and J.S. Zager. “Cancer Radiofrequency Ablation and Other Tissue Ablative Techniques - Chapter 13.” In 
Mastery of Surgery, 1:181–185. 5th ed. Boston, Massachusetts: Fischer, Josef E., 2007. 
197 Abernethy, L J, S Avula, G M Hughes, E J Wright, und C L Mallucci. „Intra-operative 3-T MRI for paediatric brain 
tumours: challenges and perspectives“. Pediatric radiology 42, Nr. 2 (February 2012): 147–157. 
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without exposure to radioactivity, enabling a high spatial and temporal resolution. Moreover,  
it is possible to use targeting tracers. 
 
 
 
Modality  Advantages  Disadvantages  Common 
Contrast 
agents/Readout  
Example  
Clinical Applications  
CT  • Unlimited depth    
   penetration  
• High spatial resolution  
• Whole-body imaging   
   possible 
• Short acquisition time 
  (minutes) 
• Moderately expensive  
• Anatomical imaging  
• Irradiation exposure  
• Poor soft tissue contrast  
• Probably not used for  
   molecular imaging – 
  currently only anatomical   
  and functional imaging  
• barium  
• iodine  
• krypton 
• xenon  
• Tumor perfusion  
PET  • Unlimited depth   
   penetration 
• Whole-body imaging  
  possible 
• Quantitative molecular 
 imaging 
• Can be combined with CT    
  or MRI for anatomical 
  information  
• Irradiation exposure  
• Expensive  
• Low spatial resolution  
  (1–2 mm; 4–8 mm3) 
• Long acquisition times 
  (minutes to hour)  
• 11C 
• 18F 
• 64Cu 
• 68Ga  
•18F-FDG-PET for 
  cancer staging  
• Diagnosis of various  
  diseases  
SPECT  • Unlimited  depth  
  penetration  
• Whole-body imaging  
  possible 
• Quantitative molecular  
  imaging  
• Theranostic: Can combine 
  imaging & radiotherapy  
• Can be combined with CT   
for anatomical information  
• Irradiation exposure  
• Low spatial resolution  
(0.3–1 mm; 12–15mm3) 
• Long acquisition time  
• 99mTc 
• 123I 
• 111In 
• 177Lu  
• Diagnosis of various  
  diseases  
• Radiotherapy for NHL:   
90Y-Bexxar  
  or 131 I-Zevalin  
• Radiotherapy of thyroid    
carcinoma with 131I-  
  iodide  
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MRI  • Unlimited depth  
penetration  
• Whole-body imaging  
possible 
• No ionizing  irradiation 
• Excellent soft tissue 
contrast  
• High spatial resolution  
• Expensive  
• Long acquisition time 
(min-hours) 
• Limited sensitivity for 
detection of molecular  
contrast agents  
• Gadolinium 
(Gd3+) 
• iron oxide 
particles  
(SPIO, USPIO) 
• manganese 
oxide  
• 19F  
• SPIOs for detection of 
lymph node metastases 
of prostate cancer 
• Characterization of 
focal hepatic lesions 
• Perfusion imaging of 
the heart  
MRS  • Whole-body imaging  
possible 
• No ionizing irradiation  
• Expensive  
• Long acquisition 
time (min - hours) 
• Low sensitivity  
• choline 
• creatine  
• lactate 
• lipids  
• polyamines 
• N-acetyl- 
  aspartate  
• Metabolite levels in 
brain tumors  
• Treatment monitoring 
of Alzheimers  
US  • No ionizing irradiation 
• Real-time imaging/short 
  acquisition time (min) 
• High spatial resolution  
• Can be applied externally   
  or internally (endoscopy) 
• Inexpensive  
• Highly sensitive  
• Wholebody imaging not 
  possible 
• Contrast agents 
  currently limited to    
  vasculature  
• Operator dependency  
• Contrast 
Microbubbles  
• Characterization of 
focal liver lesions  
• Echocardiography  
• Tumor perfusion of 
cancer  
Optical  • No ionizing irradiation 
• Real-time imaging/short 
  acquisition time (sec-min) 
• Relatively high spatial 
  resolution  
• Can be applied externally    
  or internally (endoscopy) 
• Inexpensive  
• Highly quantitative 
& sensitive 
• Multiplexing  
• Limited depth penetration  
(≤ 1 cm) 
• Wholebody imaging not 
possible  
• Fluorescent 
molecules & 
dyes  
• Light 
absorbing  
nanoparticles  
• OCT imaging of 
artherosclerosis  
• OCT imaging for 
colonoscopy screening 
• Raman imaging of 
skin cancer  
Table VIII-3: Advantages and disadvantages of medical imaging modalities used with molecularly 
targeted or non-targeted contrast agents in a clinical setting. 
-Adapted from Pysz et al. Clin Radiol. Clin Radiol. 2010 July; 65(7): 500–516.- 
MRS = magnetic resonance spectroscopy 
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IX. NIR Fluorescence imaging for intra-
operative guidance 
 
 One first attempt of translating optical techniques into clinic is the sentinel lymph 
node (SNL) mapping.  
 Being the first lymph node draining the lymphatic fluid coming from the tumor, the 
sentinel lymph node represents the first place of metastasis creation
198,199
(Figure IX-1). It has 
been shown that detection of SNL using intraoperative fluorescence imaging in patients with 
cervical and vulvar cancer using indocyanin green (ICG) is feasible and results in a high SBR 
(around 8)
200
. SNL mapping using ICG has also successfully been used in breast cancer 
melanoma, and head and neck cancer
201,202,203 
(Figure IX-2).  
 
 
 
 
 
 
 
 
 
 
                                                 
198 Schaafsma, BE, JS Mieog, M. Hutteman, JR van der Vorst, PJ Kuppen, CW Löwik, JV Frangioni, CJ van de Velde, and 
A. L. Vahrmeijer. “The Clinical Use of Indocyanine Green as a Near-infrared Fluorescent Contrast Agent for 
Image-guided Oncologic Surgery.” J Surg Oncol. 104(3), September 2011. 
199 Schaafsma, Boudewijn E, Joost R van der Vorst, Katja N Gaarenstroom, Alexander A W Peters, Floris P R Verbeek, 
Cornelis D de Kroon, J Baptist M Z Trimbos, u. a. „Randomized comparison of near-infrared fluorescence 
lymphatic tracers for sentinel lymph node mapping of cervical cancer“. Gynecologic oncology (July 10, 2012).  
200 Crane, Lucia M.A., George Themelis, K. Tim Buddingh, Niels J. Harlaar, Rick G. Pleijhuis, Athanasios Sarantopoulos, 
Ate G.J. van der Zee, Vasilis Ntziachristos, und Gooitzen M. van Dam. „Multispectral Real-time Fluorescence 
Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology“. Journal of 
Visualized Experiments : JoVE, Nr. 44 (Oktober 20, 2010). 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185642/. 
201 Mieog, J. Sven D., Susan L. Troyan, Merlijn Hutteman, Kevin J. Donohoe, Joost R. van der Vorst, Alan Stockdale, Gerrit-
Jan Liefers, u. a. „Toward Optimization of Imaging System and Lymphatic Tracer for Near-Infrared Fluorescent 
Sentinel Lymph Node Mapping in Breast Cancer“. Ann Surg Oncol. 18, 2011. 
202 van der Vorst, Joost R., Boudewijn E. Schaafsma, Floris P.R. Verbeek, Stijn Keereweer, Jeroen C. Jansen, Lilly-Ann van 
der Velden, Antonius P.M. Langeveld, u. a. „Near-infrared fluorescence sentinel lymph node mapping of the oral 
cavity in head and neck cancer patients“. Oral Oncology (o. J.). 
http://www.sciencedirect.com/science/article/pii/S136883751200245X. 
203Troyan, Susan L, Vida Kianzad, Summer L Gibbs-Strauss, Sylvain Gioux, Aya Matsui, Rafiou Oketokoun, Long Ngo, Ali 
Khamene, Fred Azar, und John V Frangioni. „The FLARE intraoperative near-infrared fluorescence imaging 
system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping“. Annals of surgical oncology 
16, Nr. 10 (Oktober 2009): 2943–2952. 
Figure IX-1: Metastatic cancer cells invade lymph 
vessels and blood vessels near a tumor and migrate to 
other parts of the body. 
-National Cancer Institute 2012- 
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Figure IX-2: NIR fluorescence labeling of lymphatic channels and SNL by ICG. 
-Schaafsma, Boudewijn E., J.Sven D. Mieog, Merlijn Hutteman, Joost R. van der Vorst, Peter J.K. Kuppen, Clemens W.G.M. 
Löwik, John V. Frangioni, Cornelis J.H. van de Velde, und Alexander L. Vahrmeijer. „The clinical use of indocyanine green 
as a near-infrared fluorescent contrast agent for image-guided oncologic surgery“. Journal of surgical oncology 104, Nr. 3 
(September 1, 2011): 323–332.- 
 
 
 Another example of image- guided surgery, not comprising cancer, is the intra-
operative fluorescent cholangiography, using ICG for robotic single site cholecystectomy
204
, 
microscope integrated ICG videoangiography during microneurosurgical treatment of 
intracranial aneurysms or cerebrovascular surgery
205
. 
 The previously mentioned SPY system was used in ICG guided open partial 
nephrectomy by Tobis et al.
206
, demonstrating the safety of this kind of surgery and the 
improved discrimination of renal cortical tumors from normal tissue. At the same time it 
highlighted renal vasculature, which could enhance nephron sparing and decrease blood loss. 
 Also in determination of flap perfusion in reconstructive breast surgery after 
mastectomy intra-operative near-infrared fluorescence imaging for the evaluation of 
                                                 
204 Buchs, Nicolas C, Monika E Hagen, François Pugin, Francesco Volonte, Pascal Bucher, Eduardo Schiffer, und Philippe 
Morel. „Intra-operative fluorescent cholangiography using indocyanin green during robotic single site 
cholecystectomy“. The international journal of medical robotics + computer assisted surgery: MRCAS (Mai 31, 
2012).  
205 Sevick-Muraca, E M. „Translation of near-infrared fluorescence imaging technologies: emerging clinical applications“. 
Annual review of medicine 63 (2012): 217–231. 
206 Tobis, Scott, Joy K Knopf, Christopher R Silvers, Jonah Marshall, Allison Cardin, Ronald W Wood, Jay E Reeder, u. a. 
„Near infrared fluorescence imaging after intravenous indocyanine green: initial clinical experience with open 
partial nephrectomy for renal cortical tumors“. Urology 79, Nr. 4 (April 2012): 958–964. 
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perforator location and flap perfusion was helpful
207
.  Verbeek et al. tried the ICG-NIR 
fluorescence imaging for hepatic colorectal metastases with promising results
208
. 
 Apart from ICG, Dam et al. lighted up ovarian cancer cells during surgery
209
 in a small 
study of 10 patients by targeting the folate receptor-α. This technique allowed surgeons to 
spot a tumor 30 times smaller than the smallest they could detect using standard techniques 
(Figure IX-3). 
 Nevertheless they used fluorescein isothiocyanate (FITC) as dye. This functional 
fluorochrome fluoresces in the green light spectrum and thus does not fulfill the advantages of 
NIR dyes. Also the use of ALA-guided microsurgical resections in glioblastomas (5-
aminolevulinic acid)
210,211
 is a method lacking the described benefits of NIR fluorescence in 
real-time imaging for surgery.  
 Other studies showing the feasibility of NIR fluorescence guided surgery with specific 
tracers in cancer surgery or for the intra-surgical identification of vessels and tubes (like the 
ureter) identification but are still in preclinics, using rodent or swine models
212,213
.  
For example Keereweer et al. showed the interest of optical guided surgery of oral cancer and 
cervical lymh node metastases. Using the EGF receptor targeting NIR probe CW800 EGF and 
the glucose transporter system targeting NIR probe CW800 2-DG, they demonstrated efficient 
targeting of orthotopic cancer in mouse models
214
. A similar study was done in the laboratory 
of Ntziachristos at the TUM (Technische Universität München). His team showed the ability 
of an αvβ3 integrin-targeting molecule (IntegriSense-680) to detect breast-tumor xenografts in 
mice and to easier identify tumor negative margins with high specificity performing real-time 
                                                 
207 Lee, Bernard T, Merlijn Hutteman, Sylvain Gioux, Alan Stockdale, Samuel J Lin, Long H Ngo, und John V Frangioni. 
„The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in perforator 
flap breast reconstruction“. Plastic and reconstructive surgery 126, Nr. 5 (November 2010): 1472–1481. 
208 Verbeek, F. et al., WMIC, 2012: SS 168 
209 Dam, Gooitzen M. van, George Themelis, Lucia M. A. Crane, Niels J. Harlaar, Rick G. Pleijhuis, Wendy Kelder, 
Athanasios Sarantopoulos, et al. “Intraoperative Tumor-specific Fluorescence Imaging in Ovarian Cancer by Folate 
Receptor-α Targeting: First In-human Results“. Nature Medicine 17, Nr. 10 (2011): 1315–1319. 
210 Cortnum, Søren, und René Johannes Laursen. „Fluorescence-guided resection of gliomas“. Danish medical journal 59, 
Nr. 8 (August 2012): A4460. 
211 Gautschi, O.P., K. van Leyen, D. Cadosch, G. Hildebrandt, und J.-Y. Fournier. „Fluorescence Guided Resection 
ofMalignant Brain Tumors – Breakthrough in the Surgery of Brain Tumors“. Praxis 98 (o. J.): 643–647. 
212De Grand, A M, und J V Frangioni. „An operational near-infrared fluorescence imaging system prototype for large animal 
surgery“. Technology in cancer research & treatment 2, Nr. 6 (December 2003): 553–562. 
213 Matsui, Aya, Eiichi Tanaka, Hak Soo Choi, Vida Kianzad, Sylvain Gioux, Stephen J Lomnes, und John V Frangioni. 
„Real-time, near-infrared, fluorescence-guided identification of the ureters using methylene blue“. Surgery 148, Nr. 
1 (Juli 2010): 78–86. 
214 Keereweer, Stijn, Jeroen D. F. Kerrebijn, Isabel M. Mol, J. Sven D. Mieog, Pieter B. A. A. Van Driel, Robert J. 
Baatenburg de Jong, Alexander L. Vahrmeijer, und Clemens W. G. M. Löwik. „Optical Imaging of Oral Squamous 
Cell Carcinoma and Cervical Lymph Node Metastasis“. Head & Neck 34, Nr. 7 (2012): 1002–1008. 
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NIR imaging during surgery compared to visual inspection
215
. Similar results were obtained 
by our team demonstrating the improved resection of micrometastases in peritoneal 
carcinomatosis in mice due to NIR-guided real-time vision
216
. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IX-3: Tumor-specific fluorescence intra-operative imaging in ovarian cancer. 
View of localized region in peritoneal cavity of an ovarian cancer patient as seen with A) the naked eye or B) 
with the aid of a tumor-targeted fluorescence dye. 
-Dam, Gooitzen M. van, George Themelis, Lucia M. A. Crane, Niels J. Harlaar, Rick G. Pleijhuis, Wendy Kelder, Athanasios 
Sarantopoulos, et al. “Intraoperative Tumor-specific Fluorescence Imaging in Ovarian Cancer by Folate Receptor-α 
Targeting: First In-human Results“. Nature Medicine 17, Nr. 10 (2011): 1315–1319.- 
 
 
 To conclude, up to now no clinically approved targeting NIR fluorescence contrast 
agents with corresponding imaging devices are available for clinical imaging of surgery.  
As described, ICG is the only injectable agent with NIR properties. But ICG has 
comparatively poor fluorescent properties compared to emerging dyes, showing a low QY. In 
a complex with human serum albumin (HAS), it reaches a 3-fold higher QY, which improves 
SLN retention
217
. Nevertheless it stays unspecific and therefore limited to perfusion and non 
specific accumulation.  Consequently, translation of the specific NIR fluorescence method 
into clinics is a combinational, investigational product of imaging device and imaging agent. 
As shown, only few clinical pilot studies and several pre-clinical approaches in NIR-guided 
surgery took place with encouraging results. 
                                                 
215 Themelis, George, Niels J Harlaar, Wendy Kelder, Joost Bart, Athanasios Sarantopoulos, Gooitzen M van Dam, und 
Vasilis Ntziachristos. „Enhancing surgical vision by using real-time imaging of αvβ3-integrin targeted near-infrared 
fluorescent agent“. Annals of surgical oncology 18, Nr. 12 (November 2011): 3506–3513. 
216 Keramidas, M, V Josserand, C A Righini, C Wenk, C Faure, und J L Coll. „Intraoperative near-infrared image-guided 
surgery for peritoneal carcinomatosis in a preclinical experimental model“. The British journal of surgery 97, Nr. 5 
(Mai 2010): 737–743. 
217 Tanaka, Eiichi, Hak Soo Choi, Hirofumi Fujii, Moungi G Bawendi, und John V Frangioni. „Image-guided oncologic 
surgery using invisible light: completed pre-clinical development for sentinel lymph node mapping“. Annals of 
surgical oncology 13, Nr. 12 (December 2006): 1671–1681. 
A B 
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 This approach could improve and assure a complete and more secure tumor resection. 
Ergo, there is interest in pushing NIR-guided intra-operative surgery techniques further into 
clinics and evaluate them under clinical conditions in different cancer types. 
 One possibility to enhance clinical translation, concerning the feasibility and 
usefulness of targeted intra-operative NIR imaging, would be the implication of natural 
occurring tumors in domestic animals like cats and dogs. This implicates real disease 
circumstances and surgical conditions. Additionally, a possible direct analogy between human 
and animal exists with less legal constraints. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
„Alle Ding' sind Gift und nichts ohn' Gift; allein die Dosis 
macht, dass ein Ding kein Gift ist.“ 
 (Omnia sunt venena, nihil est sine veneno. Sola dosis facit venenum.) 
 
Paracelsus (1493-1541) 
 
[Everything is a poison, nothing is without poison; the dose alone makes that it is not a poison.] 
  
 
 
  
RESULTS AND CONCLUSIONS 
 
  
 
Optical-guided surgery & development of SMARgeting probes for cancer                                         Results & conclusions                                          
  - 87 -  
I. OPTICAL GUIDED SURGERY OF FELINE 
FIBROSARCOMA 
 
Introduction 
 The goal of any tumor resection is to obtain complete removal of the 
malignant lesion with adequate margins within surrounding healthy tissues taking into 
account both tumor control and functional reconstruction. To date, no intra-operative 
method is available and reliable enough to help the surgeon delineate precisely tumor 
extension in the adjacent normal tissues. Thus, surgeons rely on pre-operative imaging 
techniques to delineate tumor margins which may often be blurred by peritumoral edema 
or inflammation within surrounding normal tissues. Similarly, pre- and intra-operative 
detection of metastasis, especially lung metastases, is limited by the size of the tumor 
lesions and is often suboptimal with current imaging and operating techniques. Hence, 
there is a need for improved intra-operative methods to allow better tumor margin 
visualization and metastasis detection. 
  
 Our team has been involved for a long time in the development of the 
Fluobeam™ (Figure I-1), a NIR imaging device, nowadays in preclinical studies. As well, 
based on the initial work of Pr P Dumy (Departement Chimie Moléculaire, Grenoble, 
France), our 2 teams generated, evaluated and patented a RAFT-(cRGD)4-dye probe for 
NIR-optical imaging. This tracer is now licensed to Fluoptics™ and commercialized under 
the name of AngioStamp™. 
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Figure I-1: The imaging device: Fluobeam™ 
 
 
 Using this targeted NIR probe, we previously demonstrated that optical guidance 
greatly improved the surgical quality by doubling the number of detected nodules and 
significantly reduced the duration of the surgery on mice bearing peritoneal 
carcinomatosis
218
.  
 AngioStamp™ will be administered intravenously to patients prior to surgery. It is 
therefore considered as a drug by the French regulatory commission (ANSM, agence 
nationale de sécurité du medicament et des produits de santé). As such AngioStamp™ has 
to be produced in clinical grade quality (GMP) and must prove its absence of toxicity as 
well as its capacity to augment the quality of the patients’ treatment. 
The objective of the following study was to check, on spontaneous cancers arising in pets, 
that the intra-operative NIR-guided surgery is feasible.  
 This clinical veterinary phase is based on surgery of the feline fibrosarcoma, also 
known as fibroblastic sarcoma. It is a mesenchymal tumor representing 40 to 50% of all 
skin tumors in cats. This neoplasm is one of the most common tumors in cats and shows an 
asymmetrical and infiltrating growth pattern. In general, the tumor can occur anywhere in 
the body; nevertheless, there is a preference for the interscapular region. Infiltration into 
the surrounding subcutaneous soft tissue and sometimes the underlying skeletal muscle are 
                                                 
218Keramidas, M, V Josserand, C A Righini, C Wenk, C Faure, and J L Coll. “Intraoperative Near-infrared Image-guided 
Surgery for Peritoneal Carcinomatosis in a Preclinical Experimental Model.” The British Journal of Surgery 97, 
no. 5 (May 2010): 737–743. 
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frequently observed. These characteristics account for the frequent local recurrence with 
rates ranging from 28% to 45% in different studies
219
. Wide or radical surgical excision 
currently represents the main therapeutic option
220
. It is generally accepted that complete 
resection improves the disease-free interval while incomplete resection increases the 
probability of treatment failure
221,222,223
. Because the extension of fibrosarcoma to surgical 
margins is important in predicting local recurrence, it is clear that quality of the surgery is 
crucially involved in the management of fibrosarcoma. Post-surgical therapeutic decisions 
are based on the status of surgical margins. These characteristics, added to the fact that this 
spontaneous soft tissue sarcoma mimics its human counterpart
224
sustain the possibility of 
easily transferring the system (Fluobeam™ & AngioStamp™) into human clinical studies 
for further evaluation in oncological surgery.  
 Since an agreement of the pet owners is needed, it was necessary to show them that 
the injection of AngioStamp™ will not harm the cat. We thus started a very light 
“toxicological study”, or rather called short safety observation studies, on three laboratory 
cats. At the same time we wanted to use these experiments for the definition of the starting 
1x dose that would sound adapted for detecting tumors. 
 
  
                                                 
219 V.S. Bregazzi, S. M.  LaRue, E. McNiel, D. W. Macy, W. S. Dernell, B. E. Powers, and S. J. Withrow. Treatment 
with a Combination of Doxorubicin, Surgery, and Radiation Versus Surgery and Radiation Alone for Cats with 
Vaccine-associated Sarcomas: 25 Cases (1995-2000). Journal of the American Veterinary Medical Association 
218, no. 4 (2001) 547–550.; Kobayashi T, Hauck ML, Dodge R, et al. Preoperative radiotherapy for vaccine 
associated sarcoma in 92 cats. Vet Radiol Ultrasound 2002;43:473-479. 
220 A. E.Hershey, K. U. Sorenmo, M. J. Hendrick, F. S. Shofer, and D. M. Vail. Prognosis for Presumed Feline Vaccine-
associated Sarcoma After Excision: 61 Cases (1986-1996). Journal of the American Veterinary Medical 
Association 216, no. 1 (January 1, 2000) 58–61. 
221 Kobayashi T, Hauck ML, Dodge R, et al. Preoperative radiotherapy for vaccine associated sarcoma in 92 cats. Vet 
Radiol Ultrasound 2002;43:473-479. 
222 A. E.Hershey, K. U. Sorenmo, M. J. Hendrick, F. S. Shofer, and D. M. Vail. Prognosis for Presumed Feline Vaccine-
associated Sarcoma After Excision: 61 Cases (1986-1996). Journal of the American Veterinary Medical 
Association 216, no. 1 (January 1, 2000) 58–61. 
223 K. Cronin, R. L. Page, G. Spodnick, R. Dodge, E. N. Hardie, G. S. Price, D. Ruslander, and D. E. Thrall. Radiation 
Therapy and Surgery for Fibrosarcoma in 33 Cats. Veterinary Radiology & Ultrasound: The Official Journal of 
the American College of Veterinary Radiology and the International Veterinary Radiology Association 39, no. 
1 (February 1998) 51–56. 
224E.P. Spugnini, A. Baldi, B. Vincenzi, F. Bongiorni, C. Bellelli, G. Citro, A. Porrello, Intraoperative versus 
postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous 
feline model. Cancer chemotherapy and pharmacology 59 (2007) 375-381. 
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I.1. Preliminary safety observation studies 
 
I.1.1. Introduction 
  
 The first aim of this preliminary safety observation study in cats was the evaluation 
of potential acute effects related to the administration of a single intravenous dose of 
AngioStamp™. 
 Therefore increasing doses have been tested on three cats: 0.9 mg/kg, 2.4 mg/kg 
and 4.5 mg/kg, respectively, corresponding to doses 1X, 3X and 5X (Figure-I-2), estimated 
on the bases of previous injection performed in mice and rats (further information see in 
“Materials and Methods”).  
 
 
 
Figure-I-2: Laboratory cats used for preliminary experiments with doses 1X, 3X and 5X. 
 
  
 One hour before injection of the tracer, the animals were clinically examined and 
two catheters were placed, one in the bladder and one in the cephalic vein (see “Materials 
and Methods”). 
 Before and after intravenous injection of AngioStamp™ the cats remained under 
medical control and the biochemical parameters were followed during 7 days post injection 
(Figure I-3). 
 
 
 
 
Cat 1 (1X) Cat 2 (3X) Cat 3 (5X) 
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Figure I-3: Schedule of sampling and fluorescence imaging 
 
I.1.2. Results 
 
 We expected to evaluate on these 3 cats: i) the absence of acute immediate toxicity, 
ii) the kinetic of distribution of the injected molecule as well as the level of intensity of 
fluorescence each dose was providing in the normal skin (useful for the determination of 
the working dose) and iii) the absence of biochemical disorders in blood and urines. 
 
 Absence of toxicity 
 
 No visible adverse effects due to the intravenous application of AngioStamp™ at 
the doses of 0.9, 2.4 and 4.5 mg/kg were observed.  
 
 The physical examination and follow-up of the blood and urine biochemical 
parameters confirmed that administration of AngioStamp™ at these 3 doses did not lead to 
any detectable toxicity (tables showing biochemical results in “Appendices”). 
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I.2. Fluorescecnce kinetic distribution of AngioStamp 
 
 Using the same 3cats injected with 0.9, 2.4 and 4.5 mg/kg of AngioStamp™ we ran 
a small study in fluorescence (Em780/ Ex795) on the different fluids as well as on the body 
of the animals in order to follow its kinetic of elimination and also to evaluate the amount 
of fluorescence signal in the skin. This last value would provide information on the basal 
intensities of fluorescence in the normal tissues, and on the possible detection of the signal 
expected in tumor tissues (see protocol and scheme above). We can thus see if the 
calculated dose provides a sufficient level of detection for inter-operative imaging.  
  
 The fluorescence intensity was measured in chronological sequences of blood (200 
µL), plasma (200 µL) and urine (10 µL) samples using the per-operative Fluobeam™. 
Images from T0 to 5 h 30 post injection of AngioStamp™ were also taken on the following 
shaved body regions: region of the right kidney and shoulder. The kidneys were chosen as 
the tracer has a renal elimination and the shoulder region, since it is the preferred 
localization the feline fibrosarcoma.  
  
 The unit p.d.u. (procedure defined unit) and the sampling are described in the 
Materials and Methods chapter. 
  
 The introduced term F50 describes the time needed for the fluorescent tracer signal 
to lose 50% of its maximal intensity. 
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I.2.1. Fluorescence in the plasma 
 In all animals, the fluorescence in the plasma presents a peak at 5 min post injection 
followed by a rapid decrease (Figure I-4).The maximal signal is 5-times higher in cat 2 and 
nearly 11-times higher in cat 3 compared to cat 1. 
 In cat 1 the maximal signal is decreases by 50% at 10 min (F50 = 10 min), in cat 2 
the F50 is at  25 min, thus 15 min more than in cat 1, and concerning cat 3 the F50 is reached 
at40 min post injection (p.i.) (Table I-1).  
 The fluorescence signal in cat 1 returns to the basal level after 4 h. as previously 
observed in mice, while at 5h30 (last measurement)  the level of fluorescence  in the 
plasma of cat 2 and 3 is still at 14% and 12% of their maximal peak value. 
 
 
Plasma 
Cat 1 
Dose 1X 
(0.9 mg/kg) 
Cat 2 
Dose 3X 
(2.4 mg/kg) 
Cat 3 
Dose 5X 
(4.5 mg/kg) 
Mouse 
Peak (minutes) 5 5 5 5 
p.d.u. max (/10
3
) 4 18 38 0.9 
Time F50 (min) 10 25 40 10 (40) 
% of maximal 
fluorescence at 
5h30 
0 14 12 0 
p.d.u. 5h30 (/10
3
) 0 2.6 4.7 0 
 
Table I-1: Compared fluorescence data of cat plasma. 
 
 
 
 
Figure I-4: Fluorescence kinetic of plasma samples (A & B, enlargement) and of the three cats, 
compared to mouse data. 
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I.2.2. Fluorescence in the blood 
 The total blood shows a similar fluorescence kinetic profile than that of plasma. A 
peak appears at 5 min followed by a smooth and steady decrease of the signal intensity 
after a second faint peak at the third or fourth measurement (Table I-2; Figure I-5).  
As expected, the intensities are lower in total blood compared to plasma 
measurements because blood is much more absorbing than plasma. 
As compared to cat 1 at 5 min, the maximal signal measured in cat 2, cat 3 and 
mice are 17-times, 24-times and 1-time, higher respectively. The maximal signal in cat 1 
decreases rapidly to reach the F50 at 10 min. In cat 2, cat 3 and mice, the F50 is reached after 
27 min, 18 min or 8 min p.i., respectively. In cat 1 the signal rapidly decreases and is back 
to the background levels after 4 h, as previously described in mice. This is somewhat 
delayed in cats 2 and cat 3 and 5% or 4% of the max intensity of fluorescence are still 
present at 4 h.  
 
Blood 
Cat 1           
Dose 1X (0.9 
mg/kg) 
Cat 2            
Dose 3X (2.4 
mg/kg) 
Cat 3          Dose 
5X (4.5 mg/kg) 
Mouse 
Peak (minutes) 5 5 5 5 
p.d.u. max 438 7600 10300 399 
Time F50 (min) 10 27 18 8 
% of maximal 
fluorescence at 
5h30 
0 1 3 0 
p.d.u. 5h30 0 92 340 0 
 
Table I-2: Compared fluorescence data of cat blood. 
 
 
 
 
Figure I-5: Fluorescence kinetic of blood samples (A & B, enlargement) and of the three cats, 
compared to mouse data. 
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I.2.3. Fluorescence in the urine 
 AngioStamp™ is known to be eliminated by renal excretion via the urine. In all 
three cats tested here, the urine was already showing a fluorescence peak as soon as 5 min 
post injection (Table I-3; Figure I-6).  
 In cat 2 and cat 3 the maximal signal is 4-times stronger compared to cat 1. 
4 h after injection, the fluorescent signal in the samples of cat 1 is close to the basal level.  
In cat 2 the fluorescent signal remains at 5h30 about 50% of the maximal measured signal. 
In cat 3 no decrease in the signal during time is measured.  
 
 
Urine 
Cat 1           Dose 1X 
(0.9 mg/kg) 
Cat 2            Dose 3X 
(2.4 mg/kg) 
Cat 3          Dose 5X 
(4.5 mg/kg) 
Peak (minutes) 5 5 5 
p.d.u. max 1.9*10
4
 7.1*10
4
 6.9*10
4
 
% of maximal 
fluorescence at 5h30 
0 50 100 
 
Table I-3: Compared fluorescence data of cat urine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I-6: Fluorescence kinetic of urine samples of cat 1 to 3. 
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I.2.4. Fluorescence in the kidney 
 The fluorescent signal measured at kidney level increases directly after the injection 
of AngioStamp™ and  reaches a peak at 1 h in cats 1 and 2 against 30 min in cat 3(Table 
I-4; Figure I-7). In mice the peak was already reached at 5 min. The signal then decreases 
smoothly but steadily, showing a similar profile to plasma and blood measurements. 
 When comparing the maximal signals of cats 2, 3 and mice to that of cat1, cat 2 
shows a 6.5-times, cat 3 an 82-times and mice a 3-times higher signal. In cat 1 the F50 is 
reached after 3h30, in cat2 at 3h15 and in cat 3 at 2h30 p.i. In mice the F50 is at 2 h p.i. At 
5h30 a residual fluorescence could be measured of 11 % of the maximal signal in cat 1, 18 
% in cat 2, and 29 % in cat 3.  
 Thus the dose 1x is far more rapidly eliminated with an increasing ratio between cat 
1 and cats 2 and 3, showing a difference at 5h30 of nearly 10-times (cat 1 & cat 2) and 
193-times (cat 1 & cat3). 
 
Kidney 
Cat 1           Dose 
1X (0.9 mg/kg) 
Cat 2            Dose 
3X (2.4 mg/kg) 
Cat 3          Dose 
5X (4.5 mg/kg) 
Mouse 
Peak (minutes) 60 60 30 5 
p.d.u. max 16 105 1330 50 
Time F50 (h) 3h30 3h15 2h30 2 
% of maximal 
fluorescence at 5h30 
11 18 29 n.d. 
p.d.u. 5h30 2 19 385 n.d. 
 
Table I-4: Compared fluorescence data of cat kidney. 
n.d. = no data 
 
 
 
 
 
Figure I-7: A) Fluorescence kinetic of the kidney region (B enlargement) of the three cats, compared to 
mouse data. 
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I.2.5. Fluorescence in the shoulder 
 The fluorescence measured at the level of the shoulder increased until reaching a 
maximal signal at 1 h p.i. in cat 1 and 2, and 30 min in cat 3 (Table I-5; Figure I-8). The 
maximal signal in cat 2 and cat 3 represents roughly 17- to 134 -times the one measured in 
cat 1. 
The F50 in cat 1 corresponds to 1h45, in cat 2 to 4h and in cat 3 to 3h. 
 At 4h post injection the fluorescent signal was returned to basal level in cat 1. 
Cat 2 and cat 3 still presented elevated levels of fluorescence after 5h30, being at 34% and 
44%, respectively of their maximal signal. 
 
 
Shoulder 
Cat 1 
Dose 1X (0.9 mg/kg) 
Cat 2 
Dose 3X (2.4 mg/kg) 
Cat 3 
Dose 5X (4.5 mg/kg) 
Peak (minutes) 60 60 30 
p.d.u. max 7 122 938 
Time F50 (h) 1h45 4 3 
% of maximal 
fluorescence at 5h30 
0 34 44 
p.d.u. 5h30 0 41 408 
 
Table I-5: Compared fluorescence data of cat shoulder. 
 
 
 
 
 
 
 
Figure I-8: A) Fluorescence kinetic of the shoulder region (B enlargement) of the three cats. 
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I.3. Conclusion and Discussion 
 Based on the fluorescence kinetic data obtained in mice with best conditions 
already evaluated in former studies, the dose of 0.9 mg/kg was found to be sufficient for 
further surgical experiments in cats. 
 The difference in signal, measured in kidney and plasma or blood in cat 2 and cat 3 
compared to cat 1 lead to the presumption that molecule elimination in the kidneys reaches 
a plateau due to saturation of the glomeruli in the kidneys after 5 min already. Thereafter a 
slow desaturation follows, depending on the residual tracer circulation in the organism. 
The higher the concentration, the slower the desaturation of this organ occurs. 
Consequently, a higher molecule concentration is circulating in the organism for a longer 
period of time. This reciprocal proportion is due a so-called first-order reaction, 
characterized by elimination of a constant proportion (%) per time interval, but not a 
constant amount.  
 This could explain the faster peaking of maximal signal in the shoulder of cat 3 
than cat 1 and cat 2. The difference measured in the blood and plasma fluorescence 
intensities might reflect more certainly differences in the absorption coefficient of blood as 
described in the introduction chapter.  
In conclusion we can claim, that despite minor differences, the biodistribution profile of 
AngioStamp™ in cats is comparable to the one previously described in mice.  
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I.4. Surgery of the feline fibrosarcoma 
 Since the preliminary toxicological study did not show any sign of toxicity, we 
were authorized by the veterinary university and the animal owners to perform fluorescent-
guided surgery on cat “patients”. On spontaneous tumor bearing animals several questions 
still needed to be answered: 
 How much AngioStamp™ should be injected? 
 How long before surgery AngioStamp™ should be injected? 
 Is the AngioStamp™ binding only to the tumor tissue? 
 What is the sensibility of the method? 
 What is the feeling of the surgeon regarding the technology? 
In order to answer these questions, 14 cats were enrolled and classified in six different 
groups (Table I-6). Each animal was examined and controlled by means of X-ray scans 
before being referred to the surgical department (Figure I-9). All cats but one recorded in 
this study suffered of fibrosarcoma in the shoulder region. The last one presented a tumor 
on lumbar heights (Table I-7).  
Group AngioStamp™  
(mg / kg) 
Time of surgery after 
injection (h) 
n (group size) 
1 0.6 16 1 
2 0.3 16 4 
3 0.3 24 2 
4 0.3 36 2 
5 0.15 36 3 
6 0.15 24 2 
 
Table I-6: Conditions tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I-9: X-ray scanner images of case #5.  
A) shows the slice on the level of the primary tumor. In B) developed lung metastases 
can be seen. 
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Patient & date of surgery  
 
AngioStamp™ 
(mg/kg) 
 
Surgery  
(h p.i.) 
 
Tumor 
location&he
alth status 
(before 
surgery) 
Weight 
(kg) 
 
age 
(years) 
& sex 
 
Color/ 
race 
 
Remarks  
follow-up 
1)“ Sally ” 
June 2011 
0.625 16 
Right 
shoulder & 
axillar 
region 
(punction: 
blood); 
anaemic 
3.9 
10; 
♀ 
 
Tri-
color/ 
ESH 
 
n.r. until 
August 2012 
2) ”Sunny ” 
June 2011 
 
0.3 
16 
Left 
shoulder; 
n.r.* 
2.8 
11 ; 
♀ 
 
Grey 
striped / 
ESH 
n.r. until 
August 2012 
3) ”Mousse ” 
September 2011  
 
0.3 
16 
right side 
of thorax; 
n.r.* 
4.4 
12; 
♀ 
castrated 
 
Tri-
color/ 
ESH 
 
n.r. until 
August 2012 
4) “ Lilou ” 
October 2011 
 
0.3 
16 
Left 
shoulder & 
axillar 
region until 
height of 
diaphragm 
n.r. * 
6.5 
7; 
♀ 
 
white/ 
ESH 
 
Recrudescence 
after 6 months 
– euthanasia 8 
months after 
surgery 
5) ”Comette” 
October 2011 
 
0.3 24 
Right 
shoulder 
incl. 
scapula; 
Tumor 
necrotic; 
lung-
metastases 
3.6 
13; 
♀ 
 
black / 
ESH 
 
6 months after 
surgery: 
Neoplasia (no 
metastasis) 
euthanasia 
after failure of 
treatment 
6) ”Toundra ” 
Oktober 2011 
 
0.3 16 
right side 
of thorax; 
n.r.* 
 
3.2 
9 ; 
♀ 
 
Tri-
color / 
ESH 
 
n.r. until 
August 2012 
7) “ Pepper ” 
November 2011 
 
0.3 24 
Dorsal 
(column 
vertebral, 
thoracal) 
n.r. * 
 
5.7 
9; 
♀ 
 
Tri-
color / 
ESH 
 
n.r. until 
August 2012 
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8) ”Chouchou” 
February 2012 
 
0.3 36 
Dorso-
lateral 
dexter 
(scapula & 
column 
vertebral); 3rd 
surgery 
(2ndrelaps), 
no other 
remarks 
8.2 
8; 
♂ 
castrated 
Light-
coloured 
grey-
striped / 
ESH 
 
n.r. until 
August 2012 
9) ”Aragorn” 
February 2012 
 
 
0.3 
36 
Dorsal 
(column 
vertebral, 
thoracal) 
n.r. * 
 
5.8 
8; 
♂ 
 
gray-
white-
black 
striped / 
ESH 
 
n.r. until 
August 2012 
10)“ Kochka ” 
March 2012 
 
0.15 
36 
Left 
shoulder; 
Amputation 
of left front 
leg; 
n.r.* 
4.9 
11.5; 
♀ 
castrated 
 
Black / 
ESH 
 
2 months after 
surgery: tumor 
of paw – 
euthanasia 
11) ”Nickdouille La Fripouille” 
March 2012 
 
0.15 36 
1) Left 
shoulder, 
necrotic; 2) 
right 
shoulder; 
n.r.* 
 
3.8 
10; 
♂ 
 
Red-
black 
striped / 
ESH 
 
n.r. until 
August 2012 
12) ”Isis” 
March 2012 
 
0.3 36 
Rezidive, 
tumor left 
shoulder; 
6.4 9; 
♀ 
Red-
black 
striped / 
ESH 
† 3 days after 
surgery 
because of 
probable 
septicemia 
13)”Pepere” 
June 2012 
 
0.15 24 
Left side 
inter-
scapular 
5.5 
12; 
♂ 
 
ESH 
n.r. until 
August 2012 
14) “Crackeurs” 
June 2012 
 
0.15 24 
Lumbale 
region, 
right dorsal 
5.9 
8; 
♂ 
castrated 
Red 
striped 
ESH 
n.r. until 
August 2012 
Table I-7: Patient data, showing dose and time of surgery after injection of AngioStamp™, region of 
the tumor, notable complications for surgery (health status, other than primary tumor), weight, age, 
sex, color and follow-up until august 2012. 
(n.r. *= no remarks; ESH = European short hair) 
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 Surgery was performed in the standard surgery facilities of the veterinary campus in 
Lyon (VetAgroSup, Marcy l’Etoille) in collaboration with the teams of Frédérique Ponce 
(Oncology of small animals department) and Claude Carozzo (Surgery of small animals 
department) and the pathological facilities.  
 
 The system for imaging, called Fluobeam™, was installed near the operation table 
so that the screen was visible for the surgeon’s assistant(s) only. One assistant was holding 
the Fluobeam™ in his hands during image acquisition (Figure I-10). Surgery was 
performed as usual, i.e. without the help of fluorescence. The surgeon was interrupted from 
time to time for a few minutes in order to take images and to record video sequences of the 
operation scene.  
 
 We observed that the tumors of all patients were significantly labeled by 
AngioStamp™, showing the best tumor-to-healthy tissue ratio at a dose of 0.3 mg/kg 
injected at 36 h before surgery. We also demonstrated that the percentage of tumor tissue 
per sample correlated with its profile of fluorescence intensity. 
 The results of this study initially performed on 12 first cats (group 6 was not 
studied at the time we submitted these results for publication) are presented in the 
publication: 
 
“Near-infrared optical guided surgery of highly infiltrative fibrosarcoma in cats using 
an anti-αvß3integrin molecular probe”, Wenk et al.; Cancer Letters, 2012 submitted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I-10: Intra-operative imaging by using the Fluobeam™. 
                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Near-infrared optical guided surgery of highly infiltrative fibrosarcoma in cats using 
an anti-αvß3integrin molecular probe”, 
Wenk et al.; Cancer Letters, 2012 
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I.4.1. Surgery of group 6 
 The tumor-to-muscle ratio of the sixth group (0.15 mg/kg at 24 h) confirmed the 
results presented in the publication, since: 
 
 The tumor signal was as elevated as in group 5, receiving the same dose but at 36 h 
before surgery; 
 The signal in healthy tissues was slightly more elevated than in group 5 (Figure 
I-11); 
 Finally the tumor-to-background (healthy tissue) ratio was not significantly 
improved (ratio of 10) (Figure I-12). 
 
 
 
 
 
  
Figure I-11: Fluorescence intensity compared during surgery of all 6.  
Each point corresponds to a specific measurement. The Box-Whisker represents the mean of each group, their maximum and 
minimum value and the interquartile range. 
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 Thus, the results obtained with the two additional cats studied in group 6 did not 
change our global conclusion that the best dose of AngioStamp™ was at 0.3 mg/kg 
injected 36 h before surgery. 
 
I.4.2. Dealing with the autofluorescence and “auto-LUT” during 
surgery 
 
 Normally, The Fluobeam™ functions with enabled “auto-LUT”. The LUT (Lookup 
table) is used to improve the visual presentation of an image on the screen. The 16-bit 
camera provides 65,536 gray level images. If the LUT signal is adjusted automatically, the 
sample will always appear “fluorescent” on the screen, even  if it is negative. In contrast, if 
the LUT is fixed in order to provide the best visualization of the brightest areas, then 
negative signal will not be “visible” on the screen anymore. In the example of Figure I-13, 
the LUT is fixed on [0 – 3893], which corresponded to its best adjustment to the positive 
tumor sample. We can see that in these conditions, normal tissues are negative. This is not 
true on the bottom panel, in which the auto-LUT was turned enabled. In this case, it 
presents a confusing signal on normal tissues. 
 
Figure I-12: Tumor-to-healthy tissue ratio of all 6 groups during surgery. 
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Figure I-13: Tumor-signal normalized LUT of different tissues compared to their Auto-LUT images. 
 
 
 
I.4.3. Good positioning of the camera during surgery 
 As expected, the vertical positioning of the Fluobeam™ on a given spot can 
dramatically change the quality of the recorded signal. The laser beam must be centered on 
the sample, as demonstrated in Figure I-14, if semi quantification is the issue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure I-14: Difference in measured fluorescence intensity dependent on the placement towards the 
central laser beam. 
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I.5. General conclusion 
 
 As demonstrated, the fluorescent tracer AngioStamp™ does neither show any 
visible toxicological effect, nor side-effects until one year after injection. 
In the clinical set-up, we found that the best tumor-to-healthy tissue ratio is at 0.3 mg/kg 
and surgery 36 h after injection. By lowering the dose, not all receptors are saturated, as we 
observed when using 0.15 mg/kg. Leaving less time between injection and surgery, not all 
non-specifically bound or circulating molecules are evacuated by the organism. This 
reduces the tumor-to-healthy tissue ratio as seen in the first three groups tested. 
 At the same time we demonstrated that training is important for appropriate 
handling of the Fluobeam™ imaging system as well as for correct image analysis and 
interpretation. The Fluobeam™ works with an auto adaptation of the LUT, which leads to 
the impression of false positive signal. Another result showed that the signal obtained was 
not reliable also when either the image was not correctly focused or if the measurement 
was made on the edge of the laser light cone. 
  
 As a general conclusion, we found that this system present enough interest to be 
used in surgery. Indeed, the intensity of the fluorescent signal can help the surgeon to 
detect low levels of tumor infiltration in normal tissues. However, this signal may not 
always be associated with the reactivity of the LM609 anti-human integrin in cats.  
  
 These results are extremely promising and justify the translation of this method in 
the clinics. 
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II. GELOFUSIN STUDY 
 
 As demonstrated in mice and cats, the RAFT-RGD peptide (and its fluorescent 
derivative AngioStamp™) is eliminated via the kidneys where it is strongly accumulated. 
This has several consequences that may limit its application in humans:  
 
 Elevated risk of renal toxicity when RAFT-RGD is labeled with a radionuclide, or a drug. 
 
 When fluorescent RAFT-RGD accumulates in kidneys, this will mask a possible signal 
within or beside this organ and thus limit its interest for the surgery of the peritoneal 
cavity. 
 Therefore, we decided to test different possibilities in order to decrease the RAFT-
RGD accumulation in kidneys. This was performed in collaboration with the team of Pr C 
Ghezzi. We used RAFT-RGD-A700 (AlexaFluor
®
700) in parallel with radiolabeled 
111
In-
DOTA-RAFT-RGD to study the impact of Gelofusin pre-/treatment of  mice.  
  
 In normal kidneys, reabsorption of filtered proteins occurs almost exclusively by 
receptor-mediated endocytosis in the proximal tubules. The efficient reabsorption of 
proteins in the primary urine is mediated by megalin-driven reabsorption of nearly all 
filtered plasma proteins in cooperation with the receptor protein cubilin, leading to 
receptor-mediated endocytosis in the proximal tubule
225
. As the megalin system was shown 
to be essential for kidney uptake of radiolabeled somatostatin analogs, interventions at the 
megalin level presented interesting potential targets for renal protection during peptide 
receptor radionuclide therapy
226
. 
  
 Gelofusin is a gelatin-based plasma expander, playing a role in the Megalin/Cubilin 
system. Gelofusin is known to inhibit proximal tubular reabsorption
227
.   
                                                 
225Christensen, Erik I, Henrik Birn, Tina Storm, Kathrin Weyer, und Rikke Nielsen. „Endocytic receptors in the renal 
proximal tubule“. Physiology (Bethesda, Md.) 27, Nr. 4 (August 2012): 223–236. 
226Rolleman, Edgar J, Marion de Jong, RoelfValkema, DikKwekkeboom, BoenKam, und Eric P Krenning. „Inhibition of 
kidney uptake of radiolabeled somatostatin analogs: amino acids or gelofusine?“ Journal of nuclear medicine: 
official publication, Society of Nuclear Medicine 47, Nr. 10 (Oktober 2006): 1730–1731; author reply 1731. 
227Gerritsen, Karin G., Hilde P. Peters, Tri Q. Nguyen, Maarten P. Koeners, Jack F. Wetzels, Jaap A. Joles, Erik I. 
Christensen, u. a. „Renal Proximal Tubular Dysfunction Is a Major Determinant of Urinary Connective Tissue 
Growth Factor Excretion“. American Journal of Physiology - Renal Physiology 298, Nr. 6 (Januar 6, 2010): 
F1457–F1464. 
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 Thus, regarding its importance in the tubular reabsorption of peptides and the fact 
that preinjection of Gelofusin was described to efficiently reduce renal retention of 
peptides, we tested its capacity of reducing the renal retention of RAFT-RGD-based 
molecules.  
 
 The study showed that indeed Gelofusin pretreatment of tumor-bearing mice was 
associated with a reduction of RAFT-RGD-A700 (AlexaFluor®700) as well as 
radiolabelled 
111
In-DOTA-RAFT-RGD capture in the kidneys. 
 
                                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
„Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during 
integrin αvβ3 targeting using single photon emission computed tomography and optical 
imaging“.  
Cancer science 103, Nr. 6 (June 2012): 1105–1110. 
Christiane H F Wenk & Arnaud, Briat, Mitra Ahmadi, Michael Claron, Didier Boturyn, 
Véronique Josserand, Pascal Dumy, Daniel Fagret, Jean-Luc Coll, Catherine Ghezzi, 
Lucie Sancey, Jean-Phillipe Vuillez 
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III. DESIGN & CHARACTERIZATION OF 
ACTIVATABLE PROBES FOR CANCER 
IMAGING & THERAPY 
 
 
Introduction 
  
 Integrin αvβ3 is overexpressed in response to an outside signal that indicates to the 
cell that it has to move toward a chemo-attractive gradient. Since a moving cell needs to 
degrade the ECM (e.g. collagen, fibrils) for moving, this cell must produce enzymes for 
ECM degradation. These are the so called matrix metalloproteases (MMPs) among which 
MMP-2 and MMP-9.  
 MMPs are a family of proteases that catalyze the destruction of particular peptidic 
sequences. We can thus use these sequences and the catalytic activity of MMPs to generate 
activatable molecular probes. 
 In addition, these proteases can serve as potential co-targets for new bifunctional 
derivatives of RAFT-RGD molecules with improved specificity and biological activities. 
The introduction of a cleavable bond can serve for on-target specific delivery of a prodrug, 
but we can also use this controlled degradation for fluorescence imaging like we already 
demonstrated with the introduction of a disulfide bond
228, 229
.  
 The second part of my thesis project was thus focused on the synthesis of a second 
generation of activatable probes (Figure III-1).  
 
 
 
 
 
                                                 
228
Foillard, Stéphanie, Zhao-hui Jin, Elisabeth Garanger, Didier Boturyn, Marie-Christine Favrot, Jean-Luc 
Coll, und Pascal Dumy. „Synthesis and biological characterisation of targeted pro-apoptotic peptide“. 
Chembiochem: a European journal of chemical biology 9, Nr. 14 (September 22, 2008): 2326–2332. 
229
Dufort, Sandrine, Lucie Sancey, Amandine Hurbin, StéphanieFoillard, Didier Boturyn, Pascal Dumy, und 
Jean-Luc Coll. „Targeted delivery of a proapoptotic peptide to tumors in vivo“. Journal of Drug 
Targeting 19, Nr. 7 (August 2011): 582–588. 
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At first we had to select appropriated MMP2/9 cleavable peptide sequences in order to 
combine them with the targeting molecule RAFT-c(RGD)4, thus forming the afterwards 
called RAFT-RGD-MMP.  
 We chose a set of cleavable peptide sequences, based on the studies [
230
], [
231
] and 
the MEROPS peptide database. We tested their sensibility towards MMPs in vitro first. 
Afterwards, a cleavable sequence was chosen and synthesized with NIR-dyes to generate 
the self-quenched RAFT-RGD-MMP molecule which was then tested in vitro and in vivo. 
 As described in the experimental section linear peptides were synthesized by solid 
phase peptide synthesis (SPPS) using Fmoc/tBu strategy. Functionalizations and molecular 
assemblies were carried out in solution. 
  
Figure III-1: Structure of the scaffold RAFT presenting the ligand « RGD ». 
a) fluorescent compound, b) activatable compound. 
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III.1. Results and discussion 
III.1.1. MMP-2 AND MMP-9 CLEAVAGE TEST – SEQUENCE SELECTION 
 The first step was the synthesis of peptide sequences cleaved by MMP-2 and/or 
MMP-9 (Figure III-2). Peptide 1 and peptide 2 were taken from Laure-Fields
230
, whereas 
peptide 3 was designed after information of the peptide database "Merops" 
(http://merops.sanger.ac.uk/). Scramble peptide 4 was prepared to provide the negative 
control compound. All peptides were prepared by using a standard Fmoc/tBu solid-phase 
chemistry on an acid-labile resin. Protective groups for Glutamine, Arginine and 
Tryptophan were respectively Trt, Pbf and Boc. The monitoring of MMP cleavage studies 
was performed thanks to the Dansyl labeling (abs = 320 nm) at the N-terminal of all 
peptides (Figure III-3). Finally, peptides were released from the resin by treatments with 
acid solutions. Fluorescent peptides 1-4 were then characterized by RP-HPLC analysis and 
mass spectroscopy. 
 
Figure III-2: Chromatograms of 1, 2, 3 and 4 at 214 nm and their structure. 
 
                                                 
230Lauer-Fields, Janelle L., ThilakaSritharan, M. Sharon Stack, Hideaki Nagase, und Gregg B. Fields. „Selective 
Hydrolysis of Triple-helical Substrates by Matrix Metalloproteinase-2 and -9“. Journal of Biological Chemistry 
278, Nr. 20 (Mai 16, 2003): 18140–18145. 
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Figure III-3: Grafting of Dansyl fluorescent dye on resin. 
  
 
As the MMP-9 and -2 cleavages occur at the Gly-Val bond or at the Gly-Leu bond (also by 
MMP-1;-8;-13; -14)
231,232 
the following peptidic fragments were expected: 
 
1: Dns- Gly-Pro-Leu-Gly  Leu-Trp-Ala-Arg-Gln-NH2 
2: Dns- Gly-Pro-Leu-Gly  Val-Trp-Ala-Arg-Gln-NH2 
3: Dns- Gly-Pro-Gln-Gly  Leu-Ala-Gly-Gln-NH2 
4: Dns- Gly-Leu-Arg-Gly-Pro-Trp-Leu-Ala-Gln-NH2 (none = control negative) 
 
 No full cleavage was observed for compounds 1 and 3 after incubation with MMP-
2 or MMP-9. However, peptide 3 was totally cleaved by MMP-9 and partially by MMP-2 
(Table III-1). Hence, we chose this compound for further in vitro and in vivo examinations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
231Lauer-Fields, Janelle L., ThilakaSritharan, M. Sharon Stack, Hideaki Nagase, und Gregg B. Fields. „Selective 
Hydrolysis of Triple-helical Substrates by Matrix Metalloproteinase-2 and -9“. Journal of Biological Chemistry 
278, Nr. 20 (Mai 16, 2003): 18140–18145. 
232Kline, Toni, Michael Y Torgov, Brian A Mendelsohn, Charles G Cerveny, und Peter D Senter. „Novel antitumor 
prodrugs designed for activation by matrix metalloproteinases-2 and -9“. Molecular pharmaceutics 1, Nr. 1 
(Januar 12, 2004): 9–22. 
peptide Control (RT) MMP-2 (RT) MMP-9 (RT) 
 
1 
15.40 
15.39 
16.79 
15.40 
19.80 
 
2 
19.96 19.46 
19.39 
26.8 
 
3 
15.60 
16.50 
17.21 
27.91 
9.91 
 
4 
20.17 20.29 
20.20 
27.97 
Table III-1: RT-HPLC measured retention times (RT) of compounds 1, 2, 3 and 4 of crude peptide 
(control) and of peptides after incubation with MMP-2 and MMP-9 (2 h, 37°C). 
Green represents the uncleaved peptide, orange the products after peptide cleavage by MMP-2 and blue the products after 
peptide cleaved by MMP-9 
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 Amongst others, we defined the percentage of compound 3 degradation by MMP-9. 
The test was done by means of reverse phase-HPLC (Figure III-4). We observed that 50 % 
of peptide was digested in 1 minute then digestion slowed down. After 2 h of incubation, 
13 % of peptide 3 was present (Figure III-5). 
 
 
Figure III-4: RT-HPLC analysis at 633nm of the degradation of compound 3 by MMP-9, with 
structure of molecule. 
Chromatogram A shows the HPLC profile of peptide 3, Chromatogram B shows the HPLC profile of the molecule after 2 
h of incubation with MMP-9 at 37°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure III-5: Percentage of compound 3 cleavage after incubation with MMP-9.  
Measurementsvia RT-HPLC at T0, 1 min, 2.5 min, 5 min, 15 min and 2 h after 
incubation with activated MMP-9 at 37°C. 
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III.1.2. Synthesis of activatable probes 
 
 Our macromolecular activatable fluorescent compound comprises a targeted drug 
delivery system based on the RAFT-RGD peptide and a quenched cyanine 5 (Cy5) dye-
containing MMP peptidic sequence (Figure III-1). We decided to exploit a combination of 
Cy 5 fluorescent dye and QSY quencher that were successfully used for drug monitoring in 
vivo
233
 recently. To graft these chromophores to the peptidic sequence 3, we introduced 
functionalized lysines at the C-terminal and N-terminal, protected respectively by Alloc 
and Dde groups. For the assembly of RAFT-RGD molecules and activatable fluorescent 
MMP, we used oxime ligation. For this purpose, we added protected aminooxy function at 
the N-terminal of MMP fragment. 
The linear peptide 5 Gly(boc)-Lys(Dde)-Gly-Pro-Gln(Trt)-Gly-Leu-Ala-Gly-Gln(Trt)-
Lys(Alloc)-OH was prepared using acid sensitive chlorotrityl resin. The use of an acetic 
acid solution was essential to keep protective groups at the glutamine side chain and at the 
N-terminal (Figure III-6). Deprotection was then carried out by using hydrazine and 
subsequent coupling of succinimide ester of Cy 5 provided the fluorescent peptide 6a 
Gly(boc)-Lys(Cy5)-Gly-Pro-Gln(Trt)-Gly-Leu-Ala-Gly-Gln(Trt)-Lys(Alloc)-OH.  
Purification of peptide 6a was carried out by using a microcolumn C18 (Chromafix
®
). The 
expected compound was obtained (Figure III-7) and we found the deconvoluted mass in 
total agreement with the calculated mass (Figure III-8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 233Foillard, Stéphanie, Zhao-hui Jin, Elisabeth Garanger, Didier Boturyn, Marie-Christine Favrot, Jean-Luc Coll, und 
Pascal   Dumy. „Synthesis and biological characterisation of targeted pro-apoptotic peptide“. Chembiochem: a 
European   journal of chemical biology 9, Nr. 14 (September 22, 2008): 2326–2332. 
 
Figure III-6: Molecule structure of compound 5 showing 
orthogonal and N-terminal protection groups. 
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Figure III-7: RP-HPLC analysis of 5 (top) and 6a (bottom). 
Figure III-8: Mass spectrometry analysis of 6a. 
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 Thereafter Alloc deprotection was obtained by means of Tetrakis-Palladium and 
phenylsilane. The following grafting of succinimide ester of quencher QSY21 was then 
carried out. After two days reaction, the expected compound was not obtained in sufficient 
amounts to prepare the desired activatable peptide 7a boc-Gly-Lys(Cy5)-Gly-Pro-Gln(Trt)-
Gly-Leu-Ala-Gly-Gln(Trt)-Lys(QSY21) (compounds 7a and 8a are not listed in the 
Materials and Methods chapter). We suggest that steric hindrance of protected group such 
trityl prevents QSY21 from the coupling. We then decided to exploit an activatable 
fluorescent system based on the self-quenching of two cyanine 5 fluorescent dyes
234
. 
III.1.3. Synthesis of final compound (RAFT-RGD-MMP)  
The final molecule (compound 10) was synthesized as described in the submitted article 
presented afterwards (Wenk et al. “Integrin and Matrix Metalloprotease Dual-Targeting 
with MMP substrate-RGD conjugate”). 
 
                                                 
234 Razkin, Jesus, Véronique Josserand, Didier Boturyn, Zhao-hui Jin, Pascal Dumy, Marie Favrot, Jean-Luc Coll, und Isabelle 
Texier. „Activatable fluorescent probes for tumour-targeting imaging in live mice“. ChemMedChem 1, Nr. 10 (Oktober 
2006): 1069–1072. 
 
Figure III-9: Total deprotection of compound 7a; (a) TFA 95%, H2O 2.5%, TIS 2.5%. 
7a 8a 
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III.2. Fluorescent characteristics and cleavage properties of the 
RAFT-RGD-MMP 
 
 After synthesis of the RAFT-RGD-MMP, the molecule properties were analyzed by 
means of fluorescence reflectance 2D imaging (FRI; Figure III-10) and Fluorescence 
Spectrometry and Absorbance measurements in order to define their quenching level and 
the level of dequenching by MMP-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-10: Fluorescence imaging of RAFT-RGD-MMP drops before and after incubation with  
MMP-9 and MMP-2. 
 
  
 The first study shows a steady increase in the fluorescence intensity during the first 
two hours, then slowing down to be 2.3-times more intense after 24 h of incubation with 
active MMP-9. Incubated with active MMP-2, nearly no increase can be observed. The 
values of the sample MMP-2 show a slight 0.9-times increase in fluorescence at 24 h. 
 
 Afterwards the emission spectra of the RAFT-RGD-MMP compound were 
measured and compared to those of the RAFT-RGD-Cy5 control molecule. The spectra 
were normalized by their in parallel taken absorption spectra and machine errors as well as 
bleaching aberrances were minimized by using Cy5 controls (see Materials & Methods) 
(Figure III-11) 
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Figure III-11: Fluorescence emission spectra and corresponding absorption spectra of RAFT6RGD-
MMP before and after incubation with MMP-9. 
 
 
 Comparing the emission spectra of the compound RAFT-RGD-MMP before and 
after incubation with MMP-9, a difference of the measured intensities could be observed. 
The initial molecule shows a peak of emission at 670 nm of 870 while after incubation 
with MMP-9 the maximum is at 666.5 nm with an intensity of 1972 (= 2.3 x the initial 
signal). 
 Regarding the absorption spectra the molecule initially shows a weak absorption 
peak at 650 nm compared to its spectra after MMP incubation. Furthermore a second peak 
at 610 nm before MMP incubation can be observed, which nearly disappeared after 
incubation with the enzyme. 
Analyzing the fluorescence emission spectrum, it showed at 0.25 µM a quenching of 64 %, 
while after 48 h of incubation with active MMP-9, the molecule showed 21 % of 
quenching (Figure III-12). 
 The results are presented in the article Wenk, C.H.F., Josserand, V., Coll, JL, 
Dumy, P and Boturyn, D, “Integrin and Matrix Metalloprotease Dual-Targeting with 
MMP substrate-RGD conjugate” (2012). 
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Figure III-12: Measured quenching of the compound RAFT-RGD-MMP before and after incubation 
with MMP-9. 
 
 
 In order to verify the differences in fluorescent intensity obtained, we analyzed the 
RAFT-RGD-MMP emission spectra while incubated with active MMP-9 and its 
competitive inhibitors CCT and SB3-CT and its stability in crude mouse plasma (Figure 
III-13). 
 The results obtained showed that the increase in fluorescence intensity is halved 
while incubated with the MMP inhibitors compared to the molecule incubated with MMP-
9 only. Here it is worth noting that the inhibitors loose efficacy in the course of time and 
that activated MMPs do auto-degrade. 
 In plasma the fluorescence signal measured is staying at the same level for 24 h, 
rising after another 24 h of incubation at 37°C in plasma from 194 to 339 intensity units, 
which corresponds at 1.75 times of intensity increase, thus 0.55 times less than incubated 
with MMP-9. 
 
 
 
Figure III-13: Fluorescence emission spectra of RAFT-RGD-MMP: effect of A) MMP inhibition and 
B) Plasma stability. 
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III.2.1. Conclusion 
 
 The RAFT-RGD-MMP compound is cleaved by active MMP-9, but not effectively 
by MMP-2.  
 Quenching can be observed, and dequenching due to the cleavage by MMP-9 can 
be measured by the increase in signal intensity and the RT-HPLC and mass analysis, which 
confirmed the cleavage site (see article). Another sign of the quenching – dequenching 
effect can be seen by observing the absorbance spectra and the shift in the emission 
spectra. The intact molecule has its emission peak in a slightly longer wavelength than the 
cleaved molecule.  The absorption spectra shows a smaller principal absorption peak with a 
visible “pre-peak” at 610 nm due to the energy transfer of the two Cy5 next to each other. 
After cleavage of the Cy5 engrafted to the N-terminal extremity of the MMP-cleavable 
sequence the peak at 610 nm disappears and the principal peak augments, suggesting that 
digestion of the cleavage cassette occurred. 
 Reduced cleavage can be observed using MMP inhibitors. This confirms that the 
molecule is relatively stable and specifically cleaved by MMP-9 in the tested conditions. 
The slight increase in the fluorescence intensity observed is due to the loss of inhibitor 
efficacy in course of time as well as a certain non specific degradation of the molecule 
during incubation at 37°C for 48 h.  
 The molecule is stable in plasma for at least 24 h. After this time, it is slightly 
degraded due to plasma factors as well as the non specific decay due to incubation at 37°C 
for 48 h. 
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III.3. In vitro characterization 
 
 After studying the impact of MMP-9 on the cleavable cassette of the RAFT-RGD-
MMP, the stability and its quenching / dequenching capacities, we studied the properties of 
RAFT-RGD-MMP in biological systems. 
 We firstly wanted to know, if the molecule reacted with the cell and if its specificity 
towards cancer cells was increased by the presence of the dual-recognition. Therefore we 
selected several cancer cell lines with different patterns of expression of integrin αvβ3 and 
MMP-9. 
 After testing the MMP expression via zymography (see supplementary information) 
and the integrin expression via flow cytometric analysis (FACS) using an immunolabeling 
with the LM609 antibody and RAFt-RGD-Cy5 (see supplementary information), the 
following cell lines were chosen: 
 
 
 
Cell line Integrin αvβ3 expression MMP-9 expression 
HEK293(β3) Very Strong (++++) Strong (++++) 
TS/A-pc Medium (++/+)* Medium (+++) 
HT1080 Medium (++)/Weak (+)* Strong (++++) 
A375 Medium (++)/Weak (+)* Medium(+++) 
Colo829 Strong (+++)/Negative (-)* Very weak (+) 
PC-3 Negative (-) Very weak (+) 
HEK293(β1) Negative (-) Weak (+) 
Table III-2: Degree of integrin αvβ3 and MMP-9 expression of different cell lines. 
*labeled by 0.2 µM RAFT-RGD-Cy5 at 30 min, 37°C 
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III.3.1. Analysis of the RAFT-RGD-MMP binding on cells using flow 
cytometry 
 
 The cells were incubated with either RAFT-RGD-MMP at 0.2µM or RAFT-RGD-
Cy5 at 0.4µM at 37°C for 5 min, 15 min, 30 min, 1 h and 2 h. The control RAFT-RGD-
Cy5 was used at twice the concentration of RAFT-RGD-MMP, in order to be at the same 
concentration of Cy5, since each RAFT-RGD-MMP was labeled with 2 Cy5 molecules. 
For appropriate comparison of fluorescence intensity values within all conditions and cell 
lines, we calculated the percentage of augmentation of the MFI (mean fluorescence 
intensity) based on the control autofluorescence. The according unit is pa-MFI.  
 
 The human embryonic HEK 293 cell line is naturally expressing the αv integrin but 
not the β3 chain. For this reason it has been stably transfected with β3 thus forming the 
HEK293(β3) cell line that overexpresses a massive amount of β3 and will serve as positive 
control for RGD binding. In addition, it is strongly positive also for MMP-9 expression. 
 
As expected, this cell line is immediately and strongly labeled with both molecules 
(Figure III-14). Note that we always obtain two different populations of cells after labeling 
with RAFT-RGD, suggesting that this clone is not pure, with at least one “low” β3 
expressing and one “high” β3 expressing population. 
 After 5 min of incubation, 86.2 % of the total cell population is already labeled by 
RAFT-RGD-MMP with a pa-MFI (Percentage of augmentation of the MFImean 
fluorescence intensity) of 1198. The cells treated with the control RAFT-RGD-Cy5, 
showed 80% of positive population, but a pa-MFI of 775 only. The RAFT-RGD-MMP 
over RAFT-RGD ratio is thus equal to1.56.  
Both signals then regularly augment over time and finally the quasi totality of the cell 
population is labeled by each molecule, and the advantage is conserved for the RAFT-
RGD-MMP (final ratio of 1.8 at 2h) (Figure III-15). 
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Figure III-14: Interaction of RAFT-RGD-MMP and RAFT-RGD-Cy5 (control) with HEK 293(β3) cells in vitro. 
FACS analysis of cells incubated with RAFT-RGD-MMP (0.2µM) and RAFT-RGD-Cy5 (0.4µM) respectively at 37°C at 
T0, 5 min, 15 min, 30 min, 1 h and 2 h. 
P2 indicates the auto-fluorescence, P3 the positively labeled cells. The percentage of the total population which is labeled 
positive is marked in the right upper corner. 
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Figure III-15: Evolution of pa- MFI (%) in HEK293(ß3) treated with either RAFT-
RGD-MMP (0.2µM) or RAFT-RGD-Cy5 (0.4µM) at 37°C. 
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 We then performed a competition assay in which the cells were firstly treated by 
unlabeled “cold” RAFT-RGD and later on with the fluorescent RAFT-RGD-MMP or 
RAFT-RGD-Cy5. The pretreatment with RAFT-RGD aimed at saturating the integrin αvβ3 
receptors in order to better visualize the role of the enzyme (MMP) activity as well as the 
effect of non-specific interactions. 
 A very strong inhibition of the RAFT-RGD-MMP is observed in these conditions, 
with an almost 7-times reduced final MFI (2968 instead of 20 561 initially obtained 
without competition) (Figure III-16). This suggests that binding to the integrin is necessary 
before MMP-9 can function during the internalization process, since we can see here only 
the labeled cells and not the possible presence of unbound molecules in the medium. 
 
 
 
 The same tests were performed on the human a melanotic melanoma cell line A375 
(Figure III-17). This cell line is expressing very low levels of RGD-interacting integrin as 
demonstrated by the labeling with RGD. Indeed, RAFT-RGD-Cy5 weakly labeled no more 
than 30 % of the cells after 2 h of incubation (pa-MFI = 116) (Figure III-18). 
 In contrast, nearly 100 % of these cells are fluorescent after 2 h of incubation with 
the RAFT-RGD-MMP at a pa-MFI of 298, thus providing a ratio of RAFT-RGD-MMP 
versus RAFT-RGD-Cy5 of 2.7.  
Figure III-16: FACS analysis of HEK 293(β3) pre-treated with RAFT-RGD and incubated 
with RAFT-RGD-MMP (0.2µM) and RAFT-RGD-Cy5 (0.4µM) respectively, at 37°C at T0, 5 
min and 2 h. 
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 Furthermore, the competition assay shows that the percentage of RAFT-RGD-
MMP labeled cells drops from 100 down to 30% if the cells are concomitantly incubated 
with “cold” RAFT-RGD (Figure III-19).  
This suggests that although the integrins are poorly expressed on the surface of these cells, 
the positive labeling obtained with RAFT-RGD-MMP requires its binding via RGD 
mainly. 
 
 
 
Figure III-17: Interaction of RAFT-RGD-MMP and RAFT-RGD-Cy5 (control) with A375 cells in 
vitro.  
FACS analysis of cells incubated with RAFT-RGD-MMP (0.2µM) and RAFT-RGD-Cy5 (0.4µM) respectively at 37°C at 
T0, 5 min, 15 min, 30 min, 1 h and 2 h. 
P2 indicates the auto-fluorescence, P3 the positively labeled cells. The percentage of the total population which is labeled 
positive, is marked in the right upper corner. 
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Figure III-18: Evolution of pa- MFI in A375 treated with either RAFT-RGD-MMP 
(0.2µM) or RAFT-RGD-Cy5 (0.4µM) at 37°C. 
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Figure III-19: FACS analysis of A375 pre-treated with RAFT-RGD and incubated with RAFT-RGD-
MMP (0.2µM) and RAFT-RGD-Cy5 (0.4µM) respectively, at 37°C at T0, 5 min and 2 h. 
 
 
 When the same study was performed using the murine breast adenocarcinoma cell 
line TS/A-pc expressing moderately the integrin and MMP-9, the pattern of RAFT-RGD-
MMP and RAFT-RGD-Cy5 labeling was quite similar to that of A375 (Figure III-20, 
Figure III-21). The ratio of both RAFT-RGD-MMP over RAFT-RGD-Cy5 reached a value 
of 3.2 after 2 h of incubation, confirming that MMP-9 was efficiently recruited by RAFT-
RGD-MMP. This was further confirmed by repeating the experiment at 4°C instead of 
37°C, thus strongly slowing down all enzymatic activities as well as internalization. In this 
case only 40% of the cells are labeled by RAFT-RGD-MMP after 2h, with a pa-MFI of 
315 instead of 1127 at 37°C. Nonetheless, RAFT-RGD-MMP still performs better than 
RAFT-RGD at 4°C. 
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Figure III-20: Interaction of RAFT-RGD-MMP and RAFT-RGD-Cy5 (control) with TS/A-pc cells in 
vitro.  
FACS analysis of cells incubated with RAFT-RGD-MMP (0.2µM) and RAFT-RGD-Cy5 (0.4µM) respectively at A) 
37°C  and B) 4°C at T0, 5 min, 15 min, 30 min, 1 h and 2 h. 
P2 indicates the auto-fluorescence, P3 the positively labeled cells. The percentage of the total population which is labeled 
positive, is marked in the right upper corner. 
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Figure III-21: Evolution of  pa-MFI in TS/A treated with either RAFT-RGD-MMP 
(0.2µM) or RAFT-RGD-Cy5 (0.4µM) at 37°C. 
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 The interest of using the bimodal RAFT-RGD-MMP molecule was even more 
obvious on the human sarcoma cell line HT1080 (Figure III-22 and Figure III-23). These 
weak integrin but high MMP-9 expressing cells are immediately labeled by RAFT-RGD-
MMP (100 % of cells labeled at 5 min with a pa-MFI of 593). This signal steadily 
increased in intensity during the first 2h and reached a final pa- MFI value of 1856 as 
compared to 477, when they are incubated with RAFT-RGD-Cy5. The RAFT-RGD-MMP 
over RAFT-RGD-Cy5 ratio oscillated between 4 and 5 over time, suggesting a marked 
implication of the MMP-9. This was confirmed by repeating the same experiment at 4°C. 
In this case, only 50% of the cell population was labeled after 5 min and this level 
increased to nearly 80% after 2h but the max pa-MFI remained very low (194 ).  
 
 Once more, RAFT-RGD-MMP showed a stronger labeling also at 4°C as compared 
to the control RAFT-RGD-Cy5, thus confirming that the dual targeting is efficient. 
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Figure III-22: Interaction of RAFT-RGD-MMP and RAFT-RGD-Cy5 (control) with HT1080 cells in vitro. 
FACS analysis of cells incubated with RAFT-RGD-MMP (0.2µM) and RAFT-RGD-Cy5 (0.4µM) respectively at A) 37°C  and 
B) 4°C at T0, 5 min, 15 min, 30 min, 1 h and 2 h. 
P2 indicates the auto-fluorescence, P3 the positively labeled cells. The percentage of the total population which is labeled 
positive, is marked in the right upper corner. 
Figure III-23: Evolution of pa- MFI in HT1080 treated with either RAFT-RGD-
MMP (0.2µM) or RAFT-RGD-Cy5 (0.4µM) at 37°C. 
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Observing the flow cytometry profiles at 37°C of Colo829 (Figure III-24 and  
Figure III-25) and PC-3 (Figure III-26 and Figure III-27) cells, both with low RGD-
binding and weak MMP-9 expression, a weak labeling of the cells can be observed.  
In Colo829 the RAFT-RGD-MMP showed a weak binding, with a labeling at 2 h of 98.8 
% of the population but only a pa-MFI of 220.  The control RAFT-RGD-Cy5 showed 
fairly positive labeling of only 7.6 % of the population labeled at 2 h, with a pa-MFI of 
121, thus nearly half the MFI compared to RAFT-RGD-MMP.  
In PC-3 cells a similar effect can be observed. The RAFT-RGD-MMP interacted slowly 
with the cells, but labeled them completely after 2h of incubation whereas the RAFT-
RGD-Cy5 shows only 30% labeling. These observations confirm the interest of a double 
targeting when dealing with cells expressing low levels of each target.  
 
Figure III-24: Interaction of RAFT-RGD-MMP and RAFT-RGD-Cy5 (control) with Colo829 cells in vitro.  
Flow cytometric analysis of cells incubated with RAFT-RGD-MMP (0.2µM) and RAFT-RGD-Cy5 (0.4µM) respectively 
at 37°C at T0, 5 minutes, 15 minutes, 30 minutes, 1 h and 2 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 
120 
140 
160 
180 
0 
20 
40 
60 
80 
100 
0 20 40 60 80 100 120 
 p
a
-M
F
I 
 
ce
ll
 p
o
p
u
la
ti
o
n
 (
%
) 
Time (min) 
Colo829 
RR-MMP labeled population RR-Cy5 labeled population 
RR-MMP 0.2µM MFI RR-Cy5 0.4µM MFI 
Optical-guided surgery & development of SMARgeting probes for cancer                                        Results & conclusions                                          
 
- 179 - 
 
Figure III-25: Evolution of pa-MFI in Colo829 treated with either RAFT-RGD-MMP (0.2µM) or RAFT-RGD-
Cy5 (0.4µM) at 37°C. 
 
 
Figure III-26: Interaction of RAFT-RGD-MMP and RAFT-RGD-Cy5 (control) with PC-3 cells in vitro. 
Flow cytometric analysis of cells incubated with RAFT-RGD-MMP (0.2µM) and RAFT-RGD-Cy5 (0.4µM) 
respectively at 37°C at T0, 5 minutes, 15 minutes, 30 minutes, 1 h and 2 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 The RAFT-RGD-MMP in Hek293(β1) (Figure III-28) shows weak positive 
fluorescence when the incubation is performed at 37°C, while there is none at 4°C.  
 Hek293(β1)  are αvβ3 integrin negative cells. At 37°C, 85 % of the cell population is 
labeled but only with very little intensity (pa-MFI of 186 at 2 h). Concerning RAFT-RGD-
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Figure III-27: Evolution of pa-MFI in PC-3 treated with either RAFT-RGD-MMP 
(0.2µM) or RAFT-RGD-Cy5 (0.4µM) at 37°C. 
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Cy5 there is no labeling, thus the slight positive result has to be due to the MMP sequence 
added on the molecule 
 This confirms the increase in binding towards tumor cells, even if only few 
integrins are expressed. At 4°C no labeling can be observed in HEK293(β1) cells.  
 
 
Figure III-28: Interaction of RAFT-RGD-MMP and RAFT-RGD-Cy5 (control) with Hek293(β1) cells 
in vitro. 
Flow cytometric analysis of cells incubated with RAFT-RGD-MMP (0.2µM) and RAFT-RGD-Cy5 (0.4µM) respectively 
at 37°C and 4°C at T0, 5 minutes, 15 minutes, 30 minutes, 1 h and 2 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-29: Evolution of pa- MFI in HEK(β1) treated with either RAFT-RGD-MMP (0.2µM) or 
RAFT-RGD-Cy5 (0.4µM) at 37°C. 
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Comparing the data of all cell lines tested (Figure III-30), we can classify the 
different cell lines in 3 categories: 
 HEKß3 is a particular case. Since it is expressing elevated levels of both targets, it 
is very strongly labeled by both molecules. 
 HT1080, A375 and to a certain extend TS/A-pc cells are not perfectly labeled by 
the RAFT-RGD molecule but they are clearly better detected with the dual RAFT-
MMP one. 
 PC3, Colo829 and HEB293(ß1) are normally undetected by RAFT-RGD, but these 
tumors will certainly show up after 2h of labeling by the dual molecule.  
 This indicates that the dual RAFT-RGD-MMP will improve tumor labeling and 
detect some tumors that would have been left barely detectable by the initial RAFT-RGD 
tracer. However, this can also raise some concern about the specificity of the molecules 
toward other diseases that will express massively the MMP9 target.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-30: FACS data of RAFT-RGD-Cy5 and RAFT-RGD-MMP compared. 
Labeled population of RAFT-RGD-Cy5 (RGD%) and RAFT-RGD-MMP (MMP%) and  pa-MFI of RAFT-
RGD-Cy5 (RGDi) and RAFT-RGD-MMP (MMPi) at 2 h of incubation in the cell lines and HEK293(β3), 
A375, TS/A, HT1080 and HEK293(β1), Colo829 and PC-3 at 37°C. 
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III.3.2. Analysis of the RAFT-RGD-MMP binding on cells using confocal 
microscopy 
 In the next step, we studied the interaction between RAFT-RGD-MMP and the 
cells by confocal microscopy. We wanted to see in particular if the molecule was 
internalized and where its cleavage will take place. Living cells were observed during 15 
min. The laser settings were adjusted before treatment with the molecule and kept at the 
same intensity throughout the whole acquisition in order to provide comparable 
information. 
Using the integrin αvβ3 over-expressing HEK 293(β3) cells, a strong labeling of the 
cell membrane is seen at already 5 minutes, followed by a very powerful increase of 
fluorescence that saturates the camera at T=15 min (Figure III-31). In contrast, using the 
very weak integrin expressing cell line HT1080, no membrane labeling could be observed, 
neither at 5 nor at 15 min. However, the fluorescence intensity of the surrounding medium 
is positive after 15 min of incubation. This suggests that it is mainly the MMP-9 enzyme 
present in the extracellular medium that will act first. Note that the laser settings correctly 
adjusted for HEK 293(β3) cells at 5 min was not adapted to the visualization of low levels 
of labeling with HT1080. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-31: Biphoton confocal microscopy of living cells. 
HEK 293(β3) and HT1080 at 5 min and 15 min of incubation at 37°C with 0.6µM RAFT-RGD-MMP. 
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III.3.3. Conclusion and discussion 
 
 These results suggest an important augmentation of the cell labeling when using 
RAFT-RGD-MMP instead of RAFT-RGD-Cy5, in particular for cell lines expressing 
moderate to low levels of integrin αvβ3. 
 
 The intensity of the labeling is always stronger when using RAFT-RGD-MMP in 
every cell line at 37°C. In addition, the blocking studies performed with HEK293(β3) or 
A375 cells confirmed the importance of the binding to the integrin that governs the final 
staining intensity. However, when using flow cytometry we followed the labeling of the 
cells but could not determine whether the labeling was present on the cell surface or within 
the intracellular compartments. 
 Nevertheless, the testing at 4°C compared to 37 °C lead to the conclusion that in 
cell lines with low levels of active integrin, like HT1080, PC-3 or Colo829 cells, the 
integrin binding is improved in the RAFT-RGD-MMP molecule, as seen in the higher MFI 
and percentage of labeled population, compared to the negative results obtained with 
RAFT-RGD-Cy5.  
 Here is to say, that an increase in non specific binding is not excluded, yet.     
Using HT1080 we can see that although RAFT-RGD-MMP provides a stronger labeling of 
the cells as demonstrated by FACS, the predominant activity of MMP-9 over integrin 
binding is visible by confocal microscopy. This MMP-9 activity is present in the culture 
medium surrounding the cells. This indicates that this vector could release a pro-drug in 
the periphery of tumor cells in the cases where integrins are weak but MMP-9 is 
overexpressed and active. 
 
 The other tested cell lines over-expressed the integrin strongly (HEK 293(β3)), 
moderately (TS/A-pc) or weakly (A375) while MMP-9 activity was always present. Using 
these cell lines, we confirmed the impact and predominant importance of integrin 
interaction before MMP-9 can cleave the molecule. This was particularly obvious when 
RGD binding was prevented by a pre-incubation of the cells with “cold” RAFT-RGD and 
by incubation at 4°C.  
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III.4. Double targeting effect in vivo 
III.4.1. Results 
 We then studied the interest of these molecules for in vivo tumor imaging. 
However, we were not able to run a lot of molecule-consuming experiments in vivo. This 
study is thus only preliminary. 
 Nude mice bearing subcutaneous HEK293(β3), TS/A-pc or A375 tumors, received 
an intravenous injection of 2 nmol RAFT-RGD-MMP ( n = 3 mice per group) and were 
imaged several times during 24 h using 2D-FRI (fluorescence reflectance imaging). 
 
 
Figure III-32: Biodistribution of RAFT-RGD-MMP in vivo. 
Subcutaneous tumor-bearing mice (HEK293(β3), TS/A-pc and A375) were imaged at different time, after intravenous 
injection of 2 nmol of RAFT-RGD-MMP. 
Exposition time at 500ms; LUT min-max 2185-27743 for 0.5 to 5 h and 2185-4371 for 24 h. 
 
 
 As it can be observed, all the three types of tumors are positively labeled in vivo. A 
strong signal can also be observed in the kidneys as reported before when using RAFT-
RGD derivatives, demonstrating the rapid and massive evacuation of these molecules by 
the renal elimination pathway. Accordingly, the non specific signal coming from unbound 
molecules and particularly visible in the skin, is rapidly decreasing, and reaches its 
background autofluorescence level after 2 h. 
 HEK293(β3) and A375 tumors are immediately labeled by the molecule, while the 
signal is building up more slowly in the TS/A-pc tumors. In each tumor, a positive signal 
can be detected during at least the first 24h. 
 We also compared the in vivo distribution with a quenched peptide sequence 
cleavable by MMPs (MMPSense™680, PerkinElmer, USA) and with RAFT-RGD-Cy5 in 
order to see the role of each of the two targets. Therefore, the same procedure was applied 
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as described before. Two nmol of each molecule was injected in subcutaneous tumor 
bearing mice (n = 3 mice per group) and the ratio of the fluorescence intensity over the 
measured intensity in the skin was calculated. 
 In the HEK293(β3) tumor bearing mice a quick and strong labeling of the tumor by 
RAFT-RDG-MMP is seen. It reaches a maximum at 5 h and decreases slowly afterwards 
(Figure III-33). The ratio at 5 h is 3-times more important compared to the control 
MMPSense and 1.5-fold higher compared to the RAFT-RGD-Cy5. In the weaker integrin 
A375 tumor, the ratio of tumor-to-skin is more rapidly increasing for the RAFT-RGD 
molecules compared to MMPSense680.  
 Compared to the profile in TS/A tumors, A375 show a softer increase until 5 h for 
RAFT-RGD molecules, demonstrating the importance of the initial integrin binding in 
TS/A and HEK293(β3). 
 In A375 tumors the ratio of the RAFT-RGD-MMP is decreasing very slowly 
compared to the integrin only targeting RAFT-RGD-Cy5. The ratio tumor-to-skin of 
MMPSense680 is rising very slowly, reaching the same level than RAFT-RGD-MMP but 
after 24 h.   
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Figure III-33: Compared tumor-to-skin ratio during time in vivo. 
Subcutaneous tumor-bearing mice (A) HEK293(β3), B) TS/A-pc and C) A375) were imaged at 
different times, after intravenous injection of 2 nmol of RAFT-RGD-MMP, MMPSense680 or 
RAFT-RGD-Cy5, respectively and their tumor-to-skin ratio compared. 
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 Three h after injection of 2 nmol RAFT-RGD-MMP, an accumulation of 
fluorescence in the kidney and the tumor can be observed (Figure III-34).  
 The accumulation in the three tested tumors is particularly strong in HEK293(β3) 
and nearly even in TS/A and A375 at 3 h. The signal is barely detectable at 24 h except in 
the kidneys (Figure III-35). Interestingly, in terms of intensity, the tumor is coming in 
second position after the kidney while the other organs are not labeled, indicating the good 
targeting effect of our molecule. Accordingly a good tumor-to-muscle ratio is observed at 3 
h (Figure III-36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure III-34: Distribution of RAFT-RGD-MMP in different organs. 
Fluorescence measured in different organs after sacrifice and dissection of mice at either  A) 3 h (n = 3) or B)and C) 24 h 
(n = 3) post injection of 2nmol RAFT-RGD-MMP. 
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Figure III-36: Tumor-to-muscle ratio of subcutaneous tumor bearing mice at 3 h 
post injection of 2 nmol RAFT-RGD-MMP. 
Figure III-35: Excised tumors (HEK293(β3), TS/A-pc and A375) of RAFT-RGD-MMP injected 
mice. 
Fluorescence images of tumors ex vivo at either A) 3 h or B) 24 h post injection of 2 nmol RAFT-RGD-MMP. 
Exposition time at 500 ms ; LUT min-max 1832-6779 (A) and 1832-41530 (B) 
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III.4.2. Conclusion 
 
 The RAFT-RGD-MMP labels the tumors in vivo, by reaching a best tumor-to-
muscle ratio in HEK 293(β3) tumor bearing mice, followed by TS/A-pc and A375 tumor 
bearing mice. In TS/A-pc and A375, there is a final equal balance between integrin 
expression predominant in TS/A-pc cells and the MMP over-expression existing in A375 
cells that can explain the similar patterns we observed. The molecule is obviously 
eliminated by the kidneys as RAFT-RGD-Cy5. Its excretion begins immediately after 
injection and is rapid and efficient since no or very little fluorescence can be detected at 
24h. This is definitely an asset as far as imaging is concerned. Moreover it is also in favor 
of a low toxicity. 
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III.5. General conclusion 
 
 RAFT-RGD-MMP is a peptide with a double-targeting function. Its cleavable 
cassette is sensitive to MMP-9 in vitro, which has been demonstrated by its measurable 
dequenching in the presence of this enzyme. At the same time the molecule is stable during 
24 h in serum at 37°C, followed by a slow degradation. 
It’s interaction with cells in vitro is principally mediated by the RGD motif 
targeting integrin αvβ3 as confirmed by the blocking experiments. But the affinity of the 
molecule for the MMP-9 enzyme also contributes to its augmented binding on the cells, as 
shown by their improved fluorescent labeling (MFI) as compared to that obtained with 
RAFT-RGD-Cy5only. Indeed, all tested cell lines were more intensively stained by the 
dual molecule, leading to the conclusion, that a double targeting provides a stronger 
recognition of tumor cells. 
Our preliminary tests in vivo indicates that the strongest interaction and additive 
effect can be observed as expected in HEK293(β3) cells, since these cells strongly over-
express the two targets.  
However, the gain provided by the presence of the MMP-specific sequence may 
eventually lead to a diminution of specificity. These molecules could be activated by other 
pathologies than cancer, like inflammation. However, if optical guided surgery is the issue 
this should not be a major problem since tumors are always inflammatory and should be 
more intensively labeled in their front of invasion, which is exactly, what we are looking 
for. Otherwise, removing inflammatory tissues that do not contain tumor cells would be 
augmented also, but this will need to be evaluated.   
In addition, these dual molecules also have the advantage of being activatable as compared 
to the original RAFT-RGD and could thus be used for activatable drug release also. We did 
not optimized the gain provided by the presence of the cleavable cassette, since in our case 
the double labeling with Cy5 and expected quenching/dequenching is not fully functional. 
Additional experiments should be performed in order to generate better activatable optical 
probes. 
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III.6. Supplementary data RAFT-RGD-MMP 
 
 
III.6.1. Enzyme activity control and inhibitor test 
 
 
 
Figure III-37: Control of MMP-9 activity and inhibitor by means of Fluospectrometry. 
1 µM of the MMP cleavable peptide fluorogenic substrate (EnzoLifescience) was incubated with MMP-9 and with the 
inhibitor SB3-CT and MMP-9 for 2 h. 
 
 
 The fluorogenic substrate was used to see whether the enzyme used was active or 
not and as control of the inhibition effect of SB3-CT, the inhibitor used.  
 In Figure III-37, we showed that the enzyme is degrading properly the molecule, 
seen by the increase in the fluorescence intensity measured by Fluospectrometry. The 
difference between the signals measured at time 0 and after 30 minutes is 3.75-times. 
  
 Concerning the inhibitor, the measurements show a slowing down of the enzyme 
activity, but not a complete inhibition. The SB3-CT efficacy decreases in course of time, 
visible by the slow increase of intensity during the first 40 minutes. 
  
0 
10 
20 
30 
40 
50 
60 
70 
80 
355 375 395 415 435 455 
fl
u
o
re
sc
e
n
t 
in
te
n
si
ty
 
wavelength (nm) 
MEAN FluoSubstrate 1µM +SB3CT 
0,6µM + MMP9  T0 
FluoSubstrate 1µM +SB3CT 0,6µM 
+ MMP9 10min 
FluoSubstrate 1µM +SB3CT 0,6µM 
20min 
FluoSubstrate 1µM +SB3CT 0,6µM 
40min 
FluoSubstrate 1µM +SB3CT 0,6µM 
1h 
FluoSubstrate 1µM +SB3CT 0,6µM 
2h 
control fluoSubstrate 1µM & 
MMP9 
control fluoSubstrate 1µM & 
MMP9 30min 
Results & conclusions                                        Optical-guided surgery & development of SMARgeting probes for cancer                                                                                 
 
 
 
- 192 - 
 
III.6.2. MMP-2 and MMP-9 expression of different cell lines 
 
 Zymography is a method detecting the presence of active Gelatinases, such as 
MMP-2 (65 kDa) and MMP-9 (84 kDa). After electrophoretic separation, gelatinases are 
visible because they digest the gelatin substrate in the gel and are thus visible as clear 
bands after coomassie blue staining of the gelatin in the gel. MW: MMP-9 
(zymogene/active) = 92/84 kDa; MMP-2 (zymogene/active) = 72/65 kDa 
  
 Using zymography we verified and/or confirmed the presence of MMP-9 and 
MMP-2 expressed by the different cell lines, and estimated their respective content as 
compared to the well known referenceHT1080cell line, over-expressing MMP-2 and 
MMP-9(Figure III-38; Figure III-39). 
  
 We measured that HEK293(β3) cells express nearly as much MMP9 (85%) as 
HT1080, while MMP-2 expression is even more elevated(138 %). TS/-A showed only 70% 
of MMP-9 expression and 25 % of MMP-2, followed by the cell line A375 with 40 % 
MMP-9 and 55 % MMP-2. Surprisingly HEK293(β1) cells only express 60 % of MMP-9 
and 28 % of MMP-2. The lowest expression has been measured in PC-3 cells at 8 % 
MMP-9 and 20 % MMP-2 and the cell line Colo 829 with 19 % MMP-9 and 12 % MMP-
2. 
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Figure III-38: Zymography of 10-times concentrated serum-free supernatant at 24 h of the cell lines 
A375, HEK293(β3), TS/A-pc, HEK293(β1) and HT1080 (A)and A375, PC-3, Colo829, TS/A-pc and 
HT1080 (B). 
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Figure III-39: Gelatinases expression of different cell lines used with HT1080 as reference. 
(Quantification of Zymography gels showing the mean of MMP expression in relation to HT1080) 
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III.6.3. Flow cytometry analysis of the integrin αvβ3 expression 
 
 The expression of the integrin has been tested by labeling via the antibody LM609 
(anti-integrin αvβ3) indicated by “Integrin αvβ3” and RAFT-RGD-Cy5 in FACS analysis 
(Table III-3).   
 
 
 
Table III-3: FACS analysis of integrin expression in different cell lines. 
 
 
 All cell lines except the human melanoma M301 and the human prostate carcinoma 
PC-3 are labeled by the antibody LM609 suggesting the presence of the integrin. However, 
the integrin may not always be functional and/or accessible and thus the labeling by 
RAFT-RGD–Cy5 can differ from that of the antibody. This is the case with the melanoma 
M288, the PC-3, Colo829 and the A375 cell lines.  
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III.6.4. Level of autofluorescence of mouse organs ex vivo 
 
 The autofluorescence level at the same conditions used for in vivo and ex vivo 
imaging of the RAFT-RGD-MMP studies in mouse organs is presented in Figure III-40. 
 Here, we show that the level of the organs - except tumor and kidney – correspond 
to the in vivo studies of RAFT-RGD-MMP at 24 h.  
 
 Thus, no unspecific accumulation could be observed in the previous described 
study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III-40: Fluorescence intensity in non treated mouse organs ex vivo. 
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„Eine neue Idee ist ein Licht, welches Dinge beleuchtet, die, ehe das 
Licht darauf fiel, ohne Form für uns waren.“ 
Susanne K. Langer,1984  
 
[A new idea is a light, illuminating a thing that, before the light touched it, was structureless for us.] 
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I. Near-infrared fluorescence guided 
surgery in the feline fibrosarcoma 
 
 The aim of my first project was the evaluation of an intra-operative near-infrared 
fluorescence (NIRF) imaging device in combination with a cancer targeting probe in clinical 
conditions. This clinical veterinary phase on spontaneous tumors is important for translating 
this technology towards clinical surgery in humans and was designed to provide information 
for the eventual adaption of the system.  
 The interest of this technology for cancer surgery is the based on several aspects. At 
first, tumor resection still represents the primary therapeutic indication before chemotherapy 
or radiotherapy in most cancers. Since survival strongly depends on the exhaustiveness of the 
tumor resection, innovative methods improving the quality of cancer surgery are needed to 
lower the risks of postoperative local recurrence. Second, up to now, no approved technology 
with high specificity and sensitivity, tracers included, are on the market for real-time image 
guided surgery of open surgical field. 
I.1. Feasibility of NIRF-guided surgery in veterinary clinic conditions 
 Our former results on mice bearing peritoneal carcinomatosis showed that NIRF 
optical guidance of surgery greatly improved the quality of the surgery by doubling the 
number of detected nodules and reducing two times the duration of the surgery. 
 In the present study on cats, my results show that the technology is adapted to intra-
operative guided surgery, providing good tumor-to-healthy tissue delineation in clinical 
conditions.  
 AngioStamp™ has a high specificity towards the tumor and can provide elevated 
tumor-to-healthy tissue ratios (around 14 in 0.3 mg/kg at 36 h) as compared to other 
molecules like ICG
235
.Moreover, a unique and relatively low dose of 0.3 mg/kg is sufficient. 
 No short-term toxicological effects in cats with high doses of AngioStamp™ have 
been observed. Fluorescence kinetics show that the tracer follows an efficient elimination of 
                                                 
235Crane, Lucia M.A., George Themelis, K. Tim Buddingh, Niels J. Harlaar, Rick G. Pleijhuis, Athanasios Sarantopoulos, 
Ate G.J. van der Zee, VasilisNtziachristos, und Gooitzen M. van Dam. „Multispectral Real-time Fluorescence 
Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology“. Journal of 
Visualized Experiments : JoVE, Nr. 44 (Oktober 20, 2010 
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first order, leaving a short F50 of minute range and the best labeling of the receptor after 36 h. 
This shows the suitability of AngioStamp™ for labeling cat tumors.  
 Thus my study provided important information about the absence of toxicity and 
adapted timing and dose of tracer required which are encouraging for its use in human 
afterwards.  
 Nevertheless, it still needs to be established whether optical guided surgery using such 
a system truly improves the survival and minimizes the risk of relapse, since in the present 
study, surgery was performed without optical-guidance. 
I.2. Continuation of the work 
 Further steps will imply that surgery is really guided by the system. This would allow 
to establish statistical values and to evaluate more precisely the therapeutic gain provided by 
this method.  
 The excised parts should be examined by histopathological means and compared to 
macroscopic analysis of thick tissue slices. This would give an idea of the real improvement 
concerning tumor-margin delineation. 
 At the same time, a real survival rate could be established if the instrument was really 
used for guided surgery. Even though the animals used in the present study are followed-up 
medically, the instrument wasn’t used for resection itself and thus no direct information 
concerning the impact of NIRF guided surgery using the Fluobeam™ and AngioStamp® is 
determined.  
 Performing this study on pets with natural cancer is advantageous, since on the one 
hand the pathology is relevant to the human one and, on the other hand, it is faster and less 
expensive to generate enough data. Indeed, due to their shorter life expectation, it is much 
faster to compare the survival or life expectation rate of domestic animals than those of 
humans. Furthermore, while humans usually receive several types of treatments, the survival 
rate in pets is more directly related to the efficiency of a unique and initial treatment. 
 It would also be interesting to test other type of tumors in domestic animals with 
probable high recruiting rate, like the mastocytoma, lymphoma, or osteosarcoma of dogs or 
mammary adenocarcinoma and lymphoma of cats
236
. 
                                                 
236 See : Colloque INSERM, “modèles carnivores de tumeursspontanées”, 2009 
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I.3. RGD-motif, integrin and the study 
 This study demonstrates, that the feline fibrosarcoma is responding to RGD-based 
probes, leading to the conclusion that they express an integrin that share similar structures 
than the human isoform
237
. 
Regarding the patter of expression of the integrin within tumor masses, the front of expansion 
is usually richer in integrins than the center. This is logic, regarding the role of integrins 
during invasion and spreading and might be an advantage in our case for the better definition 
of tumor margins. At the same time some analyzed tumor-free margins were “doubtfully” 
labeled by AngioStamp
™
. These samples turned out to be inflammatory tissue. As 
inflammation, like here peripheral inflammatory infiltrates, are associated with tumor 
progression
238
, it is preferable to remove also this part of “doubtful” inflamed and weakly 
fluorescent peritumoral tissue, as it may potentially be irreversibly engaged in the 
transformation process. However, this will apply only if no vital structures are present within 
these pseudo-sane margins. 
 The expression of integrin αvβ3 was analyzed by immuno-labeling of frozen slices of 
the samples taken during and after surgery. In parallel, other frozen slices were counterstained 
for histo-pathology (H&E staining) in order to evaluate the percentage of tumor cells present 
in the corresponding sample. We then compared the fluorescence staining by AngioStamp™ 
with the percentage of tumor tissue per sample and the presence of integrins. We showed that 
the fluorescence intensity was correlated with the quantity of tumor tissue but not or poorly 
with the expression of the integrin. This might be due to the limited-cross reactivity of the 
human anti-integrin antibody used. Up to now no specific cat-αvβ3-integrin antibody is 
available. Another possibility is that even if they are present and detected in vitro by the 
antibody on a thin section, these integrins may not easily be accessible for the AngioStamp™ 
in vivo because they can be already engaged with natural ligands such as vitronectin or 
fibronectin. As well the integrin can be present but in an inactive form. In addition, even if the 
integrin is active and not engaged, its accessibility may be limited because of the thickness of 
the glycocalyx
239
. Thus, one must keep in mind the extraordinary versatility of the cell-matrix 
                                                 
237Muzylak, M, A M Flanagan, K Ingham, N Gunn, J Price, und M A Horton. „A feline assay using osteoclasts generated in 
vitro from peripheral blood for screening anti-resorptive agents“. Research in veterinary science 73, Nr. 3 
(Dezember 2002): 283–290. 
238Hanahan, Douglas, und Robert A. Weinberg. „Hallmarks of Cancer: The Next Generation“. Cell 144, Nr. 5 (März 4, 
2011): 646–674. 
239Boettiger, David. „Mechanical control of integrin-mediated adhesion and signaling“. Current opinion in cell biology 
(August 1, 2012). 
Discussion & Perspectives                                        Optical-guided surgery & development of SMARgeting probes for cancer  
 
- 204 - 
 
interactions in 3D living tissues, and not only the presence of a molecule at a given location 
on a fixed tissue. When a RAFT-RGD-molecule is injected in vivo it circulates for a certain 
period of time in the organism, before it interacts with the receptor and can be internalized, as 
shown by Sancey et al
240
. Consequently the tracer has time to accumulate in the cells, even in 
those with low levels of integrin. On the contrary, depending on the microenvironment of the 
tumor cell, and thus the kind of natural ligands the integrin will encounter, active and/or 
numerous integrins may be “occupied” and the RAFT-RGD-tracer will have difficulties to 
label them.  
 In addition, the -RGD- motif we use is highly specific for integrin αvβ3but it can also 
interact, with lower affinities, with integrins αvβ5
241
, α5β1 and αIIbβ3
242,243
. This could lead to a 
positive labeling of integrin αvβ3 negative areas (as determined with the LM609 antibody). 
Knowing that the αvβ3 integrin is especially and almost always overexpressed by 
neoangiogenic endothelial cells, the vast majority of solid tumors are always labeled, as 
demonstrated by numerous pre-clinical and clinical studies. Of interest, this angiogenesis as 
well as the infiltration of tumor stroma by immune cells, such as macrophages which are also 
αvβ3 positive, should clearly help to the delineation of tumor margins by AngioStamp™. 
 Finally, it should be pointed out that the use of multifunctional RGD derivatives 
carrying short half-live radio-nuclides in addition to the fluorescent tracer could be interesting 
because they could be evaluated first using approved medical imaging methods such as PET 
or SPECT. Furthermore, they would combine pre-operative whole body imaging with 
augmented, optical-guided surgery
244
. 
I.4. Clinical set-up of instrumentation 
 During this study we observed that several artifacts could generate erroneous 
interpretation. 
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 The level of autofluorescence varies between individuals. This is due to several 
phenomenons, but one of the most important one is the skin color. Bright skin reflect light 
while dark skin absorb it. The amount of fat can also generate elevated inter- as well as intra-
individual variations. 
 The geometry of the system (distance and angles between the camera and the object) 
will also influence the quality and relevance of a signal. It is of great importance that the 
image is sharp, i.e. taken with an adequate focus. If not, light scattering and sometimes 
weakened or intensified information may lead to false interpretation. With respect to the 
experience during surgery we recommended the introduction of an autofocus in order to 
overcome this problem and to avoid wrong data interpretation. At the same time it facilitates 
the use of the system, being more comfortable to manipulate. The introduction of an 
autofocus is currently in progress. 
 The auto-LUT of the Fluobeam™ adapts the image on the screen to the highest signal 
obtained and adjusts the whole grayscale on this signal, lightning up even autofluorescence if 
no stronger signal is present. This might be confusing for the interpretation as well, and a real 
measurement of the intensity should be performed in order to avoid false interpretation. 
Therefore it might be of advantage to fix the LUT by using a defined “threshold”. In our 
study, we defined such a correct threshold, but this could be an important problem for un-
experienced users who would like to begin a new protocol without validation first. 
 Introduction of a threshold should be an option though, as different tumor models 
might lead to different thresholds, due to different levels of target expression or different 
access for the molecule towards the tumor site. Also legal recommendation would not 
recommend the definition of a threshold. Indeed, introduction of a threshold classifies the 
instrument no longer as guiding device but as diagnostic device and thus demands proof of 
accuracy of diagnostics with all additional tests demanded by legal authorities. This would 
slowdown the process of permission for clinic use of such technology and demands greater 
expenses.  
 Other difficulties are faced when starting a clinical investigation.  
One of them concerns the sterilization process of the imaging device, before it can enter the 
operating room. It is not possible to drown the device in sterilization baths, specially the 
imaging head. Therefore we cover it with a sterile cover. The properties of different covers, 
concerning their shape and how to design them for easy and smooth handling in the clinical 
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environment, were tested and one was finally selected. The study showed the unproblematic 
use of the sterile cover, in handling as well as for imaging. Nevertheless the cover has to be 
improved, that is to say seamless in the distal section in order to be more resistant during 
exertions while wrapping up the imaging head. Another possibility would be the development 
of a shell around the imaging head allowing dip sterilization and thus making wrapping in 
sterile covers unnecessary. In the long-term this would also reduce the current expenses for 
the use of this device.  
 As already mentioned sharp images are crucial for correct interpretation of the images. 
This is difficult to do when the Fluobeam™ is manipulated at arm length and hand held. 
Therefore the idea of using a fixed holder emerged. Again, this is not a simple work, since 
everything should be sterilized. 
 Also the white light emerging from the LED should cover a very large radius in order 
to enable a bright, clear and full view of the operation field for the surgeon without changing 
the colors of the tissues. The conventional surgical light might even be replaced by the filtered 
white light of the imaging head. This has to be evaluated during real NIRF-guided surgery. 
 Another version of the device itself is the FluoSTIC, which is currently studied
245
. The 
FluoSTIC has 22 mm in diameter, 200 mm in height and weights less than 200g. It is a low-
cost near-infrared imaging fluorescence system optimized for clinical use during oncologic 
surgeries that combines both white light and NIR excitation. FluoSTIC is lighter and thus 
should be easier to keep in hand. It is also smaller and thus appropriate for reaching deep or 
difficult zones of the operation field, whereas the Fluobeam™ is needed to cover a large 
surface. 
I.5. Surgeon’s impression 
 Apart from the technical aspects, the surgeon himself declared the interest of such a 
technology for surgery improvement. Although the system was not used in image-guided 
resection, the information mediated by the images after tumor resection and of ex-vivo pieces 
was of great interest for him.  
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In the study, zones which seemed doubtful for the experienced surgeon’s eye were detected as 
“tumor negative” by the system. This was afterwards confirmed by histological analysis of 
these samples and showed the good specificity of this technology. In real conditions, that is to 
say operating while relying on the fluorescence information, several structures like vessels or 
nerves could be spared. 
  Finally, the next step is the translation into human clinics. This can be taken in 
consideration as soon as the tracer has the allowance of the authorities to be used in humans. 
Here I’d like to mention that AngioStamp™ is currently in a toxicological study according to 
regulations.  
 I precise also, that all the studies we have done are based on the follow-up of the fluorescence 
of the tracer. If the fluorophore is intact we can detect fluorescence even if the molecule itself 
is degraded. Hence we speak of fluorescence kinetics or implemented the term F50 and did not 
speak of pharmacokinetics and T1/2 as this could lead to confusion with conventional 
pharmacological studies.  
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II. Reduction of renal retention of RAFT-
RGD by pre-injection of gelofusin 
 
 Small peptidic molecules are known to be retained in the kidneys because of tubular 
reabsorption.  
Knowing that AngioStamp
™
 is eliminated via the kidneys we thought about decreasing the 
accumulation in these organs. A rapid excretion of these compounds would be preferable to 
minimize toxicity but also to obtain high-quality images with low background signal and 
consequently allow improved detection a delineation of even tiny tumors in the vicinity of 
kidneys. This would be particularly important to lower the risk of toxicity when radio-
nuclides are used instead of fluorescence. 
Therefore we decided to study possibilities of reducing the accumulation of the RAFT-RGD 
compounds in the kidneys in collaboration with the group of C. Ghezzi. 
 In a fist attempt we have been working on the chemical composition of the RAFT-
RGD. Glucose was engrafted on the RAFT-RGD-molecule
246
 in order to obtain a molecule of 
higher hydrophilic property which could facilitate excretion. The affinity for integrin αvβ3 was 
shown to be unaffected by this modification as well as tumor uptake, but it failed to reduce 
renal reabsorption. Another attempt was to enhance the renal excretion and dilution by 
administration of a diuretic like Furosemid or co- and post-administration of PBS. None of 
these assays were successful (unpublished data).  
 Other approaches for reduction of renal retention described in the literature consisted 
in the pre- or co-administration of Lysine, Arginin or albumin
247
. This was aiming at targeting 
the megalin receptor in tubular cells, since it has been shown that some ligands bind to 
megalin via their cationic sites and that co-administration of basic compounds can inhibit 
their renal reabsorption. But none of these inhibit renal reabsorption completely. Therefore we 
tried to reduce retention in these cells by a pre-injection of gelofusin. Our results show that 
there is a significant reduction in the kidneys when using gelofusin, even without total 
inhibition of reabsorption. 
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Therefore a combination of the plasma expander and gelofusin and a renal uptake reducing 
amino acid like Arginine or Lysine or even a combination with albumin might be additive
248
. 
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peptides. J Nucl Med 2007; 48: 596–601. 
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III. Introduction of a bi-functional RAFT-
RGD derivative: the RAFT-RGD-MMP 
 
 
 The aim of my work consisted in the development and evaluation of an innovative 
molecule for optical imaging of cancer and cancer therapy, capable of releasing a drug in the 
tumor with a high specificity. 
 We already demonstrated the interest of RAFT-RGD for tumor imaging, as well as its 
capacity to deliver a toxic KLAKLAK peptide specifically in the cytoplasm of the targeted 
tumor cells
249
. In the present work, we wanted to improve its capacity to detect tumor cells 
with low levels of integrins, and also to introduce an activatable function specific of an 
enzyme that would be overexpressed in tumors, rather than the non-specific disulfide bridge 
we initially used. Targeting two tumor-specific receptors by a single dualmolecule was 
expected to augment its specificity but also eventually to generate original biological 
activities due to the physical interaction it could promote between the 2 targets. 
 This approach has also been employed by the group of Chen, who combined MMP-2 
and -9 cleavable sequences with an integrin αvβ3 ligand
250
. Like us, they tried to combine the 
double targeting by addressing a molecule to the ανβ3 integrin and the MMP. The rationale 
for a MMP-2/MMP-9-cleavable linker was that MMP-2 and MMP-9 bind to integrin αvβ3 and 
both are overexpressed in tumor vasculature. Their compound MMP-P-RGD (c(RGDyK)) 
serves as integrin ligand, while Gly-Pro-Leu-Gly-Val-Arg-Gly-Lys-Gly-Gly represents the 
MMP cleavable sequence (between Gly and Val), Cy5.5 and BHQ-3 as fluorophore – 
quencher pair (ex / em; 675 / 695 nm; abs. 650 nm). After conjugation of the RGD-part to 
NHS ester activated C-terminal carboxyl group in fully protected MMP substrate, the labeling 
NHS ester of the NIR dye followed. Then the NHS ester of the quencher was conjugated. 
Their molecule showed the interest of this principle as there was less non-specific 
accumulation without visible impact on the target affinity. 
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 Our molecule is based on the previously described RAFT-(cRGD)4, a scaffold with 4 
integrin αvβ3binding-domains, known to present a stronger Kd to the integrin as compared to 
the monomeric RGD. In addition its multivalency also allows integrin clustering and an 
efficient internalization
251
. By grafting an MMP-activatable and optically active cassette on 
the RAFT-RGD, we wanted to obtain a molecule for functional imaging of cancer presenting 
an improved signal-to-background ratio in vivo, which could also serve as template for a next 
generation of tumor specific pro-drugs. 
III.1. Additional properties of the activatable dual-molecule 
 The results show that the tumor-to-muscle ratio in vivo was higher than that of the 
control molecules. It is also worth noting that these satisfactory results were obtained after 
injection of only 2 µM per mouse, instead of the usual dose of 10 µM normally required for 
RAFT-RGD. This activatable probe accumulates with high specificity in tumors and 
dequenching after cleavage of RAFT-RGD-MMP can be correlated to the level of integrin 
expression. 
 Integrin αvβ3 is co-overexpressed, particularly during the angiogenic switch and during 
metastasis, with MMP-9. Furthermore, the integrin and MMP-2 or-9 are known to interact 
physically, as a result of the action of mechanisms like SIBLINGs. The binding of the dual 
molecule on the integrin can thus induce MMP-2 and consequently activate MMP-9. Hence, it 
is possible that a cooperative and cumulative binding of this dual molecule can take place, but 
this will need further investigation in vivo. This phenomenon would give the molecule an 
advantage to address tumors with not enough integrins to generate a positive signal with the 
original RAFT-RGD, as we already noticed in vitro on the different cell lines. As an example, 
Gelatinase expression is surprisingly low in HEK293(β1) as compared to HEK293(β3) cells. 
This could be a simple consequence of clonal variations between these 2 stable transfectants 
of the original HEK293 parental cell. However, another possible explication would be related 
to this integrin-MMP-interaction since integrin αvβ3 can influence gelatinase activity and vice 
versa. Presuming, in a highly simplified manner as demonstrated in Figure III-1, that integrin 
αvβ3 leads to activation of MMP-9 and MMP-2, which for its part activates MMP-9, the two 
enzymes degrade substrates, like collagen of the ECM. Degradation of these substrates leads 
to an easier recognition of their RGD-motif for the integrin, which up-regulates MMP-9 on 
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the transcription level due to substrate interaction and cell signaling
252. This “positive feed-
back loop” might thus cause a higher expression of MMP-9 in integrin αvβ3 positive cells 
compared to the same cell line but expressing theβ1variant.  
 
 
Figure III-1: Highly simplified diagram of integrin-gelatinases interaction. 
 
III.2. In vivo studies 
 The profile of MMPSense in vivo shows a tumor-to-skin ratio in HEK293(β3) and 
TS/-A cells which does not correspond to the level of gelatinase expression, though the 
molecule is MMP-sensitive. This might be due to the so called enhanced permeability and 
retention (EPR) effect as the molecule is not captured by a fixed receptor. The slowly growing 
HEK293(β3) tumors present a well-structured, neo-angiogenic vasculature with tight 
endothelial junctions compared to TS/-A, where the tumor vasculature is totally disorganized 
and leaky. Thus, we previously classified HEK293(β3) tumors as EPR- while in contrastTS/-
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A tumors are strongly EPR
+253
. Accordingly, not-targeted and bio-available MMPSense 
molecules would accumulate more efficiently by passive EPR effect in TS/A tumors than in 
HEK293(β3). This could explain the enhanced cleavage of MMPSense in TS/-A tumors 
compared to HEK293(β3) tumors, although the later express gelatinases at a higher 
concentration. This is not happening with our RAFT-RGD-MMP molecule, which provides a 
fluorescence profile directly related to the cumulative index of integrin and MMP in these 
tumors. 
 It is very encouraging to observe the stability of the molecule in plasma, because it is a 
prerequisite for in vivo application. Indeed, the molecule is slowly degraded after 24 h in 
plasma. This is more than enough for imaging purposes, but additionally suggests, that the 
molecule will be slowly degraded and evacuated of the body, thus potentially less toxic. Like 
the parental RAFT-RGD, the RAFT-RGD-MMP is eliminated by renal excretion, eventually 
leading to possible damages in the kidneys. The already discussed gelofusin could thus be 
useful in this case. 
III.3. Possible complementary studies 
 It would be necessary to further demonstrate the role of MMP-9 in our double-
targeting approach. This would have to be carried out by a siRNA approach, in order to 
inhibit this enzyme. That is of particular importance since we showed that the signal provided 
by the dual probe is always more important than the one obtained with the parental RAFT-
RGD on all the tumor cell line tested. Thus it is possible that this probe is not that specific and 
could generate false positive signal. Therefore, in addition and/or in parallel with the siRNA 
studies, we should test the molecule with normal cells.   
 The molecule we used was “self-quenched” by the close vicinity of two Cy5 
molecules. However, it is not possible to distinguish the fluorescence emitted of these two 
Cy5, while following molecule cleavage. Additionally, we cannot determine the percentage of 
degraded molecule when fluorescence is appearing, since the initial intact molecule 
theoretically should not be visible. In order to study in more details how efficiently, at what 
time and where exactly the cleavage of the MMP cassette occurs, it would be interesting to 
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replace the two Cy5 by a FRET pair like Cy3 on one side and Cy5 on the other (Figure III-2). 
In FRET, we excite the donor. The emitted fluorescence of the donor then serves to excite the 
acceptor, which in turn will produce light at its emission wavelength. If molecule cleavage 
occurs, the two fluorophores have a greater distance between them and will recover their 
independent original emission spectra. Consequently, each part of the molecule can be traced 
separately, and, furthermore, we can evaluate the percentage of the probe that has been 
cleaved. Alternatively, a “dark” quencher at the place of one of the two initial Cy5 (Figure 
III-3), could also be used. In this case no light is emitted from the intact quenched molecule, 
but quenching would disappear as a direct function of the MMP activity. 
 Thus, on the one hand, using FRET would let us determine, which part of the molecule 
is internalized, the kinetic of cleavage, where this degradation takes place in the cell or 
organism. On the other hand, using a dark quencher would render the initial molecule 
completely invisible, and thus augment the tumor-to-noise signal. Additionally, each photon 
emitted can be correlated to an enzymatic degradation of one molecule. This approach is 
easier to follow in vivo, and gives simple and reliable interpretation. In contrast, FRET 
imaging in vivo is much more complicated in terms of data analysis since at least three 
different measurements should be done at each time. Finally, FRET needs also a good 
calibration of the system and quite an extensive knowledge of photochemistry. 
 Concerning our self-quenched molecule, the quenching is present but definitely not 
complete, leaving a lot of un-quenched signal (output-fluorescence). In our case we did not 
have a real “ON-OFF” quenching. Part of this could be due to the steric conformation of the 
molecule, and thus the donor-acceptor orientation in space. Since the molecule is always 
trying to get a stable conformation with the lowest energy input, the engrafted Cy5 
fluorophores are orientated differently within a certain area in space and might show torsions 
in different directions, leading to changes in the distance of the two fluorophores of one 
molecule. This could influence the quenching efficiency since the transfer of energy 
decreases, when distance increases. Efficient quenching requires proximity between the donor 
and acceptor molecule of approximately 10 to 100 Å
254
. Nevertheless, the efficiency of 
quenching increases with decreasing distance of the two fluorophores. It has been described 
that a very good quenching can be achieved with a donor-acceptor distance of 10 to 30 Å
255
. 
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Spectral overlap of the absorption spectrum of the acceptor with the emission spectrum of the 
donor is necessary.  
 When regarding the RAFT-RGD-MMP, we do have a distance of 30 Å between the 
two orthogonal Lys side chains of the MMP-sequence, on which the Cy5 is engrafted. This 
shows, that the distance between the Cy5 makes quenching feasible, but won’t be in a perfect 
distance, which would be < 30 Å. As already mentioned, it is an autoquenching and thus the 
spectra of absorption and emission only partially overlapping. This results also in a decrease 
of the quenching efficacy.  
 
  
  
Figure III-2: Illustration of RAFT-RGD-MMP and FRET via Cy3 & Cy5 engraftment. 
Figure III-3: Illustration of RAFT-RGD-MMP and Quenching via QSY & Cy5 engraftment. 
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III.4. Double-targeting approach with other enzymes 
 It would be interesting to employ other enzymes, for example like Weissleder et al. 
targeting cathepsins
256
. Other enzymes like ADAMTs
257
, MMPs - like MT1-MMP - or 
Human tissue kallikreins - which play a role in tumor development and angiogenesis
258
- and 
type II transmembrane serine proteases
259
 are also of interest. In the case of caspases it has to 
be taken in consideration, that these enzymes are intracellular and thus need specific delivery 
mechanism, like cell-penetrating peptides (CPPs), consisting of a Lysine rich sequence or 
Arginine residues contain positively charged guanidinium groups. Their efficacy has already 
been tested by Maxwell et al. for imaging Apoptosis
260
.  
III.5. SMARgeting molecule as prodrug and theranostic 
 Up to now, toxicity of chemotherapeutics towards normal cells and non-diseased 
tissues, especially fast growing cells - like blood, bone marrow and mucous membrane cells - 
cause serious side-effects that impose an administration of chemotherapeutic agents at sub-
optimal doses
261
. Maximizing the therapeutic index of a chemotherapeutic agent could be 
achieved by strictly localizing its pharmacological activity to the site or tissue of action. This 
is the hallmark of so called prodrugs, which are transformed after administration, either by 
metabolism or spontaneous chemical breakdown, to pharmacologically active species.  
 Theranostics, that is to say the combination of a therapeutic agent and diagnostic agent 
in one, have the advantage, that one can follow the drug, evaluate the dose or accumulation of 
the molecule in the area of interest and measure the efficacy of the treatment at the same time. 
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 As suggested by Shapira et al., a theranostic nanomedicine must be multifunctional, 
and combine several components: (1) a selective targeting moiety, (2) a diagnostic imaging 
aid for the localization of the malignant tumor and its micro- or macrometastases, (3) a 
cytotoxic, small molecule drug(s) or novel biological therapeutic(s), and (4) a 
chemosensitizing agent, aimed at neutralizing a resistance mechanism, or exploiting a 
molecular "Achilles hill" of drug resistant cells
262
.  
 Overcoming their non-specific signal due to the EPR effect, specification by 
engrafting activatable sequences resulting in dequenching and drug-release is an interesting 
point. This would allow simultaneous monitoring of not only targeting, but also possibly 
efficacy of therapy. 
 Kratz et al. used a divalent peptide cRGDfK with an introduced octapeptide, cleaved 
by MMP-2 and -9, to deliver Doxorubicin, a commonly used anti-cancer drug. They showed a 
tumor inhibition capacity of 6- to 10-fold higher compared to the unformulated control 
molecule
263
. In our case, the enzymatic cleavage takes place in the extracellular space, 
surrounding the cells. This is seen especially with the HT1080 cell line, overexpressing 
soluble MMP-9, but also during the internalization of the molecule. Therefore, such a drug 
delivery system will be particularly adapted to the drug release in the vicinity of the target 
cells. Accordingly, we must chose and attach drugs, which will be capable of entering the 
target cells on their own, after their release in the pericellular space. The presence of a tracer 
will help to follow the nanovector accumulation in the tumors (Figure III-4, A). Thus in its 
intact pro-drug form this molecule would be non-toxic, and its therapeutic activity will 
concentrate mainly within the tumor mass as well as directly into the target cells. This should 
eventually reduce the amount of molecule we need to administer, and reduce the apparition of 
side-effects. 
 The molecule could also be used to deliver two complementary therapeutic agents at 
the same time (Figure III-4, B), in order to increase the toxicological impact on the tumor 
cells and the neo-vasculature. 
However, increasing the complexity of the nanovectors will also augment its non-specific 
binding, as already discussed in the results section, since the presence of the MMP cassette on 
                                                 
262Shapira, Alina, Yoav D Livney, Henk J Broxterman, und Yehuda G Assaraf. „Nanomedicine for targeted cancer therapy: 
towards the overcoming of drug resistance“. Drug resistance updates: reviews and commentaries in antimicrobial 
and anticancer chemotherapy 14, Nr. 3 (Juni 2011): 150–163. 
263Ryppa, Claudia, Hagit Mann-Steinberg, Iduna Fichtner, Holger Weber, RonitSatchi-Fainaro, Martin L Biniossek, und 
Felix Kratz. „In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that 
targets integrin alphavbeta3“. Bioconjugate chemistry 19, Nr. 7 (Juli 2008): 1414–1422. 
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the RAFT-RGD augmented the labeling of all the tested cell lines. However, this was not 
observed in vivo, since no non-specific accumulation of fluorescence was detected. 
 Indeed, only the tumor and kidneys, which are eliminating the probe, were positively 
labeled by the molecule. The molecule efficiency was such that we were able to reduce 5-
times the amount of RAFT-RGD-MMP in vivo (2 nmol/mouse), compared to the 
conventional RAFT-RGD-Cy5. Therefore, it would have been very surprising to detect a sign 
of toxicity at such a low concentration. Thus we can anticipate that, if this is also true when 
the final molecule will deliver a pro-drug, we can really expect to generate active molecules 
with reduced side effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The double targeting concept could also be used for imaging other diseases 
overexpressing proteases and receptors, like inflammatory diseases such as arthritis
264
 or 
asthma
265
, as well as for imaging of atherosclerotic lesions. In atherosclerosis plaques MMPs, 
especially MMP-2 and MMP-9, as well as the integrin αvβ3 are two current targets used and 
                                                 
264
Wunder A, Tung CH, Muller-Ladner U, et al. In vivo imaging of protease activity in arthritis: anovel approach 
for monitoring treatment response. Arthritis Rheum. 2004 Aug; 50(8):2459–2465. 
265
 Cortez-Retamozo V, Swirski FK, Waterman P, et al. Real-time assessment of inflammation and treatment 
response in a mouse model of allergic airway inflammation. J Clin Invest. 2008 Dec;118(12):4058–
4066. 
Figure III-4: Example of prodrug design based on the RAFT-RGD-MMP. 
A) Theranostic approach with release of a drug, e.g. small molecules. 
B) Prodrug approach with two different kinds of drugs: drug I for delivery in the tumor 
environment and drug II for activation in the cells due to internalization of the RAFT-RGD 
moiety.  
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studied for molecular imaging
266
. MMPs are mostly secreted by lipid-engorged macrophages 
(foam cells) and proof-of-concept studies in imaging gelatinase activity in mice have already 
been done by the team of Weissleder. The integrin is expressed by neoformed blood vessels in 
advanced lesions. A theranostic approach using gadolinium-based paramagnetic 
nanoparticles, encapsulating the antiangiogenic agent fumagillin, yielded an increase in MRI 
signal as well as it showed a therapeutic effect
266
. 
The RAFT-RGD-MMP represents thus a potential functional molecule for theranostic 
purpose in cancer but also in several other diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
                                                 
266Quillard, Thibaut, und Peter Libby. „Molecular Imaging of Atherosclerosis for Improving Diagnostic and Therapeutic 
Development“. Circulation Research 111, Nr. 2 (Juni 7, 2012): 231–244. 
  
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
« Ne crains pas d'avancer lentement, crains seulement de t'arrêter. » 
Chinese wisdom 
[Don’t worry about progressing slowly, but only about standing still.]  
  
 
  
  
 
MATERIALS AND METHODS
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I. Preliminary safety observation studies 
 
I.1. Animals 
 Three healthy laboratory cats of the veterinary university were included in the 
preliminary toxicological study.  
I.2. Fluorescent tumor-targeting probe 
 AngioStamp
TM
 (Fluoptics, Grenoble, France) is a NIR dye-labelled molecular probe 
targeting the vß3 integrin derived from the previously published RAFT(c[-RGDfK-])4. 
AngioStamp™ was injected in the jugular vein at a concentration of either 0.9 mg/kg, 2.4 
mg/kg or 4.5 mg/kg. 
I.3. General examination of the cats  
 General examination of the animal was done by checking the pulse, the 
heartbeat/noise, capillary refill, reflex (interdigital claw reflex, papillary and eyelid closure 
reflex) and observation of the animal’s comportment. 
I.4. Physical and biochemical parameters 
 A urinary catheter as well as a catheter in the cephalic vein was placed under short 
anesthesia with Domitor
®
 (medetomidine; 0.05 ml/kg) and Ketamin (0.05 ml/kg). The 
anesthesia was reversed by i.v. injection of Antisedan
® 
(atipamezole; 0.02 ml/kg).  
 After awaken of the animal, the tracer AngioStamp™ was injected in the jugular vein.  
Medical control of the animals was done by survey of the hematological parameters including 
total blood cell count, white blood cell (WBC) fractions, including lymphocytes (LYM), 
monocytes (MON) and granulocytes (GRA) with their sub-class eosinophiles (EOS), red 
blood cell (RBC) fraction, hematocrit (HCT), platelets (PLT), the mean platelet volume 
(MPV), MCH (mean corpuscular hemoglobin), MCV (mean cell volume), MCHC (mean 
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corpuscular hemoglobin concentration), Urea
267
, Creatinine, activities of enzymatic markers 
of liver dysfunction (ALT (liver transaminase) and PAL (phosphatase alkaline) activities, as 
well as the bilirubin rate
268
, and a blood ionogram (Cl, K, Na) as well as the evaluation of the 
RPCU of urine (urinary protein/creatinine ratio). These parameters were chosen as control of 
direct toxicological response and control of kidney nuisance as the AngioStamp
TM
 is 
eliminated via the renal pathway. Physical parameters (body weight, food and water intake) 
were studied 6 hours after of injection. 
 These parameters were determined just before injection of the tracer (T0) and until 7 
days post injection. 
 Blood was withdrawn at the jugular vein with one-way catheters. Blood samples were 
taken directly before administration of AngioStamp™ (T0), then 5 min, 15min, 30 min, 1 h, 2 
h, 4 h, 5 h 30, 24h and 7 days after injection. The urine samples of about 5mL were obtained 
via a steady urine catheter at the same time as the blood withdrawal took place. 
I.5. Calculation for the dose 1X for cats 
 The dose for cats was estimated from the optimal dose used for tumor imaging in 
mice
269
 and rats (unpublished data). In mice the dose, providing the best tumor/healthy tissue 
ratio, is 10 nmol for a mouse of 25 g. In rats 20, 50, 70 and 100 nmol were evaluated and the 
best tumor/healthy tissue ratio was obtained with the dose 50 nmol for a rat of 250 g. 
Drawing a linear correlation line between dose and body weight, we obtained the formula y = 
0.177x + 5.555 (Figure I-1). This leads to an estimated dose of 895 nmol for cats (average 
weight of 5 kg) and 1784 nmol for dogs (average weight of 10 kg). Thus we chose the dose of 
0.9 mg/kg for cats (Table I-1). 
 
                                                 
267 Tamta, Anupama, Manu Chaudhary, und Rajesh Sehgal. „A 28-Days Sub-Acute Toxicity Study in Swiss Albino Mice to 
Evaluate Toxicity Profile of Neurotol Plus (Mannitol and Glycerol Combination)“. International Journal of 
Biomedical Science 5, Nr. 4 (Dezember 15, 2009): 428–433. 
268 Hamden, Khaled, Serge Carrea U, Fatma Ayadi Marki, Hatem Masmoudi, and Abdelfattah El Feki. „Positive effects of 
Green Tea on hepatic dysfunction, lipid peroxidation and antioxidant defence depletion induced by cadmium“. 
Biological Research 41, Nr. 3 (Januar 2008): 331–339. 
269 Garanger, E., D. Boturyn, P. Dumy, MC Favrot, und JL Coll. „New multifunctional molecular conjugate vector for targeting, 
imaging, and therapy of tumors“. Molecular Therapy. 12(6), Dezember 2005. 
Jin, Z.H., J. Razkin, V. Josserand, und et al. „In vivo noninvasive optical imaging of receptor-mediated RGD internalization using 
self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4)“. Mol Imaging. 6, 2007. 
Jin, ZH, V. Josserand, S. Foillard, D. Boturyn, P. Dumy, MC Favrot, und JL Coll. „In vivo optical imaging of integrin alphaV-beta3 
in mice using multivalent or monovalent cRGD targeting vectors“. Molecular Cancer. 6, Juni 2007. 
Sancey, L., E. Garanger, S. Foillard, G. Schoehn, A. Hurbin, C. Albiges-Rizo, D. Boturyn, u. a. „Clustering and internalization of 
integrin alphavbeta3 with a tetrameric RGD-synthetic peptide“. Molecular Therapy. 17(5), Mai 2009. 
Keramidas, M., V. Josserand, CA Righini, C Wenk, C Faure, und JL Coll. „Intraoperative near-infrared image-guided surgery for 
peritoneal carcinomatosis in a preclinical experimental model“. British Journal of Surgery. 97(5), 2010. 
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Figure I-1: Estimation of AngioStamp™ dose for cats. 
 
 
 
 
Table I-1: Species specific dose of AngioStamp™. 
 
I.6. Image analysis and unit definition 
 Fluorescence data were analyzed by means of the software WASABI (Hamamatsu, 
Germany). The initial autofluorescence of the samples (blood, plasma, urine and body 
regions) was measured before administration of AngioStamp™ and was subtracted from the 
signal measured afterwards. Thus the values obtained were comparable each other. 
The fluorescence is calculated using the semi-quantitative data obtained by drawing 
regions of interest (ROIs) on the spots ought to be studied.  The fluorescence quantifications 
are expressed as a procedure defined unit (p.d.u.). This corresponds to the number of relative 
light units per pixel per millisecond (RLU/pix/ms) in the case of tissues and RLU per 
microliters per millisecond (RLU/µL/ms) in the case of liquids, with regard to the 
autofluorescent level.  
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I.7. Portable clinical fluorescence imaging device 
 Real time in vivo fluorescence imaging was performed using the Fluobeam
™ 
NIR 
imaging system (Fluoptics, Grenoble, France).  This hand-held system is compact (7 cm in 
diameter and 20 cm in length, with a weight of 600 g) and consists of two parts: a control unit 
with a laser source emitting at the excitation wavelength 780 nm and a power supply for light-
emitting diodes (LEDs), next to an optical head with a highly sensitive charge-coupled device 
camera and white LEDs for the illumination of the field of view at 5 kLux of high quality 
light (Color Rendering Index about 90%). The laser beam is fiber-guided from the control 
unit to the optical head. The detection of the emitted fluorescence is under 800 nm. The laser 
beam was spread to reach a 6-cm spot diameter at the working distance of 17 cm. The power 
density of the laser irradiation was 96 μW/mm2. The NIR fluorescence image was 696×512 
pixels and provided a resolution of two line pairs per millimeter (spatial resolution of 110 
µm/pixel) allowing visualization of sub-millimeter structure
270
. The exposure time can be 
adjusted from 1 ms to 1 sec. The Sensitivity of the system is 1 picomol of fluorophore. The 
Fluobeam™ system has been used with a dedicated single use CE marked sterile cover 
bearing an optical window compatible with NIR fluorescence measurements
271
. 
II. Intra-operative surgery 
II.1. Patient recruitment 
 Cats were addressed by veterinary practitioners. Twelve cats (3 males and 9 females; 
9.8 ± 1.7 years old, weighing 4.7 ± 1.7 kg) were included in the study after obtaining the 
owners’ information and consent. Diagnosis was based on clinical and morphological data 
(fine needle aspirations and biopsies), Extent of the disease as local staging of the tumour and 
metastatic spreading were evaluated by contrast enhanced CT (computed Tomography) 
                                                 
270 Heuveling, DA, GW Visser, M. de Groot, JF de Boer, M. Baclayon, WH Roos, GJ Wuite, CR Leemans, R. de Bree, und 
GA van Dongen. „Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention 
in the sentinel lymph node“. Eur J Nucl Med Mol Imaging. 39(7), Juli 2012. & 
Mery, E., E. Jouve, S. Guillermet, M. Bourgognon, M. Castells, M. Golzio, P. Rizo, JP Delord, D. Querleu, und B. Couders. 
„Intraoperative fluorescence imaging of peritoneal dissemination of ovarian carcinomas. A preclinical study.“ 
Gynecol Oncol. 122(1), Juli 2011. 
271 D. Wachter, K. Kallenberg, A. Wrede, W. Schulz-Schaeffer, T. Behm, V. Rohde, Fluorescence-Guided Operation in 
Recurrent Glioblastoma Multiforme Treated with Bevacizumab-Fluorescence of the Noncontrast Enhancing Tumor 
Tissue? J Neurol Surg A Cent Eur Neurosurg (2012). & 
T. Tykocki, R. Michalik, W. Bonicki, P. Nauman, Fluorescence-guided resection of primary and recurrent malignant gliomas 
with 5-aminolevulinic acid. Preliminary results. Neurol Neurochir Pol 46 (2012) 47-51. 
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(Figure 1A).CT scanning was performed by a series of transverse 2 mm slices of the thorax, 
once without contrast agent and once after an intravenous iodide injection containing a 
contrast agent (iohexol). The contrast agent identified the tumour tissue as a homogenous 
mass. This three-dimensional CT provided essential information for proper planning of 
aggressive surgical approach. 
II.2. Fluorescent tumor-targeting probe 
 AngioStamp
TM
 (Fluoptics, Grenoble, France) was injected in the cephalic vein of the 
animals at 0.6, 0.3 and 0.15 mg/kg. Surgical intervention was performed at 16, 24 and 36 h 
post-injection.  
II.3. Surgical fibrosarcoma resection and imaging 
 Tumour excision was carried out according to the conventional surgical procedure. Per 
operative imaging was conducted in parallel and was not used to influence the resection 
gesture.  
 After preparation of the operation field and before incision of the skin, initial 
fluorescent images of the tumour were taken. After the beginning of the tumour resection, 
fluorescence imaging was performed at several steps of the surgery (tumour tissue, tumour 
margins and surrounding healthy tissues).  
After surgery was completed, the operation field and especially the margins or doubtful 
structures were imaged. Afterward, surgical specimens were dissected into samples for 
histopathological analysis under fluorescent guidance. After the recovery phase, the cats 
returned home and the owners were asked to bring them back regularly for long-term clinical 
follow-up. 
II.4. Histo-pathological and immuno-histological analyses 
 Surgical specimens were sampled into two pieces for the histo-pathological and 
immuno-histological analyses of the αvβ3 integrin expression level. A portion of samples were 
fixed in formaldehyde, embedded in paraffin and cut in 4-µm slices before Haematoxylin-
Eosin standard staining, and other samples were frozen by placing them in isopentane and 
shock freezing them in liquid nitrogen. They were cut into 6 µm slices (microcryotome) and 
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conserved at -80°C until fixation and staining. After warming up the frozen slices by leaving 
them at room temperature, they were fixed during 10 min in methanol at room temperature. 
After 5 min of rinsing in water, the slices were loaded in an automated instrument 
(BenchMark, Ventana Medical Systems, Strasbourg, France) and labelled with the mouse 
anti-human-integrin αvβ3 antibody clone LM609 (Chemicon, USA) for 32 minutes at room 
temperature at 5µg/ml (1/200). After an automatic rinsing, the slices were incubated with the 
OptiView DAB detection kit (Ventana Medical Systems) according to the manufacturer’s 
instructions. Incubation with control mouse IgG1 at 5μg/ml served as negative control. 
II.5. Analysis of NIR fluorescence data 
 The fluorescent data collected using Fluobeam™ was quantified with the image 
analysing program WASABI (Hamamatsu Photonics GmbH, Germany) and Microsoft Excel. 
The intensity value of the different tissues was defined as the mean fluorescence intensity of 
the region of interest (ROI) minus the mean fluorescence intensity of the background divided 
by the exposure time in milliseconds, resulting in the relative light unit per pixel per 
millisecond (RLU/pixel/ms).Three to ten different ROIs were measured for each animal. 
These ROIs were taken on the tumour and the healthy tissues. The number of chosen ROIs 
depended on the exploitation possibilities of the images taken (e.g. tumour sample not 
covered by thick muscle layers or skin; sloping or blurred images). 
II.6. Statistical analysis 
 Statistical analysis was carried out using Statview software (SAS Institute, San 
Francisco, CA, USA). Tumor and tissue values were compared after Mann-Whitney (pair) 
and Kruskal-Wallis. A p-value under 0.05 was considered as significant (*), under 0.01 very 
significant (**) and under 0.001 as extraordinary significant (***). 
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III. Protocols for peptide synthesis 
III.1. Material and Equipment 
 Rink-amide MBHA
®
 was obtained from Calbiochem-Novabiochem, Fmoc-Gly-
SASRIN
® 
resin from Bachem Biochimie SARL (Voisin-LesBretonneux, France) and 2-
chlorotritylchloride
®
 resin from Advanced ChemTech Europe (Brussels, Belgium). The 
protected amino acids were purchased from Activo tec (Cambridge, UK), Bachem Biochemie 
SARL (Voisins-les-Bois, France) or Calbiochem-Novabiochem (Merck Biosciences-VWR, 
Limonest, France). PyBOP
®
 was procured from Calbiochem-Novabiochem, whereas other 
reagents were obtained from Aldrich (Saint-Quentin Fallavier, France) and Acros (Noisy-le-
Grand, France). Cyanine
TM
5 Mono NHS ester was purchased from Amersham Biosciences 
(Orsay, France) and QSY
® 
21 NHS from Invitrogen (Cergy Pontoise, France). 
 
 Waters equipment was used for analyses by means of RP-HPLC. This comprises a 
Waters 600 controller, a Waters 2487 Dual Absorbance Detector and a Waters In-Line 
Degasser. The column used was a Nucleosil 120 Å A3 µm C18 particles, 30 x 4 mm
2
 
operated at 1.3 mL min
-1
 with a linear gradient program in 15 minutes run time (classical 
program 5 to 100% B in 15 minutes). UV monitoring was realized at 214 nm and 250 nm, 
respectively 320 nm with Dansyl group and 650 nm with Cy5/QSY dyes. Solvent A consisted 
of H2O containing 0.1% TFA and solvent B of CH3CN containing 9.9% H2O and 0.1% TFA. 
 Electron spray ionization (ESI-MS) mass spectra were obtained on an Esquire 3000 
(Bruker). 
III.2. General Peptide synthesis procedures 
 All linear protected peptides were synthesized manually or automatically by means of 
solid-phase peptide synthesis (SPPS) using the standard Fmoc/tBu protection strategy
272,273
. 
For manual production a glass reaction vessel fitted with a sintered glass frit was used as 
device as it allows the removal of reagent excess and solvents under compressed air. To 
                                                 
272 P. Lloyed-Williams, F. Albericio, and E. Giralt. “Chemical Approaches to the Synthesis of Peptides and Proteins”. Ed. by 
Ed. C.W. Rees. CRC Press, NY, 1997, p. 278. 
273 R.B. Merrield. “Solid-Phase Peptide Synthesis. 3. An Improved Synthesis of Bradykinin." In: Biochemistry 3 (1964). 
SPPS, pp. 1385-1390. 
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prevent resin beads from sticking at the inside of the vessel, it is treated at least 12 hours 
before use with (CH3)2SiCl2 for lubrication. 
Washings with DCM (10 mL/g resin) were carried out until the complete clearance of acid 
traces. Resin was then swollen with DCM (10 mL/g resin) once for 30 min and twice for one 
minute, washed three times with DMF (10 mL/g resin) for 1 minute. Coupling reactions were 
performed using, relative to the resin loading, 2 equiv. of N
α
-Fmoc-protected amino acid, 2 
equiv. PyBOP and 3-4 equiv. of DIPEA, in order to obtain pH 8, DMF (10 mL/g resin) for 30 
minutes. Then the resin was washed five times with DMF (10 mL/g resin) and once with 
DCM (10 mL/g resin) for one minute. The completeness of amino acid coupling reaction was 
checked by the TNBS test. 
N
α
-Fmoc-protection groups were then removed by treatment with a solution of 20% 
piperidine in DMF (10 mL/g resin) for 5 minutes twice and then once for 10 minutes (Figure 
III-1).  
 
 
 
 
 
 
 
 
 
 
 
 
The resin beads were washed five times with DMF (10 mL/g resin).  
Fmoc removal can be monitored spectrophotometrically because of the formation of 
dibenzofulvene or fulvene-piperidine adducts (λ = 299 nm). Thus cleavage and washing 
solutions were collected in a Vial and the volume adjusted to a known value (V) with MeOH. 
The absorbance at 299 nm gave the amount of Fmoc protecting groups released from the 
cleavage according to the Beer-Lamber relation: 
 
Figure III-1: Scheme of the removal of Fmoc with Piperidine 
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nFmoc=(OD299nm x V)/(ε299vµ x l) 
A λ = Alu x 30 (3fold dilution), A = ε x l x c 
 
with l = length of optical path; ε = 7800 M-1 cm-1 and l = 1 
 
 This method was commonly used to determine the loading and thus indirectly allows 
the monitoring of the synthesis. Automated syntheses were performed on the “AB433A” 
Peptide Synthesizer (Applied Biosystems) with an UV/VIS Detector using standard solid-
phase methods. 
Finally, linear peptides were recovered from the resin beads under acidic conditions (Table 
III-1). 
 
Resin Cleavage solution Procedure 
 
2-chlorotritylchloride 
 
TFE/AcOH/DCM (20/20/60) 
 
(10 mL/g resin) 2 hrs 
 
 
Rink-amide MBHA 
 
TFA/Tis/H2O (90/5/5) 
 
(10 mL/g resin) 2 hrs 
 
 
SASRIN 
 
TFA/DCM (1/99) 
 
(10 mL/g resin) 1 min 10 times 
 
 
Table III-1: Procedures for cleavage from the resin 
 
 Cyclization reactions of peptides in solution were performed using protected linear 
peptides. They were dissolved in DMF (0.5 mM) at pH adjusted to 8-9 by addition of DIPEA. 
PyBOP (1.1 equiv.) was added and the solution was stirred at room temperature for 30 
minutes. The solvent was removed under reduced pressure and the residue dissolved in a 
minimum of DCM. Ether precipitation and washing afforded crude peptide that was used 
without further purification. 
 
 TNBS test 
 Four drops of a solution containing 1% trinitrobenzene sulfonic acid in DMF and a 
solution containing 10% DIPEA in DMF were added to a small amount of resin beads. The 
mixture was left at room temperature for 1 minute. Remaining free amino functions resulted 
in a red coloration of the beads (positive TNBS test). Consequently the coupling reaction with 
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the protected amino acid should be repeated until the beads remain colorless (negative TNBS 
test). 
 The cleavage of side-chain protecting groups in solution phase 
 
 • Deprotection of Boc, Pbf, Trt 
 The removal of protecting groups was carried out in a solution containing 95 % TFA, 
2.5% Tis and 2.5% H2O for 1 hour at room temperature. The solution was concentrated, and 
the crude peptide was triturated and washed with ether. 
 
 • Deprotection of Dde 
 
 
 
 
 
 
 
 
 Deprotection of Dde at the lysine side-chain was performed using a solution 
containing Hydrazine (4%) and allyl alcohol (6%). To remove the Hydrazine, we used a C18 
micro colomn (Chromafix). Afterwards, peptide was characterized by using HPLC analysis 
and mass spectroscopy.  
 
 • Deprotection of Alloc 
 The deprotection of Alloc at the lysine side-chain was performed by means of 
Tetrakis-Palladium [Pd(PPh3)] under inert atmosphere. Therefore the peptide was dissolved in 
anhydrous DCM under argon and phenylsilane (25 eq.) was added. The solution was stirred 3 
minutes before adding 0.2 equiv. of Pd(PPh3)4 and stirring for 1 hour at room temperature. 
The mixture was treated with Methanol for 15 minutes before evaporation of the solvents 
under reduced pressure. Finally the product was triturated and washed with ether. The peptide 
was then characterized by using HPLC analysis and mass spectroscopy. 
 
Figure III-2 Scheme of the removal of Dde 
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 Fluorescent dye coupling 
 The peptide was dissolved in DMF extra dry (10x10
-6
 moles). One equiv. Cy5 was 
added and the solution was adjusted to pH 8 by adding 4 equiv. DIPEA and stirred for 1 hour. 
The reaction was checked by RP-HPLC. Then, peptide was obtained after an ether 
precipitation. 
The same procedure was applied to graft QSY21 dye. 
 
  
Figure III-3: Scheme of the Palladium assisted removal of Alloc 
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III.3. Compounds 
1: Dansyl-Gly-Pro-Leu-Gly-Leu-Trp-Ala-Arg-Gln-NH2 
The peptide was assembled on RINK amide resin 
(110 mg, loading of 0.7 mmol/g) as described in 
the General Peptide synthesis procedures. 
Dansyl-containing peptide was obtained as a 
yellow fluffy powder (100 mg). Peptide 1 was 
then characterized by using RP-HPLC and mass 
spectrometry. HPLC purification of 10 mg gave 
pure peptide (1.4 mg). 
 
 
 
 
 
RP-HPLC peak: RT = 7.8 min 
(C18, 214 nm /320 nm, 5-10% B in 15 min) 
Found mass: 1229 g mol
-1
 
Calculated mass = 1229 g mol
-1 
Yield: 16 % 
 
2: Dansyl-Gly-Pro-Leu-Gly-Val-Trp-Ala-Arg-Gln-NH2 
The peptide was synthesized on RINK amide 
resin (357 mg, 0.7 mmol/g) by using the peptide 
synthesizer “AB433”. Dansyl-containing peptide 
was obtained as a yellow fluffy powder (500 
mg). Peptide 2 was then characterized by using 
RP-HPLC and mass spectrometry. HPLC 
purification of 10 mg gave pure peptide (3.8 mg). 
 
 
 
 
 
RP-HPLC peak: RT = 8.23 min 
(C18, 214 nm/320 nm, 5-10% B in 15 min) 
Found mass: 1215 g mol
-1
 
Calculated mass = 1215 g mol
-1
L 
Yield: 24 % 
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3: Dansyl-Gly-Pro-Gln-Gly-Leu-Ala-Gly-Gln-NH2 
The peptide was synthesized on RINK amide 
resin (250mg, 0.7 mmol/g) by using the peptide 
synthesizer “AB433”. Dansyl-containing peptide 
was obtained as a yellow fluffy powder (100 
mg). Peptide 3 was then characterized by using 
RP-HPLC and mass spectrometry. HPLC 
purification of 10 mg gave pure peptide (4.1 mg). 
 
 
 
 
 
RP- RP-HPLC peak: RT = 5.98 min 
(C18, 214 nm/320 nm, 5-10% B in 15 min) 
Found mass: 959 g mol
-1
 
Calculated mass = 959 g mol
-1
 
Yield: 6 % 
 
4: Dansyl-Gly-Leu-Arg-Gly-Pro-Trp-Leu-Ala-Gln-NH2 
The peptide was synthesized on RINK amide 
resin (110 mg, 0.7 mmol/g) by using the peptide 
synthesizer “AB433”. Dansyl-containing peptide 
was obtained as a yellow fluffy powder (100 
mg). Peptide 4 was then characterized by using 
RP-HPLC and mass spectrometry. HPLC 
purification of 10 mg gave pure peptide (9 mg). 
 
 
 
 
 
RP-HPLC peak: RT = 7.57 min 
(C18, 214nm/320nm, 5-10% B in 15 min) 
Found mass: 1229 g mol
-1
 
Calculated mass = 1229 g mol
-1
 
Yield: 16 % 
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5:Gly(boc)-Lys(Dde)-Gly-Pro-Gln(Trt)-Gly-Leu-Ala-Gly-Gln(Trt)-Lys(Alloc)-OH 
The peptide was synthesized manually on 
Chlorotrityl resin (450 mg, 0.4 mmol/g). Peptide 
5 was obtained as a white powder (50 mg) and 
used for the next step without purification. 
 
 
 
 
 
 
RP-HPLC peak: RT = 7.01 min 
(C18, 214 nm/250 nm, 5-10% B in 15 min) 
Found mass: 1874 g mol
-1
 
Calculated mass = 1875 g mol
-1
 
Yield: 4 % 
 
6a:Gly(boc)-Lys(Cy5)-Gly-Pro-Gln(Trt)-Gly-Leu-Ala-Gly-Gln(Trt)-Lys(Alloc)-OH 
Starting from compound 5 (50 mg), Dde removal 
and Cy5 coupling afforded the cyanine 5-
containing peptide 6a as a blue powder (26 mg). 
Compound 6a was then characterized by using 
RP-HPLC and mass spectrometry. The 
compound was used to engraft QSY21, which 
was abandoned due to low affinity of the 
reaction. 
 
 
 
 
 
 
 
 
RP-HPLC peak: RT = 11.07 min 
(C18, 214nm/250nm, 5-10% B in 15 min) 
Found mass: 2347 g mol
-1 
Calculated mass = 2346 g mol
-1
 
Yield: 52 % 
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6b: H2NO-CH2-CO-Gly-Lys-Gly-Pro-Gln-Gly-Leu-Ala-Gly-Gln-Lys-Gly-OH 
Peptide synthesis was carried out as described in 
the general procedure. Full deprotection of 
protected peptide  5 ((Boc)2NO-CH2-CO-Gly-
Lys(Boc)-Gly-Pro-Gln(Trt)-Gly-Leu-Ala-Gly-
Gln(Trt)-Lys(Boc)-Gly-OH (20 mg, 9.8 μmol)) 
was done from a solution of TFA/H2O/TIS/EDT 
(90:5:2.5:2.5) during 2 h. The product was 
directly purified by RP-HPLC to yield compound 
6b as a white powder (6 mg, 4 μmol). 
 
 
 
 
 
RP-HPLC peak: RT = 11.4 min 
(C18, 214nm/250nm, 5-100% B in 20 min; 1 
mL/min) 
Found mass: 1170 g mol
-1
 
Calculated mass = 1169 g mol
-1 
Yield: 41 % 
 
7: cyclo[-Arg-Gly-Asp-DPhe-Lys(-CO-CHO)-] 
In parallel, the synthesis of cyclo(RGDfK) ligand 
was carried out as described
274
. 
The linear peptide D(tBu)-f-K[BocS(tBu)]-
R(Pmc)-G was produced via the SPPS method by 
using Fmoc-Gly-SASRIN resin (310 mg 0,8 
mmol/g). Peptide cyclo[-Arg-Gly-Asp-DPhe-
Lys(-CO-CHO)-] was obtained in three steps: (1) 
head-to-tail cyclization, (2) acid deprotection by 
using a solution of TFA/TIS/H2O (95:2.5:2.5) 
and (3) a following periodate oxidation by using 
10 equiv. NaIO4 for 15 min in H2O furnished the 
aldehyde-containing cyclopeptide cyclo[-Arg-
Gly-Asp-DPhe-Lys(-CO-CHO)-]from HPLC 
purification (160 mg). 
 
 
 
 
 
RP-HPLC peak: RT = 5.8 min 
(C18, 214nm/250nm, 5-100% B in 20 min; 1 
mL/min) 
Found mass: 695 g mol
-1
 
Calculated mass = 695 g mol
-1 
Yield: 84 % 
 
  
                                                 
 274 Boturyn, Didier, und Pascal Dumy. „A convenient access to αVβ3/αVβ5 integrin ligand conjugates: regioselective solid-
phase functionalisation of an RGD based peptide“. Tetrahedron Letters 42, Nr. 15 (April 9, 2001): 2787–2790. 
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8: RAFT = 
c[-Lys(-CO-CH2ON=C(CH3)OEt)-Lys(-CO-CH(NH(Boc))-CH2-O(tBu))-Lys(-CO-
CH2ON=C(CH3)OEt)-Pro-Gly-Lys(-CO-CH2ON=C(CH3)OEt)-Ala-Lys(-CO-CH2ON=C(CH3)OEt)-
Pro-Gly-] 
 
 
Linear peptide was prepared using building blocks as previously described.
275
 linear peptide (0.5 mM) 
was dissolved in DMF and the pH values were adjusted to 8-9 by addition of DIPEA. PyBOP (1 
equiv) was added and the solution stirred at room temperature for 1 h. Solvent was removed under 
reduced pressure and the residue dissolved in the minimum of methylene chloride. Diethyl ether was 
added to precipitate peptide. Then it was triturated and washed three times with diethyl ether to obtain 
crude material that was used in the next step without further purification. Yield: 31% 
 
9: HC2O2-RAFT-(c[-RGDfK-])4 
                                              
 
 
 
 
 
 
 
Full deprotection of compound 8 (157.2 mg, 86 μmol) was carried out using 10 mL of a solution 
containing TFA/H2O/TIS (95:2.5:2.5) at room temperature during 3 h. The product was isolated after 
removal of solvents under reduced pressure and precipitation from diethyl ether to yield deprotected 
peptide as a white powder in quantitative yield (169 mg, 86 μmol). In parallel, cyclo[-Arg-Gly-Asp-
                                                 
 275 Foillard, Stéphanie, Martin Ohsten Rasmussen, Jesus Razkin, Didier Boturyn, und Pascal Dumy. “1-Ethoxyethylidene, a 
 new group for the stepwise SPPS of aminooxyacetic acid containing peptides“. The Journal of organic chemistry 
 73, Nr. 3 (February 1, 2008): 983–991. 
RP-HPLC peak: RT = 17.9 min 
(C18, 214nm/250nm, 5-100% B in 30 
min; 2 mL/min) 
Found mass: 3935 g mol
-1 
Calculated mass = 3934 g mol
-1 
Yield: 77 % 
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DPhe-Lys(-CO-CHO)-] was synthesized as previously described.
276
 
To an aqueous solution (2 mL) containing the deprotected peptide (20 mg, 10.2 μmol) was added 
freshly prepared cyclo[-Arg-Gly-Asp-D Phe-Lys(-CO-CHO)-] (67.5 mg, 87 μmol). The reaction was 
stirred for 1 h at 25°C. The RGD-containing conjugate was isolated after purification by RP-HPLC as 
a white powder (40.1 mg, 8.8 μmol, 86%). A serine oxidation of RGD-containing conjugate (20 mg, 
4.3 μmol) by an aqueous solution containing 10 equiv. of NaIO4 (10.8 mg, 50.4 μmol) afforded the 
aldehyde component 9. The product was directly purified by RP-HPLC to yield compound 9 as a 
white powder (14.6 mg, 3.3 μmol). 
 
10: RAFT-RGD-MMP = 
[RAFT-c(RGDfK)4]-Gly-Lys(Cy5)-Gly-Pro-Gln-Gly-Leu-Ala-Gly-Gln-Lys(Cy5)-Gly-OH 
 
 
                                                                            
 
 
 
 
 
 
 
 
 
 
 
To a solution containing the derivative 9 (17 mg, 3.8 μmol) in 400 μL of H20/CH3CN (1:1) was added 
the peptide 6b (6 mg, 4 μmol). The reaction was stirred for 3 h at 25 °C. MMP-containing conjugate 
was isolated after purification by RP-HPLC as a white powder (10 mg, 1.7 μmol, 46%). To a solution 
containing the MMP-containing conjugate (4 mg, 0.7 μmol) in 180 μL of DMF was added 3 μL 
DIPEA and Cyanine 5-mono NHS ester (1.7 mg, 1.8 μmol). The reaction was stirred overnight at 
room temperature. The product was directly purified by RP-HPLC to yield compound 10 as a blue 
powder (1.5 mg, 0.22 μmol). 
                                                 
276 Boturyn, Didier, und Pascal Dumy. „A convenient access to αVβ3/αVβ5 integrin ligand conjugates: regioselective solid-
phase functionalisation of an RGD based peptide“. Tetrahedron Letters 42, Nr. 15 (April 9, 2001): 2787–2790. 
 
RP-HPLC peak: RT = 17.9 min 
(C18, 214nm/250nm, 5-100% B in 30 
min; 2 mL/min) 
Found mass: 6364 g mol
-1 
Calculated mass = 6364 g mol
-1 
Yield: 31% 
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 RP-HPLC profile and ESI-MS analysis of 9 
 
RP-HPLC profile of 9 monitored at 214 nm. 
Nucleosil column (300Å 6 µm C18 particles, 125 x 3 mm); linear gradient (5 to 100% B in 20 
min; flow rate: 1mL/min). 
 
RT  = 9.9 min 
 
 
ESI-MS analysis of compound 9 
 
 
 
 Deconvoluted mass: Mfound = 3935.2; Mcalc = 3934.9  
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 RP-HPLC profile and ESI-MS analysis of 6b 
 
RP-HPLC profile of 6b monitored at 214 nm. 
Nucleosil column (300Å 6 µm C18 particles, 125 x 3 mm); linear gradient (5 to 100% B in 20 
min; flow rate: 1mL/min). 
 
 RT  = 11.4 min 
 
 
ESI-MS analysis of compound 6b 
 
 
 
Deconvoluted mass: Mfound = 1170.6; Mcalc = 1169.6  
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 RP-HPLC profile and ESI-MS analysis of 10 
 
RP-HPLC profile of 10 monitored at 214 nm. 
Nucleosil column (100Å 5 µm C18 particles, 250 x 4.6 mm); linear gradient (5 to 100% B in 
30 min; flow rate: 2 mL/min). 
 
  RT = 17.9 min 
 
 
 
 ESI-MS analysis of compound 10 
 
 
 
Deconvoluted mass: Mfound = 6364.9; Mcalc = 6364.9 
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 RP-HPLC profile and ESI-MS analysis of cleavage product 11 
 
RP-HPLC profile of MMP cleavage affording peptide fragment 11 monitored at 214 nm. 
Nucleosil column (100Å 5 µm C18 particles, 250 x 4.6 mm); linear gradient (5 to 100% B in 
30 min; flow rate: 2 mL/min). 
2 µM of compound 10 in Tris Buffer (pH 7.8) was incubated with 5 nM of MMP-9 at 37°C 
for 24 hours, and analyzed by using RP-HPLC. The products observed were afterwards 
characterized using mass spectrometry. 
 
 
RT (10) = 17.9 min; RT (11) =17.4 min 
 
ESI-MS analysis of compound 11 
 
 
 
Deconvoluted mass: Mfound = 5171.4; Mcalc = 5171.4 
IV. Cleavage studies of linear peptide 
sequences 
 
 Therefore human purified pro-MMP-2 and pro-MMP-9 were used (EnzoLifeScience). 
After activation of the enzymes using aminophenyl mercuric acetate (APMA, 20 mM), the 
enzymes were diluted in Tris buffer (50 nM, pH 7.5) to 0.2 ng/µL MMP-2 and 0.4 ng/µL 
MMP-9. Thereafter the incubation with 20 µM of substrate was followed (2 hrs, 37°C). The 
cleavage study was monitored by using RP-HPLC (C18, Nucleosil column, CC250/4.6; 30 
min linear program).  
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V. Cell culture 
 
 The cell lines HEK293(β3) and HEK293(β1) are sub-clones of the human embryonic 
kidney cells HEK293, stably transfected by means of human Integrin β3 and β1 coding 
plasmid (cell line from J-F. Gourvest, Aventis, France). These cell lines are cultivated in the 
cell culture medium DMEM (Gibco), with 4.5 g/l glucose, 10 % fetal calf serum, which was 
treated 30 minutes at 56°C for decomplemenation, and G418 (700 µg/ml) (Gibco). 
 The cell line TS/A-pc derives of a mouse breast cancer carcinoma model. The cells 
are cultivated in RPMI medium (Gibco), containing 10 % fetal calf serum decomplemented, 1 
% glutamine and 25µM beta-mercaptoethanol.   
 The cell line HT1080 is a human fibrosarcoma cell line. The cells are cultivated in 
DMEM medium (Gibco), containing 10 % fetal calf serum decomplemented and 1 % 
glutamine. 
 The cell line A375 is a human melanoma cell line. These cell lines are cultivated in the 
cell culture medium DMEM (Gibco), with 4.5 g/l glucose and 10 % fetal calf serum. 
The cell line PC3 is a human prostate adenocarcinoma (cell line of G. Divita, UMR-5237 
CNRS, Centre de Recherches de Biochimie Macromoléculaire, Montpellier, France). The 
cells are cultivated in RPMI medium (Gibco), containing 10 % fetal calf serum 
decomplemented and 1 % glutamine. 
 Colo829 are cells derived from human melanoma. The cells are cultivated in RPMI 
medium (Gibco), containing 10 % fetal calf serum decomplemented and 1 % glutamine. 
The cells are cultivated at 37°C in humid atmosphere enriched with 5% CO2. Cell-passage is 
done twice each week by dissociating the cell bed with trypsin/EDTA (Gibco). 
 The cell lines HEK293(β3), TS/A-pc are strongly Integrin αvβ3 positive and A375 as 
well as HT1080 and Colo829 are weakly Integrin αvβ3 positive. The cell lines HEK293(β1) 
and PC3 are Integrin αvβ3 neagtive. 
 Concerning the expression of MMP-9, HT1080 is used as control cell line as it is 
known to overexpress the active form of MMP-9
277
. 
  
Cell viability is estimated by the exclusion technique Trypan blue. 
                                                 
277
 Faust, A. et al. Synthesis and evaluation of a novel fluorescent photoprobe for imaging matrix 
metalloproteinases. Bioconjug. Chem. 19, 1001–1008 (2008). 
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VI. Fluospectrometry 
 
 
 For the fluospectrometric analysis 200 µL of 0.25 µM of RAFT-RGD-MMP 
(compound 10) and 0.5 µM of RAFT-RGD-Cy5 (provided by Didier Boturyn) were analyzed 
in 50mM Tris Buffer at pH 7.5 with 150 mM NaCl, 5mM CaCl2 and 0.05% Brij-35 at 37°C.  
Fluorescence Emission spectra from 650 to 750 nm were recorded on a Perkin-Elmer LS 55 
Fluorescence Spectrometer with PTP – 1 Fluorescence Peltier System equipped with a 
thermo-stated compartment (37°C) using a 120 V pulsed xenon lamp (excitation wavelength: 
640 nm). In parallel the absorption spectra were recorded of each sample using the UV-visible 
Spectrophotometer Evolution 201 of ThermoScientific. 
 The ΦF values were determined by the equation
278
: 
Ф = Фref * (Fsample / Asample)*(Aref /Fref) 
F=k*A*Ф    => F= (A* Ф)/(Aref* Фref) * Fref 
where F and A are the measured fluorescence (area under the emission peak) normalized by 
its absorption spectrum and the absorbance at the excitation wavelength (640 nm). Cyanin 5 
at 0.5 µM in Tris Buffer 7.5 was used as reference [ΦF(ref)= 0.28] 
 The Quenching was then calculated by using the following equation: 
Quenching = (Ф ref- Фsample)/ Ф ref 
 The samples were incubated at 37°C and their spectra measured before incubation 
with the enzyme MatrixMetalloproteinase-9 (human recombinant MMP-9 catalytic domain, 
EnzoLifescience, Villeurbanne, France). Then the samples were incubated with 5nM of 
MMP-9 at 37°C, for 2 h, 24 h, and 48 h respectively (all spectra: T0 & T48h). 
For the plasma test 1 µM of the molecule was incubated with 100 µL of fresh mouse plasma. 
The spectra were then analyses by the same procedure. 
 For MMP-Inhibition, the MMP-9 was pre-incubated with 600nM SB-3CT and 
50µMCTT (specific competitive MMP inhibitors, EnzoLifescience, Villeurbanne, France) 
before incubated with 1 µM of RAFT-RGD-MMP.  
 The activity of the MMP and the inhibitors was controlled by using the fluorogenic 
substrate  Mca-RPPGFSAFK(Dnp) (EnzoLifescience, Villeurbanne, France) which is cleaved 
by MMP-2 and -9. 
                                                 
278
Gravier, Julien, Raphaël Schneider, Céline Frochot, Thierry Bastogne, Frédéric Schmitt, Jacques Didelon, François 
Guillemin, und Muriel Barberi-Heyob. „Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer 
selectivity with folate-based targeted delivery. synthesis and in vivo delivery studies“. Journal of medicinal chemistry 
51, Nr. 13 (Juli 10, 2008): 3867–3877. 
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VII. MMP -2 and -9 expression study 
 
 Zymography 
 For the detection of active enzymes we used the electrophoretic technique called 
zymography. The substrates are co-polymerized with the polyacrylamid gel and the enzymes 
are separated by gel electrophoresis. Negative staining of the substrate gel reveals enzymatic 
activity because the protease has degraded the substrate in the gel
279
 (white bands on blue 
gel). This method gives relative information about the quantity of active enzyme of the tested 
sample.  
 For gelatin zymography the supernatant of the different cell lines (24 to 48h in FCS-
free medium) was collected and stored at -20°C like done by the team of Faust
280
. Thereafter 
the samples were diluted in non reducing sample buffer pH 6.8 (Tris 0.5M, SDS 10%, 20 % 
saccharose, bromphenol blue). Then the samples are deposed on an SDS-PAGE 10% which 
contains 0.1% gelatin. As control of the molecular weight human purified MMP-2 and MMP-
9 with haemopexin domain were used (0.1 ng/µL; EnzoLifescience). After migration at 4°C 
for 30 minutes at 90V and another 2h30 at 140 V, the gel is washed twice for 30 minutes in 
Triton X-100 2.5%. Incubation at 37°C for 20 hours in incubation buffer at pH 7.2 (Tris 
52mM, NaCl 200 mM, CaCl2 5mM, Triton X-100 0.01%) follows. The next step consists in 
staining of the gel, which takes place at room temperature for 30 minutes in staining buffer 
(Comassie brilliant blue G-250 in diluted methanol and acetic acid). The same buffer, but 
without Comassie blue is used to decolorize the gel for 1 hour at room temperature. 
 Afterwards the gel is scanned and dried via a gel drying pad on non laminated 
Whatman paper with under-pressure. Images are analyzed via ImageJ gel analyzing blot. 
  
                                                 
279
 Overall, C. M. & Kleifeld, O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer 
therapy. Nat Rev Cancer 6, 227–239 (2006). 
280
 Faust, A. et al. Synthesis and evaluation of a novel fluorescent photoprobe for imaging matrix 
metalloproteinases. Bioconjug. Chem. 19, 1001–1008 (2008). 
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VIII. Flow cytometry analysis of integrin 
αvβ3 expression 
 
 
 For expression analysis, adherent cells are suspended with trypsin, washed once with 
cold PBS, and another time with PBS containing 1 mM CaCl2 and 1 mM MgCl2 (Ca
2+
/Mg
2+
). 
One million cells in a final volume of 200 mL are fixed with 2% PFA for 15 minutes, washed 
with PBS Ca
2+
/Mg
2+
 twice and suspended in 500µl PBS containing 20 µL of the antibody 
CD51/CD61 R-Phycoerythrin clone 23C6 mouse anti-human (Pharmingen, BD Bioscience). 
After 1 hour of incubation at 4°C the volume was adjusted to 5 mL and the samples were 
centrifuged for 15 min at 4 °C. The solutions are removed and pellets carefully rinsed twice 
with PBS Ca
2+
/Mg
2+
 (1 mM) at 4 °C. Cells are then rapidly analyzed by flow cytometry 
(FACS LSRII, BD bioscience, France). The results are reported as mean fluorescence 
intensity (MFI of Cy5) histogram counts. 
 Percentage of augmentation in MFI (mean fluorescence intensity) is calculated on the 
autofluorescence level. The results are expressed thus in pa-MFI (percentage of augmentation 
in MFI).  
IX. Cell – molecule-interaction 
 
  
 The analysis of the molecule RAFT-RGD-MMP and cells is realized by means of flow 
cytometric and fluorescence microscopic analysis. 
IX.1. Flow cytometry analysis (FACS) of the molecule – cell 
interaction 
 One day before the actual trial 6 well dishes were prepared with 500 000 cells per 
well. The cells are incubated in 2mL of the corresponding Medium without FCS. 4 hours 
before FACS the cells are rinsed with 2 mL PBS (1mM CaCl2 + 1mM MgCl2). Then 800µL 
of FCS free medium (DMEM colorless, 10% GlutaMax, ITSpremix™ (BD, USA) 1mL/1L) is 
added. Three hours before analysis 200µL of RAFT-RGD-MMP (0.2µM final) or 200µL of 
RAFT-RGD-Cy5 (0.4µM final) as control is added and gently swiveled. This corresponds at 2 
hours of incubation. The incubation is either at 37°C in a standard cell incubator or at 4°C (all 
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ingredients and plates placed on ice 10 minutes before). Incubation for 1 hour, 30 minutes, 15 
minutes and 5 minutes followed. The liquid is removed gently and the cells rinsed once with 
cold PBS. After that the adherent cells are quickly suspended by trypsination (1-2mL) and 
diluted in excess of PBS (10mL) to be rapidly centrifugated by 4°C for 10 minutes at 
1500rpm. Then a second centrifugation in 5 mL cold PBS follows. The liquid is removed and 
pellets carefully resuspended in 200µL PBS and the tubes are kept on ice and away from 
light. Cells are then rapidly analyzed by FACS (FACS LSRII, BD bioscience, France). The 
results are reported as MFI (Cy5) histogram counts. 
 For the Integrin inhibition study, the cell lines are incubated 5 minutes before each 
treatment with 20X RAFT-RGD (= 8µM). 
IX.2. Fluorescence microscopy analysis of the molecule – cell 
interaction 
 For the analysis by means of confocal microscopy 4-well Lab-Tek™ chamber (ultra 
thin, borosilicate; ThermoFisher) are used. After coating with fibronectin, 50 000 cells are 
seed in 48 hours before the trial and incubated in the corresponding medium. The day before 
the trial, the medium is removed before the cells were gently rinsed and incubated in FCS-free 
medium over night. One hour before microscopic analysis, the medium was removed, the 
cells are gently washed with PBS and 300 µL Dulbecco’s modified Eagle’s medium w/o red 
phenol was added. After two hours 1µL Hoechst is added (for cell nucleus detection) and 
analysis of living cells with 0.6µL of RAFT-RGD-MMP occurred. During acquisition the cell 
containing Lab-Tek™ chamber is kept in a heated chamber at 37°C and 4% CO2. 
 Confocal microscopy was performed on the Axiovert 200 LSM510 LNO Meta 
microscope (Carl Zeiss, Germany) using a 63× oil immersion objective of 1.4 N.A. A pinhole 
adjustment resulted in a 1 μm optical slice at scan zoom 1.5 and an image resolution of 516 x 
516 pixel. The laser gain was fixed at 800. The 633 nm helium-neon laser (5mW) intensity 
was set up at 20% of its maximum intensity, which was set on the autofluorescence of the non 
treated cells. For imaging the Hoechst-labeled nucleus we used the laser Tsunami 1,5W 
sapphire-titan. The operating program was LSM software.  
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X. In vivo fluorescence imaging 
 
 All the animal experiments are performed in agreement with the EEC guidelines and 
the ‘‘Principles of Laboratory Animal Care” (NIH Publication No. 86-23, revised 1985).  
Female NMRI Nude mice (6–8 weeks old, JANVIER, Le Genest Saint Isle, France) 
receive a sub-cutaneous xenograft of HEK293(b3) cells (20 x 10
6
 per mouse), HT1080 (10 x 
10
6
  per mouse), A375 (10 x 10
6
 per mouse), or TS/A-pc cells (5 x 10
6
 per mouse). Once 
tumors reached approximately 200 mm
3
, mice
281
 are anesthetized (isoflurane/oxygen 
4%/3.5% for induction and 2% thereafter) and are injected intravenously via the tail vein with 
200 µL of RAFT-RGD-MMP or RAFT-RGD-Cy5 control peptide (2 nmol) (Cy5 Ex/Em: 633 
nm/660 nm) or 150 µL of MMPSense680 (2 nmol; PerkinElmer’s, Boston, USA) (Ex/Em: 
680 nm/700 nm). 
In vivo fluorescence imaging is realized with the Aequoria Hamamatsu system 
(Hamamatsu, Massy, France). Mice are illuminated by 633 nm (RAFT-RGD’s) or 660 nm 
(MMPSense680) light-emitting diodes equipped with interference filters. Fluorescence 
images as well as black and white pictures are acquired by a back-thinned CCD camera at -80 
°C (ORCAII-BT-512G) fitted with a high pass RG665 (Schott, Jena, Germany) for the 633 
nm excitation or a high pass filter RG 9 (Schott, Jena, Germany) for the 660 nm excitation. 
All acquisitions are made with a medium gain and a binning 1x1 with an exposition time of 
30 ms to 1s (depending on fluorescence level).After imaging at different time points after 
injection (30 min, 1 h, 2 h, 3 h, 5 h and 24 h), the mice are sacrificed (at either 3 h or 24 h 
after injection) and dissected for the imaging of organs ex vivo. The tumors are frozen in 
OCT and liquid nitrogen for storage at -80°C. Image display and analysis are performed using 
the Wasabi software (Hamamatsu, Massy, France).Semi-quantitative data of tumor and skin 
are obtained by drawing ROIs on the subcutaneous tumors and on the skin (shoulder region 
with no tumor; images in vivo). The tumor/skin ratio is then calculated using the semi-
quantitative data obtained. The organ fluorescence quantifications are expressed as a number 
of relative light units per pixel per milliseconds (RLU/pix/ms) and the tumor/muscle ratio is 
calculated from these values. For all measurements the background noise is subtracted. All 
the data are expressed as mean ± standard deviation (SD) of three independent measurements.
                                                 
281 n = 3 for each group (per cell line; each cell line with sacrifice of one group at 3 h and one at 24 h, thus a total of n = 6 per 
cell line 
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
« Ne me dites pas que ce problème est difficile. S'il n'était pas difficile, 
ce ne serait pas un problème. »  
 Maréchal Ferdinand Foch (1851-1929) 
 
[Don’t tell me that this problem is difficult. If it wouldn’t be difficult, it wouldn’t be a problem.] 
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I. Supplementary Data – Preliminary 
Safety Observation Study In Cats 
 
3 Tables: Hemogram and Ionogram before and during trial with indication of physiological 
parameters. 
 The red numbers indicate the values superior to the norm 
 The yellow numbers indicate the values inferior to the norm 
Cat 1 T0 T0 +2h T0+5h30 T0+24h T0+7 days 
Physiologic 
parameters 
WBC 10,6.10^3/mm3 / / 11,5 10,4 5,5-19,5.10^3/mm3 
LYM 5,5.10^3/mm3 / / 5,6 4,9 1,5-7,0.10^3/mm3 
MON 0,3 .10^3/mm3 / / 0,2 0,1 0,0-0,85.10^3/mm3 
GRA 4,8 .10^3/mm3 / / 5,7 5,5 2,5-14.10^3/mm3 
EOS 0,38 .10^3/mm3 / / 0,64 0,8 0,0-1,5.10^3/mm3 
RBC 11,47.10^6/mm3 / / 11,62 9,85 5,0-10,0.10^6/mm3 
HGB 13,9 g/dL / / 14,1 12,6 8,0-15,0 g/dL 
HCT 50,4% / / 51,1 43,5 24,0-45,0% 
MCV 44 μm^3 / / 44 44 (3955μm^3) 
MCH 12,2 pg / / 12,1 12,8 (12,5-17,5pg) 
MCHC 27,6 g/dL / / 27,6 29 (30,0-36,0 g/dL) 
RDW 13,6% / / 13,9 13,8 (17,0-22,0%) 
PLT 355 10^3/mm3 / / 393 415 (300-80010^3/mm3) 
MPV 14,4 μm^3 / / 14,3 14,4 (6,5-15,0μm^3) 
Urée 10,3 mmol/L 7,9 11,6 14,1 11,9 (2-8mmol/L) 
Creat 65 μmol/L 65 64 65 68 (20-135 μmol/L) 
PAL 84 UI/L 58 40 49 46 (5-200 UI/L) 
ALT 100 UI/L 124 114 72 66 (5-80) 
CL 123 mmol/L. 124 123 119 127 140-158 mmol/L 
K 4,7 mmol/L 4,3 4,3 4,15 3,8 3,6-5,6 mmol/L 
Na 162 mmol/L 159 160 158 158 105-122 mmol/L 
RPCU 0,3 / 0,8 / / <0,5 
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Cat 2 T0 T0+2h T0+5h30 T0+24h T0+7jours 
Physiologic 
parameters 
WBC 4,4 .10^3/mm3 7,1 6,7 8,5 9,4 5,5-19,5.10^3/mm3 
LYM 2,0.10^3/mm3 1,7 1,6 3,7 4,7 1,5-7,0 10^3/mm3 
MON 0,0 .10^3/mm3 0 0 0,1 0,2 0,0-0,85.10^3/mm3 
GRA 2,4 .10^3/mm3 5,4 5,1 4,7 4,5 2,5-14 10^3/mm3 
EOS 0,3310^3/mm3 0,48 0,19 0,69 0,56 0,0-1,5 10^3/mm3 
RBC 15,3.10^6/mm3 13,61 14,34 12,56 13,32 5,0-10,0 10^6/mm3 
HGB 17,5 g/dL 15,2 15,8 14,2 14,7 8,0-15,0g/dL 
HCT 61,8% 55,6 58,4 50,7 54,2 24,0-45,0% 
MCV 40 μm^3 41 41 40 41 (3955μm^3) 
MCH 11,4pg 11,2 11,0 11,3 11,0 (12,5-17,5pg) 
MCHC 28,3 g/dL 27,4 27,1 28,1 27,1 (30,0-36,0 g/dL) 
RDW 13,6% 15,0 14,3 14,5 14,8 (17,0-22,0%) 
PLT 1045.10^3/mm3 952 1190 1036 1127 
(300-800 
10^3/mm3) 
MPV 18,0 μm^3 17,4 17,0 17,1 17,2 (6,5-15,0μm^3) 
Urée 7,4 mmol/L / 5,8 9,8 8,6 (2-8mmol/L) 
Creat 81 μmol/L / 74 85 78 (20-135 μmol/L) 
PAL 69 UI/L / 60 42 46 (5-200 UI/L) 
ALT 74 UI/L / 76 92 56 (5-80) 
PROT 72 g/L / 68 61 64 (55-75) 
CL 123 mmol/L / 123 120 152 140-158 mmol/L 
K 4,7 mmol/L / 3,7 3,9 3,7 3,6-5,6 mmol/L 
Na 155 mmol/L / 157 152 117 105-122 mmol/L 
RPCU 0,8 / 0,9 0,6 0,4 <0,5 
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Cat 3 T0 T0+5h30 T0+24h T0+7jours Physiologic parameters 
WBC 22,8 10^3/mm3 29,7 12,2 10,7 5,5-19,5 10^3/mm3 
LYM 8,9 10^3/mm3 5,9 2,7 3,7 1,5-7,0 10^3/mm3 
MON 1,6 10^3/mm3 0,4 0,3 0,2 0,0-0,85 10^3/mm3 
GRA 12,3.10^3/mm3 23,3 9,1 6,9 2,5-14 10^3/mm3 
EOS 4,4 10^3/mm3 1,9 1,3 1,1 0,0-1,5 10^3/mm3 
RBC 9,30 10^6/mm3 9,85 7,42 7,14 5,0-10,0 10^6/mm3 
HGB 12,3 g/dL 13,3 10,2 9,7 8,0-15,0g/dL 
HCT 45 % 48 35,7 34,9 24,0-45,0% 
MCV 48 μm^3 49 48 49 (3955μm^3) 
MCH 13,3 pg 13,4 13,8 13,6 (12,5-17,5pg) 
MCHC 27,4 g/dL 27,6 28,6 27,8 (30,0-36,0 g/dL) 
RDW 14,8% 14,8 14,9 15,0 (17,0-22,0%) 
PLT 235 10^3/mm3 126 254 234 (300-800 10^3/mm3) 
Urée 9,2 mmol/L 7,8 7,1 8,3 (2-8mmol/L) 
Creat 98 µmol/L 109 84 80 (20-135 μmol/L) 
PAL 37 UI/L 32 46 68 (5-200 UI/L) 
ALT 65 UI/L 78 71 68 (5-80) 
PROT 0,69 g/L 0,39 1,21 0,68  
CL 115 mmol/L 118 114 117 140-158 mmol/L 
K 4,6 mmol/L 4,5 4,4 4,2 36-5,6 mmol/L 
Na 146 mmol/L 152 147 149 105-122 mmol/L 
RPCU 0,3 0,4 0,4 0,4 <0,5 
 
 
 The data show no strong parameters aberrations, which would indicate acute toxicity. 
The renal elimination of AngioStamp™ does not lead to measurable damage in the organ. 
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II. Table Of Amino Acids 
 
 
 
 
 
 
 
Table II-1: The 20 natural amino acids. 
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CHIRURGIE GUIDEE PAR FLUORESCENCE DU FIBROSARCOME FELIN ET DEVELOPPEMENT 
ET CARACTERISATION D’UN VECTEUR BI-FONCTIONNEL POUR LE CIBLAGE DU CANCER  
 
Actuellement, la chirurgie représente la première indication pour la thérapie du cancer. Néanmoins, la résection 
complète du tissu tumoral, la détection des micrométastases et la préservation des tissus sains pendant 
l’intervention représentent un enjeu majeur et influencent fortement le pronostic du patient. Les récents 
développements technologiques en imagerie pour la chirurgie guidée des cancers ont conduit à des résultats 
précliniques prometteurs et les premiers essais cliniques utilisant des traceurs non-spécifiques confirment déjà le 
potentiel de ces systèmes pour l’amélioration de la chirurgie. De plus, le diagnostic précoce des tumeurs, ainsi 
que le développement de thérapies ciblées sont également des axes majeurs de recherche en cancérologie. Dans 
ce contexte notre équipe a précédemment développé un vecteur synthétique ciblant un récepteur cellulaire 
l’intégrine αVβ3. Ce vecteur est constitué d’un châssis décapeptidique cyclique RAFT (Regioselectively 
Addressable Functionalized Template) et présentant deux domaines indépendants permettant de séparer les deux 
fonctions du vecteur. Sur un domaine, la fonction de ciblage est assurée par la présentation multivalente de 
ligands -RGD- spécifiques du récepteur. L'autre domaine du vecteur porte les molécules d'intérêt à vectoriser, 
agents thérapeutiques ou de détection pour l'imagerie médicale.  
Dans la première partie de ces travaux, nous avons évalué la combinaison de ce vecteur couplé à un fluorophore 
avec une sonde portative pour imager et guider le chirurgien pendant la chirurgie des fibrosarcomes spontanés 
chez le chat. Cette étude représente une preuve de concept pour la translation clinique chez l’homme. Les 
résultats ont montré que l’injection du traceur ne provoquait pas d’effets toxiques chez le chat et permettait un 
marquage spécifique de la tumeur avec un bon ratio tumeur/tissu sain, qui devrait améliorer la qualité de la 
résection tumorale en aidant le chirurgien à mieux délimiter les marges du tissu tumoral.  
Dans la seconde partie de ces travaux nous avons développé un nouveau vecteur bi-fonctionnel dérivé du RAFT-
RGD. Au composé d’origine a été ajoutée une séquence peptidique clivable par la matrixmetalloprotease-9, une 
enzyme surexprimée dans la tumorigénèse. Cette molécule à fluorescence activable a montré une amélioration 
du ciblage tumoral in vitro et in vivo comparée au RAFT-RGD suggérant un effet additionnel lié au double 
ciblage. Ces résultats préliminaires  encouragent la poursuite de sa caractérisation pour son potentiel de « pro-
drug » mais également pour l’étude des interactions entre l’intégrine et l’environnement  tumoraux. 
 
OPTICAL-GUIDED SURGERY OF THE FELINE FIBROSARCOMA AND DEVELOPMENT AND 
CHARACTERIZATION OF A BI-FUNCTIONAL VECTOR FOR CANCER TARGETING 
 
Cancer surgery is still the gold standard therapy in most cancers. Nevertheless, total tumor resection and 
metastasis detection while preserving healthy tissues represent a crucial point for further prognosis. 
Development of imaging technologies for intra-operative guided surgery provided promising results and efficient 
application in preclinical studies and first clinical trials using non-specific tracers already confirmed the 
improved out-come in surgery. Moreover early and precise diagnosis and targeted therapies are major domains 
of cancer research. In this context our team previously developed a synthetic vector based on a cyclic 
decapeptide scaffold RAFT (Regioselectively Addressable Functionalized Template) which allows the 
independent functionalizing of two domains: a targeting domain with multivalent RGD-ligand targeting the cell 
receptor integrin v3, and a vehicle domain grafted with a pro-drug or an imaging agent. One part of this work 
consisted in the evaluation of the combination of this molecule carrying a fluorophore with a portable fluorescent 
imaging device for image-guided surgery of natural occurring feline fibrosarcoma. This study represents a proof 
of concept for further translation into human clinics. No toxic effects in cats after administration of the tracer 
could be reported. Furthermore the tumors were specifically labeled showing a good tumor-to-healthy tissue 
ratio. This should improve tumor resection by helping the surgeon to delineate tumor margins. In parallel we 
developed a bi-functional derivative of the RAFT-RGD. Therefore we engrafted a peptide sequence flanked by 
two fluorophores, which is activatable by matrixmetalloprotease-9, an enzyme overexpressed in tumors. This 
molecule showed an improved tumor labeling in vitro and in vivo compared to the conventional RAFT-RGD, 
suggesting an additional effect of the double targeting. These preliminary results encourage further 
characterization for its potential as pro-drug vehicle, as well as for studying interactions between the integrin and 
the tumor environment. 
 
Mots Clés : tumeur, peptides ciblés, imagerie de fluorescence in vitro et in vivo, imagerie per-opératoire, RAFT-RGD, 
chirurgie du cancer guidée par la fluorescence 
Keywords: cancer, targeting peptides, in vitro and in vivo fluorescence imaging, inter-operative imaging, RAFT-
RGD, fluorescent guided cancer surgery 
